Note: Descriptions are shown in the official language in which they were submitted.
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
AUTOTAXIN INHIBITORS AND USES THEREOF
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent
Application No.
62/167,216 filed on May 27, 2015, which is herein incoporated by reference in
its entirety.
FIELD OF THE INVENTION
[0002] Described herein are methods of using autotaxin inhibitors, and
pharmaceutical
compositions and medicaments thereof, in the treatment of conditions,
diseases, or disorders
associated with autotaxin activity.
BACKGROUND OF THE INVENTION
[0003] Autotaxin (ATX), also known as ectonucleotide
pyrophosphatase/phosphodiesterase
family member 2 or ENNP2, is an adipocyte secreted lysophospholipase D that
catalyzes the
formation of the lipid mediator, lysophosphatidic acid (LPA). Autotaxin
expression is enhanced
in individuals with certain conditions or diseases.
SUMMARY OF THE INVENTION
[0004] The autotaxin-lysophosphatidic acid signaling pathway has been
implicated in a variety
of signaling pathways involved in cell migration, proliferation, and survival.
Due to its role in
these pathways, autotaxin has been explored as a drug discovery target for the
treatment of
chronic inflammation, neuropathic pain, fibrotic disease, and various cancers.
Intensive efforts
have focused on identifying autotaxin inhibitors in the treatment of these
disorders.
[0005] In one aspect, provided herein are methods of using one or more
autotaxin inhibitors for
the treatment or prevention of diseases or conditions in which autotaxin
and/or LPA participates,
is involved in the etiology or pathology of the disease, or is otherwise
associated with at least
one symptom or complication of the disease. Inhibition of the physiological
activity of autotaxin
and/or LPA is useful in a variety of diseases or conditions. The autotaxin-LPA
signaling
pathway has been implicated in fibrotic diseases, colitis, cancer, pruritus,
angiogenesis,
inflammation, autoimmune diseases, reproduction, neurological diseases, and
tumor progression.
[0006] In one aspect, the methods described herein involve the use of one or
more autotaxin
inhibitor compounds for the treatment of diseases or conditions in which
autotaxin activity
contributes to the symptomology or progression of the disease, disorder or
condition. These
diseases, disorders, or conditions may arise from one or more of a genetic,
iatrogenic,
immunological, infectious, metabolic, oncological, toxic, surgical, and/or
traumatic etiology. In
one aspect, the methods, compounds, pharmaceutical compositions, and
medicaments described
herein comprise autotaxin inhibitors.
-1-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0007] In one aspect, the autotaxin inhibitors are useful for the treatment of
diseases or
conditions such as, but not limited to, fibrosis, colitis, cell proliferative
disease, inflammatory
disease, autoimmune diseases, reproductive diseases, abnormal angiogenesis-
associated disease,
scleroderma, brain or heart reperfusion injury, neurodegenerative disease,
neuropathic pain,
peripheral neuropathy, ocular disease, diabetic retinopathy, proliferative
vitreoretinopathy,
cicatricial pemphigoid, metabolic disorder, and glaucoma.
[0008] In one aspect, provided herein are pharmaceutical compositions
comprising one or more
autotaxin inhibitors, pharmaceutically acceptable salts, or solvates thereof
useful for the
treatment or prevention of one or more diseases or conditions. In some
embodiments, the
pharmaceutical composition attenuates or reverses one or more signs or
symptoms associated
with the one or more disease or conditions. In some embodiments, the
pharmaceutical
composition prevents the onset of one or more complications associated with
the one or more
diseases or conditions. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor A. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor B. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor C. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor D. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor E. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor F. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor G. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor H. In some embodiments, the pharmaceutical composition
comprises
autotaxin inhibitor I. In some embodiments, the pharmaceutical composition
further comprises
an additional therapeutic agent. In some embodiments, the pharmaceutical
composition is
administered in combination with one or more additional treatments for a
disease, disorder or
condition. In some embodiments, the pharmaceutical composition comprises at
least one
pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical
composition is
formulated for administration to a mammal by intravenous administration,
subcutaneous
administration, oral administration, inhalation, nasal administration, dermal
administration, or
ophthalmic administration. In some embodiments, the pharmaceutical composition
is in the form
of a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a
solution, an emulsion, an
ointment, or a lotion.
[0009] In one aspect, described herein is a method of treating or preventing
any one of the
diseases or conditions described herein comprising administering a
therapeutically effective
amount of an autotaxin inhibitor, or a pharmaceutically acceptable salt, or
solvate thereof, to a
mammal in need thereof.
-2-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0010] In one aspect, described herein is a method of treating or preventing
any one of the
diseases or conditions described herein comprising administering a
therapeutically effective
amount of an autotaxin inhibitor, or a pharmaceutically acceptable salt, or
solvate thereof, to a
mammal in need thereof, wherein the autotaxin inhibitor, or the
pharmaceutically acceptable salt
or solvate thereof, does not cause hepatobiliary damage in the mammal.
100111 In one aspect, described herein is a method of treating or preventing
any one of the
diseases or conditions described herein comprising administering a
therapeutically effective
amount of an autotaxin inhibitor, or a pharmaceutically acceptable salt, or
solvate thereof, to a
mammal in need thereof; wherein one or more liver proteins are not
significantly elevated in the
subject after the administration of the autotaxin inhibitor, or the
pharmaceutically acceptable salt
or solvate thereof. In some embodiments, a significant elevation in the
concentration of a liver
protein is at least a 50%, 100%, 200% or 500% increase in the concentration of
the liver protein.
In some embodiments, the liver protein is aspartate transaminase. In some
embodiments, the
liver protein is alkaline phosphatase. In some embodiments, the liver protein
is bilirubin.
[0012] In another aspect, described herein is a method for treating or
preventing fibrosis,
pruritus, colitis, cancer, an inflammatory disease or condition, an airway
disease or condition, an
autoimmune disease or condition, a neurological disease or condition, obesity,
intraocular
pressure, neuropathic pain, or combinations thereof in a mammal comprising
administering a
therapeutically effective amount of an autotaxin inhibitor, or a
pharmaceutically acceptable salt,
or solvate thereof, to the mammal. In some embodiments, the administration of
an autotaxin
inhibitor, or a pharmaceutically acceptable salt, or solvate thereof
attenuates at least one
symptom of fibrosis, pruritus, colitis, cancer, an inflammatory disease or
condition, an airway
disease or condition, an autoimmune disease or condition, neurological disease
or condition,
obesity, intraocular pressure, neuropathic pain, or combinations thereof.
[0013] In one aspect, described herein is a method for treating or preventing
a disease, disorder
or condition described herein, the method comprising administering an
autotaxin inhibitor to a
mammal in need thereof; wherein following the administration of the autotaxin
inhibitor, blood
lysophosphatidic acid levels in the mammal decrease by at least about 5%, 10%,
20%, 30%,
40% or 50%.
[0014] In one aspect, described herein is a method for treating or preventing
a disease, disorder
or condition described herein, the method comprising administering an
autotaxin inhibitor to a
mammal in need thereof; wherein following the administration of the autotaxin
inhibitor, blood
autotaxin levels in the mammal decrease by at least about 5%, 10%, 20%, 30%,
40% or 50%.
[0015] In one aspect, described herein is a method for treating or preventing
a disease, disorder
or condition described herein, the method comprising administering an
autotaxin inhibitor, or a
-3-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
pharmaceutically acceptable salt or solvate thereof, wherein the autotaxin
inhibitor is formulated
for administration to a mammal in need thereof by intravenous administration,
subcutaneous
administration, oral administration, inhalation, nasal administration, dermal
administration, or
ophthalmic administration
[0016] In one aspect, described herein is a method for treating or preventing
a disease, disorder
or condition described herein, the method comprising administering an
autotaxin inhibitor, or a
pharmaceutically acceptable salt or solvate thereof, wherein the autotaxin
inhibitor is in a
pharmaceutical composition having the form of a tablet, a pill, a capsule, a
liquid, a suspension,
a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.
[0017] In one aspect, described herein is a method for the treatment or
prevention of fibrosis in
a mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
some embodiments,
accumulation of extracellular matrix or the rate of accumulation of
extracellular matrix in a
tissue having fibrosis is reduced following administration of the autotaxin
inhibitor, or a
pharmaceutically acceptable salt, or solvate thereof In some embodiments, the
fibrosis
comprises peritoneal fibrosis, lung fibrosis, liver fibrosis, kidney fibrosis,
ocular fibrosis or
cutaneous fibrosis. As an example, the method comprises administering an
autotaxin inhibitor to
a mammal having liver fibrosis. In some instances, the onset of cirrhosis or
liver failure is
delayed or prevented following administration of the autotaxin inhibitor, or a
pharmaceutically
acceptable salt, or solvate thereof. In some instances, the accumulation of
fibrogenic cells and/or
the deposition of extracellular matrix proteins within the liver is attenuated
or prevented
following administration of the autotaxin inhibitor, or a pharmaceutically
acceptable salt, or
solvate thereof. In one example, the method comprises administering an
autotaxin inhibitor to a
mammal having kidney fibrosis. In some instances, administration of an
autotaxin inhibitor to
the mammal prevents renal failure. As another example, the method comprises
administering an
autotaxin inhibitor to a mammal having peritoneal fibrosis. As a further
example, the method
comprises administering an autotaxin inhibitor to a mammal having skin
fibrosis. In some
instances, dermal thickness of a skin sample having fibrosis is decreased by
at least about 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% following administration of the
autotaxin
inhibitor, or a pharmaceutically acceptable salt, or solvate thereof.
[0018] In one aspect, described herein is a method for the treatment or
prevention of fibrosis in
a mammal comprising administering to the mammal a therapeutically effective
amount of an
autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate thereof
and a second
therapeutic agent. In some embodiments, the second therapeutic agent comprises
an angiotensin
inhibitor, colchicine, corticosteroid, an endothelin inhibitor, interferon-
alpha, interleukin 10, an
-4-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
antioxidant, a hepatic stellate cell (HSC) inhibitor, an ACE inhibitor, an
ADAM inhibitor, a
metalloenzyme, pirfenidone, tranilast, fluorofenidone, an anti-inflammatory
agent, an
immunosuppressant, or a combination thereof.
[0019] In one aspect, described herein is a method for the treatment or
prevention of colitis in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
one aspect,
described herein is a method for the treatment or prevention of inflammatory
bowel disease in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
some instances, the
colitis is acute colitis. In some instances, the colitis is chronic colitis.
In some embodiments, the
colitis is autoimmune colitis, idiopathic colitis, latrogenic colitis,
vascular disease or infectious
colitis.
[0020] In one aspect, described herein is a method for the treatment or
prevention of ulcerative
colitis in a mammal comprising administering a therapeutically effective
amount of an autotaxin
inhibitor, or a pharmaceutically acceptable salt, or solvate thereof, to the
mammal. In some
embodiments, administration of the autotaxin inhibitor, or a pharmaceutically
acceptable salt, or
solvate thereof, reduces ulcer size in ulcerative colitis by at least about
10%, 20%, 30%, 40%,
50%, 60%, 70%, 80% or 90% following the administration.
[0021] In some embodiments, one or more signs or symptoms of colitis are
reduced in the
mammal following administration of the autotaxin inhibitor. Signs or symptoms
include, without
limitation, abdominal pain, diarrhea, mucus in stool, cramping, abdominal
tenderness, fever,
bloody stool, distension, colonic mucosal erythema and ulcers.
[0022] In one aspect, described herein is a method for the treatment or
prevention of colitis in a
mammal comprising administering to the mammal a therapeutically effective
amount of an
autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate thereof
and a second
therapeutic agent. In some embodiments, the second therapeutic agent comprises
a steroid, an
anti-inflammatory agent, an immunosuppressant, or a combination thereof. In
one aspect,
provided herein is a method for the treatment or prevention of colitis in a
mammal, the method
comprising the administration of an autotaxin inhibitor and cyclosporine A. In
one aspect,
provided herein is a method for the treatment or prevention of colitis in a
mammal, the method
comprising the administration of an autotaxin inhibitor and sulfasalazine.
[0023] In one aspect, described herein is a method for the treatment or
prevention of a
neurological disease or disorder in a mammal comprising administering a
therapeutically
effective amount of an autotaxin inhibitor, or a pharmaceutically acceptable
salt, or solvate
thereof, to the mammal. In one aspect, described herein is a method for the
treatment or
-5-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
prevention of multiple sclerosis in a mammal comprising administering a
therapeutically
effective amount of an autotaxin inhibitor, or a pharmaceutically acceptable
salt, or solvate
thereof, to the mammal. In some embodiments, administration of the autotaxin
inhibitor, or a
pharmaceutically acceptable salt, or solvate thereof, attenuates, reverses, or
inhibits
demyelination in the mammal. In some embodiments, administration of the
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof to a mammal having
multiple sclerosis,
decreases the frequency, severity and/or duration of a relapse of multiple
sclerosis symptoms in
the mammal. Multiple sclerosis symptoms include, without limitation, numbness
or weakness in
a limb, partial or complete loss of vision, double vision, blurring of vision,
tingling sensation,
tremors, lack of coordination, unsteady gait, slurred speech, fatigue and
dizziness.
[0024] In one aspect, described herein is a method for the treatment or
prevention of a
neurological disease in a mammal, the method comprising administering to the
mammal a
therapeutically effective amount of an autotaxin inhibitor, or a
pharmaceutically acceptable salt,
or solvate thereof and a second therapeutic agent. In some embodiments, the
second therapeutic
agent comprises a corticosteroid, a beta interferon, glatiramer acetate,
dimethyl fumarate,
fingolimod, teriflunomide, natalizumab, mitoxantrone, a muscle relaxant, or a
combination
thereof. In some instances, the neurological disease is multiple sclerosis.
[0025] In one aspect, described herein is a method for treating or preventing
pruritus in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
some embodiments,
the pruritus is associated with dermatitis herpetiformis, dermatomyositis,
pemphigoid, Sjogren's
syndrome, Darier's disease, Hailey-Hailey disease, Ichthyoses, Sjogren-Larsson
syndrome,
dermatophytosis, folliculitis, impetigo and other bacterial infections, insect
bites, pediculosis,
scabies, viral infection, asteatosis, atopic eczema, contact dermatitis, drug
reaction, lichen
planus, lichen simplex chronicus, mastocytosis (urticaria pigmentosa),
miliaria, psoriasis,
scar(s), urticaria, cutaneous T-cell lymphoma or mycosis fungoides, cutaneous
B-cell
lymphoma, leukemia cutis, pemphigoid gestationis, polymorphic eruption of
pregnancy or
prurigo gestationis. In one aspect, described herein is a method for treating
or preventing
cholestatic pruritus in a mammal comprising administering a therapeutically
effective amount of
an autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate
thereof, to the mammal
in need thereof. In some embodiments, following administration of the
autotaxin inhibitor, the
number of scratch movements exhibited by a mammal having pruritus decreases by
at least
about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%. In one aspect, described
herein is a
method for the treatment or prevention of a pruritus in a mammal, the method
comprising
administering to the mammal a therapeutically effective amount of an autotaxin
inhibitor, or a
-6-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
pharmaceutically acceptable salt, or solvate thereof and a second therapeutic
agent. In some
embodiments, the second therapeutic agent comprises topical capsaicin.
[0026] In one aspect, described herein is a method for treating or preventing
cancer in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
some embodiments,
the cancer is a solid tumor. In some embodiments, the cancer is bladder
cancer, colon cancer,
brain cancer, breast cancer, endometrial cancer, heart cancer, kidney cancer,
lung cancer, liver
cancer, uterine cancer, blood and lymphatic cancer, ovarian cancer, pancreatic
cancer, prostate
cancer, thyroid cancer, or skin cancer. In some embodiments, the cancer is a
sarcoma,
carcinoma, or lymphoma. In some embodiments, the cancer is amenable to
treatment with an
autotaxin inhibitor. In some embodiments, the method further comprises
administering a second
therapeutic agent to the mammal in addition to the autotaxin inhibitor, or a
pharmaceutically
acceptable salt, or solvate thereof. In one aspect, described herein is a
method for the treatment
or prevention of cancer in a mammal, the method comprising administering to
the mammal a
therapeutically effective amount of an autotaxin inhibitor, or a
pharmaceutically acceptable salt,
or solvate thereof and a second anti-cancer agent or therapy.
[0027] In one aspect, described herein is a method of reducing or inhibiting
angiogenesis in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal. In
some embodiments,
reducing or inhibiting angiogenesis in the mammal treats atherosclerosis,
hypertension, tumor
growth, inflammation, rheumatoid arthritis, wet-form macular degeneration,
choroidal
neovascularization, retinal neovascularization, or diabetic retinopathy. In
one aspect, described
herein is a method for the reduction or inhibition of angiogenesis in a
mammal, the method
comprising administering to the mammal a therapeutically effective amount of
an autotaxin
inhibitor, or a pharmaceutically acceptable salt, or solvate thereof and a
second therapeutic agent
or therapy. In some instances, the second therapeutic agent comprises an
angiogenesis inhibitor,
for example, a VEGF inhibitor (bevacizumab), sorafenib, sunitinib, pazopanib,
everolimus, or a
combination thereof.
[0028] In another aspect, described herein is a method of treating or
preventing an
inflammatory disease or condition in a mammal comprising administering a
therapeutically
effective amount of an autotaxin inhibitor, or a pharmaceutically acceptable
salt, or solvate
thereof, to the mammal. In some embodiments, the inflammatory disease or
condition is
psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease,
dermatitis, osteoarthritis,
asthma, inflammatory muscle disease, allergic rhinitis, vaginitis,
interstitial cystitis, scleroderma,
eczema, lupus erythematosus, dermatomyositis, Sjogren's syndrome, thyroiditis,
myasthenia
-7-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis,
chronic relapsing
hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, allergic
conjunctivitis or
atopic dermatitis. In one aspect, described herein is a method for treating or
preventing an
inflammatory disease or condition in a mammal, the method comprising
administering to the
mammal a therapeutically effective amount of an autotaxin inhibitor, or a
pharmaceutically
acceptable salt, or solvate thereof and an anti-inflammatory drug. In some
embodiments, the
anti-inflammatory drug comprises a non-steroidal anti-inflammatory drug.
[0029] In another aspect, described herein is a method of treating or
preventing an autoimmune
disease or condition in a mammal comprising administering a therapeutically
effective amount
of an autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate
thereof, to the
mammal. In one aspect, described herein is a method for treating or preventing
an autoimmune
disease or condition in a mammal comprising administering to the mammal a
therapeutically
effective amount of an autotaxin inhibitor, or a pharmaceutically acceptable
salt, or solvate
thereof and an immunosuppressant. In some embodiments, the immunosuppressant
comprises a
glucocorticoid, cytostatic, antibody, drug, or a combination thereof.
[0030] In another aspect, described herein is a method of treating or
preventing an airway
disease or condition in a mammal comprising administering a therapeutically
effective amount
of an autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate
thereof, to the
mammal. In some embodiments, the airway disease is chronic obstructive
pulmonary disease,
cystic fibrosis or asthma.
[0031] In another aspect, described herein is a method of treating or
preventing intraocular
pressure in a mammal comprising administering a therapeutically effective
amount of an
autotaxin inhibitor, or a pharmaceutically acceptable salt, or solvate
thereof, to the mammal. In
some embodiments, the intraocular pressure is associated with glaucoma.
[0032] In another aspect, described herein is a method of treating or
preventing neuropathic
pain in a mammal comprising administering a therapeutically effective amount
of an autotaxin
inhibitor, or a pharmaceutically acceptable salt, or solvate thereof, to the
mammal. In some
embodiments, the neuropathic pain is the result of a nerve injury.
[0033] In one aspect, described herein is a method of treating or preventing a
metabolic
disorder, and/or one or more conditions associated with a metabolic disorder,
the method
comprising administering an autotaxin inhibitor to a mammal in need thereof.
In another aspect,
described herein is a method for preventing or delaying the onset of at least
one metabolic
disorder in a mammal at risk for developing a metabolic disorder, comprising
administering to
the mammal an autotaxin inhibitor. In some embodiments, the metabolic disorder
is treated by
reducing blood glucose levels. In some instances, blood glucose levels
decrease in the subject by
-8-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
at least bout 10% following administration of the autotaxin inhibitor. h1 some
embodiments, the
metabolic disorder is treated by reducing plasma lysophosphatidic acid levels.
In some
embodiments, the metabolic disorder is treated by improving insulin
sensitivity. In some
embodiments, the metabolic disorder is treated by increasing insulin
secretion. In some
embodiments, the metabolic disorder is treated by improving glucose tolerance.
In some
embodiments, the metabolic disorder is treated by decreasing adipose tissue
expansion. In some
embodiments, the metabolic disorder does not induce hypoglycemia. In some
embodiments, the
metabolic disorder is selected from the group consisting of: metabolic
syndrome, elevated blood
glucose levels, insulin resistance, glucose intolerance, type 2 diabetes, type
1 diabetes, pre-
diabetes, non-alcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH),
obesity, or a combination thereof. In some embodiments, the mammal has a body
mass index of
at least 25 kg/m2 and at least one or more of the diabetes risk factors
selected from the group
consisting of: physical inactivity, a first-degree relative with diabetes, a
high-risk race or
ethnicity, a woman that delivered a baby weighing more than 9 pounds, a woman
previously
diagnosed with gestational diabetes, hypertensive, HDL cholesterol levels
lower than at least 0.9
mmol/L (35 mg/dL), triglyceride levels at least 2.82 mmol/L (250 mg/dL) or
greater, a woman
with polycystic ovarian syndrome, severe obesity, acanthosis nigrican, and
cardiovascular
disease.
[0034] In another aspect, described herein is a method of treating or
preventing obesity in a
mammal comprising administering a therapeutically effective amount of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt, or solvate thereof, to the mammal.
[0035] In one aspect, described herein is a method for reducing blood glucose
levels of a
mammal comprising administering to the mammal an autotaxin inhibitor, thereby
decreasing the
blood glucose levels of the mammal. Further provided is a method for
preventing or delaying
the onset of an elevated blood glucose level in a mammal at risk for
developing an elevated
glucose level, the method comprising administering to the mammal an autotaxin
inhibitor. In
some embodiments, the mammal has an elevated blood glucose level. In certain
embodiments,
the method comprises measuring the blood glucose level of the mammal. In
certain
embodiments, the method comprises selecting a mammal having an elevated blood
glucose
level. The measured blood glucose level is inclusive of fasted blood glucose
level, post-prandial
blood glucose level, whole blood glucose level and plasma blood glucose level.
In some
embodiments, the blood glucose level is reduced to below 200 mg/dL, 175 mg/dL,
150 mg/dL,
125 mg/dL, 120 mg/dL, 115 mg/dL, 110 mg/dL, 105 mg/dL, or 100 mg/dL after
treatment with
an autotaxin inhibitor.
-9-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0036] In one aspect, described herein is a method for reducing plasma
lysophosphatidic acid
levels of a mammal comprising administering to the mammal an autotaxin
inhibitor; and thereby
decreasing plasma lysophosphatidic acid levels of the mammal. In some
embodiments, the
mammal has an elevated blood glucose level. In some embodiments the mammal is
insulin
resistant.
[0037] In one aspect, described herein is a method for improving insulin
sensitivity, delaying
the onset of insulin resistance, and/or increasing insulin secretion in a
mammal comprising
administering to the mammal an autotaxin inhibitor; and thereby improving
insulin resistance in
the mammal.
[0038] In one aspect, described herein is a method for improving glucose
tolerance in a
mammal comprising administering to the mammal an autotaxin inhibitor; and
thereby improving
glucose tolerance.
[0039] In one aspect, described herein is a method for decreasing adipose
tissue expansion in a
mammal comprising administering to the mammal an autotaxin inhibitor; and
thereby
decreasing adipose tissue expansion in the mammal. In some embodiments, the
mammal has an
elevated blood glucose level In some embodiments, the mammal is insulin
resistant.
[0040] In any of the aforementioned aspects are further embodiments in which
the effective
amount of the autotaxin inhibitor, or a pharmaceutically acceptable salt
thereof, is: (a)
systemically administered to the mammal; and/or (b) administered orally to the
mammal; and/or
(c) intravenously administered to the mammal; and/or (d) administered by
inhalation; and/or (e)
administered by nasal administration; or and/or (f) administered by injection
to the mammal;
and/or (g) administered topically to the mammal; and/or (h) administered by
ophthalmic
administration; and/or (i) administered rectally to the mammal; and/or (j)
administered non-
systemically or locally to the mammal.
[0041] In any of the aforementioned aspects are further embodiments comprising
single
administrations of the effective amount of the autotaxin inhibitor, including
further
embodiments in which the autotaxin inhibitor is administered once a day to the
mammal or the
autotaxin inhibitor is administered to the mammal multiple times over the span
of one day. In
some embodiments, the autotaxin inhibitor is administered on a continuous
dosing schedule. In
some embodiments, the autotaxin inhibitor is administered on a continuous
daily dosing
schedule.
[0042] In any of the aforementioned aspects involving the treatment of
autotaxin dependent
diseases or conditions are further embodiments comprising administering at
least one additional
agent in addition to the administration of an autotaxin inhibitor, or a
pharmaceutically
-10-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
acceptable salt thereof. In various embodiments, each agent is administered in
any order,
including simultaneously.
[0043] In any of the embodiments disclosed herein, the mammal is a human.
[0044] In some embodiments, autotaxin inhibitors provided herein are
administered to a
human.
[0045] In some embodiments, autotaxin inhibitors provided herein are orally
administered.
[0046] Articles of manufacture, which include packaging material, an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, within the packaging material, and a
label that
indicates that the autotaxin inhibitor or composition, or pharmaceutically
acceptable salt,
tautomers, pharmaceutically acceptable N-oxide, pharmaceutically active
metabolite,
pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate
thereof, is used for
inhibiting the activity of autotaxin, or for the treatment, prevention or
amelioration of one or
more symptoms of a disease or condition that would benefit from inhibition of
the activity of
autotaxin, are provided.
[0047] Other objects, features and advantages of the autotaxin inhibitors,
methods and
compositions described herein will become apparent from the following detailed
description. It
should be understood, however, that the detailed description and the specific
examples, while
indicating specific embodiments, are given by way of illustration only, since
various changes
and modifications within the spirit and scope of the instant disclosure will
become apparent to
those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Fig. 1 provides hydroxyproline levels in skin biopsies from PBS-
injected or bleomycin-
inj ected mice treated with an autotaxin inhibitor. Cmpd A attenuates skin
fibrosis when dosed
prophylactically (pro) or therapeutically (ther) in a mouse subcutaneous
bleomycin model.
[0049] Fig. 2 provides hydroxyproline levels in non-ligated and ligated
kidneys from UU0-
mice after prophylactic (A) or therapeutic (B) treatment with an autotaxin
inhibitor. Cmpd A
attenuates renal fibrosis when dosed prophylactically (A) or therapeutically
(B) in a mouse UUO
model.
[0050] Fig. 3 provides hydroxyproline levels in mice peritoneum from vehicle
or chlorhexidine
gluconate injected mice treated with an autotaxin inhibitor. Cmpd A attenuates
peritoneal
fibrosis when dosed prophylactically in a mouse chlorhexidine gluconate model.
[0051] Fig. 4 provides percent PSR positive area in the livers from CDAA/HFD
fed mice
treated therapeutically with vehicle or autotaxin inhibitors Cmpd A and cmpd B
attenuate
hepatic fibrosis when dosed therapeutically in a mouse CDAA/HFD model.
-11-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
DETAILED DESCRIPTION OF THE INVENTION
Autotaxin and LPA
[0052] Autotaxin (ATX, NPP2, or ENPP2), an approximately 120 kDa glycoprotein,
is a
secreted nucleotide pyrophosphatase/phosphodiesterase (NPP) with
lysophospholipase D
activity that converts extracellular lysophosphatidylcholine (LPC) and other
lysophospholipids
to lysophosphatidic acid (LPA). Autotaxin is considered to be responsible for
the majority of
circulating LPA production.
[0053] LPA acts through sets of specific G protein-coupled receptors (GPCRs),
such as LPA1,
LPA2, LPA3, LPA4, LPA5, LPA6, LPA7, LPA8, in an autocrine and paracrine
fashion to
produce a variety of biological responses. For example, lysophospholipids,
such as LPA, are
known to affect such biological functions as cellular proliferation,
differentiation, survival,
migration, adhesion, invasion, and morphogenesis. In addition, LPA is known to
play a role in
such processes as platelet activation, smooth muscle contraction, actin stress
fiber formation,
and cell migration.
[0054] Autotaxin and LPA have been detected in various biological fluids such
as serum,
plasma, cerebrospinal fluid, seminal fluid, urine, and saliva, both in animals
and humans,
suggesting that they are potential biomarkers to predict certain diseases. For
example, serum
autotaxin concentration and activity is elevated in patients with chronic
liver diseases and in
pregnant women. As another example, autotaxin activity is increased in
cerebrospinal fluid and
serum of relapse/remitting multiple sclerosis patients compared to patients
with other
neurological diseases. In addition, autotaxin is known to be essential for
normal development.
For example, autotaxin-deficient mice die at embryonic day 9.5 with profound
vascular defects
in both the yolk sac and the embryo. Furthermore, at embryonic day 8.5,
autotaxin-deficient
embryos were found to have malformed allantois, neural tube defects, and
asymmetric
headfolds.
[0055] In one aspect, provided herein are methods of using autotaxin
inhibitors and
pharmaceutical compositions comprising autotaxin inhibitors for the prevention
and/or treatment
of a condition, disease or disorder associated with autotaxin activity. In
some embodiments, the
methods disclosed herein comprise the administration of an autotaxin inhibitor
to a subject
having a disease, condition or disorder described herein. In some embodiments,
the methods
disclosed herein comprise the administration of an autotaxin inhibitor to a
subject suspected of
having or developing a disease, condition or disorder described herein.
[0056] In one aspect, provided herein are methods for the treatment or
prevention of one or
more signs, symptoms or complications in a subject resulting from a disease,
condition or
-12-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
disorder described herein, the methods comprising administration of an
autotaxin inhibitor to the
subject.
[0057] In one aspect, provided herein are methods for the prevention of a
condition, disease or
disorder associated with autotaxin activity, the methods comprising
administering an autotaxin
inhibitor in combination with another preventative therapy.
[0058] In one aspect, provided herein are methods for the treatment of a
condition, disease or
disorder associated with autotaxin activity, the methods comprising
administering an autotaxin
inhibitor in combination with another treatment.
[0059] In one aspect, provided herein are methods for the attenuation,
reversal and/or inhibition
of a sign, symptom or complication of a condition, disease or disorder
associated with autotaxin
activity, the methods comprising administering an autotaxin inhibitor.
[0060] In one aspect, provided herein are methods for the attenuation,
reversal and/or cessation
of a sign, symptom or complication of a condition, disease or disorder
associated with autotaxin
activity, the methods comprising administering an autotaxin inhibitor in
combination with one or
more additional therapies.
[0061] In some embodiments, the administration of an autotaxin inhibitor or
the administration
of a pharmaceutical composition comprising an autotaxin inhibitor described
herein, comprises
the administration of an autotaxin inhibitor at a therapeutically effective
dose. In some
embodiments, a therapeutically effective dose is between about 0.01 mg to 5000
mg. For
example, a therapeutic dose is between about 0.1 mg and about 5000 mg, between
about 0.1 mg
and about 1000 mg, between about 0.1 mg and about 500 mg, between about 0.1 mg
and about
250 mg, between about 1 mg and about 1000 mg, between about 1 mg and about 100
mg,
between about 1 mg and about 10 mg, or any integer between the aforementioned
values. In
some embodiments, a therapeutically effective dose is administered
continuously. In some
implementations, a therapeutically effective dose is administered 4 times a
day, 3 times a day, 2
times a day, once a day, 6 times a week, 5 times a week, 4 times a week, 3
times a week, twice
per week, once per week, or less often. In some embodiments, an autotaxin
inhibitor is
administered for a therapeutically effective amount of time in any of the
methods described
herein comprising the administration of an autotaxin inhibitor or
pharmaceutical composition
comprising an autotaxin inhibitor. In some instances, a therapeutically
effective amount of time
is the time it takes to decrease or eliminate one or more signs or symptoms of
a disease,
condition or disorder described herein. For example, a therapeutically
effective amount of time
is between 1 day and 1 year. The aforementioned therapeutic dosage examples
are not limiting.
Additional therapeutic regimens are further described elsewhere herein.
-13-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Fibrosis
[0062] In some embodiments, disclosed herein are methods of treating fibrosis
with an
autotaxin inhibitor. In some embodiments, disclosed herein are methods of
preventing fibrosis
with an autotaxin inhibitor. In some embodiments, disclosed herein are methods
of attenuating,
reversing, or inhibiting a sign or symptom of fibrosis.
[0063] In some embodiments, disclosed herein are methods comprising the
administration of an
autotaxin inhibitor to a subject having fibrosis. In some embodiments,
disclosed herein are
methods comprising the administration of an autotaxin inhibitor to a subject
susceptible to
fibrosis.
[0064] In some embodiments, disclosed herein are methods of reducing fibrosis
in a tissue
comprising contacting a fibrotic cell or tissue with an autotaxin inhibitor,
in an amount sufficient
to decrease and/or inhibit the fibrosis. In some embodiments, the fibrosis
includes a fibrotic
condition. In some cases, the amount sufficient to decrease and/or inhibit
fibrosis is a
therapeutically effective amount.
[0065] In some embodiments, reducing fibrosis, or treatment of a fibrotic
condition, includes
reducing or inhibiting one or more of: formation or deposition of
extracellular matrix proteins;
the number of pro-fibrotic cell types (e.g., fibroblast or immune cell
numbers); cellular collagen
or hydroxyproline content within a fibrotic lesion; expression or activity of
a fibrogenic protein;
reducing fibrosis associated with an inflammatory response; or a combination
thereof.
[0066] "Fibrosis," as used herein, refers to the accumulation of extracellular
matrix constituents
that occurs following trauma, inflammation, tissue repair, immunological
reactions, cellular
hyperplasia, and/or neoplasia. Examples of tissue fibrosis include, but are
not limited to,
pulmonary fibrosis, renal fibrosis, cardiac fibrosis, cirrhosis and fibrosis
of the liver, ocular
fibrosis, skin scars and keloids, kidney fibrosis, peritoneal fibrosis,
adhesions, fibromatosis,
atherosclerosis, and amyloidosis.
[0067] In some embodiments, the fibrotic condition is primary fibrosis. In
some embodiments,
the fibrotic condition is idiopathic. In some embodiments, the fibrotic
condition is associated
with (e.g., is secondary to) a disease (e.g., an infectious disease, an
inflammatory disease, an
autoimmune disease, a malignant or cancerous disease, and/or a connective
disease); a toxin; an
insult (e.g., an environmental hazard (e.g., asbestos, coal dust, polycyclic
aromatic
hydrocarbons), cigarette smoking, a wound); a medical treatment (e.g.,
surgical incision,
chemotherapy or radiation), or a combination thereof.
[0068] In some embodiments, the fibrotic condition is a fibrotic condition of
the lung, a fibrotic
condition of the liver, a fibrotic condition of the heart or vasculature, a
fibrotic condition of the
kidney, a fibrotic condition of the skin, a fibrotic condition of the
gastrointestinal tract, a fibrotic
-14-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
condition of the eye, a fibrotic condition of the bone marrow or a
hematopoietic tissue, a fibrotic
condition of the nervous system, fibrotic condition of the peritoneum, or a
combination thereof.
[0069] In some embodiments, the fibrotic condition affects a tissue chosen
from one or more of
muscle, tendon, cartilage, skin (e.g., skin epidermis or endodermis), cardiac
tissue, vascular
tissue (e.g., artery, vein), pancreatic tissue, lung tissue, liver tissue,
kidney tissue, uterine tissue,
ovarian tissue, neural tissue, testicular tissue, peritoneal tissue, colon,
small intestine, biliary
tract, gut, bone marrow, or hematopoietic tissue.
[0070] In some embodiments, the fibrotic condition is a fibrotic condition of
the liver. In
certain embodiments, the fibrotic condition of the liver is chosen from one or
more of: fatty liver
disease, steatosis (e.g., nonalcoholic steatohepatitis (NASH)), cholestatic
liver disease (e.g.,
primary biliary cirrhosis (PBC)), cirrhosis, alcohol-induced liver fibrosis,
biliary duct injury,
biliary fibrosis, cholestasis or cholangiopathies. In some embodiments,
hepatic or liver fibrosis
includes, but is not limited to, hepatic fibrosis associated with alcoholism,
viral infection, e.g.,
hepatitis (e.g., hepatitis C, B or D), autoimmune hepatitis, non-alcoholic
fatty liver disease
(NAFLD), progressive massive fibrosis, and exposure to toxins or irritants
(e.g., alcohol,
pharmaceutical drugs and environmental toxins).
[0071] In some embodiments, described herein are methods for the treatment or
prevention of
fibrosis of the liver in a subject, the methods comprising administration of
an autotaxin inhibitor
to the subject. In some instances, the fibrosis is chronic or acute. In some
cases, administration
of an autotaxin inhibitor results in the attenuation, delay or prevention of a
sign, symptom and/or
complication of liver fibrosis. For example, the method attenuates, delays or
prevents the onset
of cirrhosis, liver failure, portal hypertension, and/or complications
thereof. Exemplary
complications of cirrhosis include ascites, renal failure, hepatic
encephalopathy, and variceal
bleeding. In some cases, administration of an autotaxin inhibitor inhibits the
accumulation of
fibrogenic cells and/or prevents the deposition of extracellular matrix
proteins (e.g., collagen)
within the liver. Autotaxin inhibitors used in a method provided herein are
useful for the
treatment of liver fibrosis caused by any source of liver damage. Examples of
liver fibrosis
causes include, without limitation, viral infection (e.g., hepatitis C),
autoimmune hepatitis,
congenital hepatic fibrosis, bacterial infection (e.g., Brucellosis),
parasitic infection (e.g.,
Echinococcosis), alcohol abuse, primary sclerosing cholangitis, drugs (e.g.,
amiodarone,
chlorpromaxine, isoniazid, methotrexate, methyldopa, oxyphenisatin,
tolbutamide), mechanical
obstruction (e.g., surgery) nonalcoholic steatohepatitis (NASH), and
combinations thereof.
[0072] In some cases, described herein are methods for the reversal of
fibrosis or fibrosis
regression of the liver in a subject, the methods comprising administration of
an autotaxin
inhibitor to the subject.
-15-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0073] In some embodiments, any method provided herein comprising the
administration of an
autotaxin inhibitor, further comprises the administration of one or more
additional fibrosis
therapies. Additional fibrosis therapies include, for example, the
administration of an
angiotensin inhibitor, colchicine, corticosteroid, endothelin inhibitor,
interferon-alpha,
interleukin 10, antioxidant, hepatic stellate cell (HSC) inhibitor, or
combination thereof.
[0074] In some embodiments, the fibrotic condition is a fibrotic condition of
the kidney. In
some embodiments, the fibrotic condition of the kidney is chosen from one or
more of: renal
fibrosis (e.g., chronic kidney fibrosis), nephropathies associated with
injury/fibrosis (e.g.,
chronic nephropathies associated with diabetes (e.g., diabetic nephropathy)),
lupus, scleroderma
of the kidney, glomerular nephritis, focal segmental glomerular sclerosis, IgA
nephropathy renal
fibrosis associated with human chronic kidney disease (CKD), chronic
progressive nephropathy
(CPN), tubulointerstitial fibrosis, ureteral obstruction, chronic uremia,
chronic interstitial
nephritis, radiation nephropathy, glomerulosclerosis, progressive
glomerulonephrosis (PGN),
endothelial/thrombotic microangiopathy injury, HIV-associated nephropathy, or
fibrosis
associated with exposure to a toxin, an irritant, or a chemotherapeutic agent.
[0075] In some embodiments, described herein are methods for the treatment or
prevention of
fibrosis of the kidney in a subject, the methods comprising the administration
of an autotaxin
inhibitor to the subject. In some instances, administration of an autotaxin
inhibitor to the subject
attenuates, delays or inhibits the progression of kidney fibrosis. In some
cases, administration of
an autotaxin inhibitor results in the attenuation, delay or prevention of a
sign, symptom and/or
complication of kidney fibrosis. In some instances, administration of an
autotaxin inhibitor
reduces the accumulation of extracellular matrix or the rate of accumulation
of extracellular
matrix in the kidney. In some cases, kidney fibrosis is the result of acute or
chronic, sustained
injury to kidney tissue. In some cases, kidney fibrosis is characterized by
glomerulosclerosis. In
some cases, kidney fibrosis is characterized by tubulointerstitial fibrosis.
[0076] In some cases, described herein are methods for the reversal of
fibrosis or fibrosis
regression of the kidney in a subject, the methods comprising administration
of an autotaxin
inhibitor to the subject.
[0077] In some embodiments, any method provided herein comprising the
administration of an
autotaxin inhibitor, further comprises the administration of one or more
additional fibrosis
and/or kidney disease therapies. An additional therapy comprises, for example,
inhibiting
profibrotic TGF-P/Smad signaling. As another example, an additional therapy
comprises
increasing the concentration of antifibrotic factors in the kidney, for
example, hepatocyte growth
factor (HGF) and bone morphogenetic protein-7 (BMP-7), which can antagonize
fibrogenic
action of TGF-P. Exemplary fibrosis treatments also include, without
limitation, the
-16-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
administration of one or more of: pirfenidone (5-methyl-N-phenyl-2-(1H)-
pyridone), tranilast,
fluorofenidone, blockade of renin-angiotensin-aldosterone, ACE inhibitors,
ADAM inhibitors,
and an anti-CTGF monoclonal antibody.
[0078] In some embodiments, the fibrotic condition is a fibrotic condition of
the skin. In some
embodiments, the fibrotic condition of the skin is chosen from one or more of:
skin fibrosis,
scleroderma, nephrogenic systemic fibrosis (e.g., resulting after exposure to
gadolinium which is
frequently used as a contrast substance for MRIs in patients with severe
kidney failure), scarring
and keloid.
[0079] In some embodiments, described herein are methods for the treatment or
prevention of
fibrosis of the skin in a subject, the methods comprising the administration
of an autotaxin
inhibitor to the subject. In some instances, administration of an autotaxin
inhibitor to the subject
attenuates, delays or inhibits the progression of skin fibrosis. In some
cases, administration of an
autotaxin inhibitor results in the attenuation, delay or prevention of a sign,
symptom and/or
complication of skin fibrosis. In some instances, administration of an
autotaxin inhibitor reduces
the accumulation of extracellular matrix or the rate of accumulation of
extracellular matrix in the
skin. In some cases, skin fibrosis is the result of acute or chronic,
sustained injury to skin tissue.
[0080] In some embodiments, following administration of an autotaxin inhibitor
to a subject
having skin fibrosis, the dermal thickness of the fibrotic skin decreases. For
example,
administration of an autotaxin inhibitor decreases dermal thickness of skin
fibrosis by at least
about 5%, 10%, 20%, 30%, 40% or 50% as compared to dermal thickness prior to
autotaxin
inhibitor administration.
[0081] In some embodiments, described herein are methods for the reversal of
fibrosis or
fibrosis regression of the skin of a subject, the methods comprising
administration of an
autotaxin inhibitor to the subject.
[0082] In some embodiments, any method provided herein comprising the
administration of an
autotaxin inhibitor, further comprises the administration of one or more
additional fibrosis
and/or skin disease therapies. Skin fibrosis therapies include, without
limitation, administration
of D-penicillamine, bovine collagen, methotrexate, mycophenolate mofetil,
human relaxin,
interferon-alpha, anti-transforming growth factor beta antibodies, or a
combination thereof.
[0083] In some embodiments, the fibrotic condition is a fibrotic condition of
the eye. In some
embodiments, the fibrotic condition of the eye is chosen from one or more of:
glaucoma,
subretinal fibrosis, age-related macular degeneration (ARMD), diabetic
retinopathy (DR),
retinopathy of prematurity (ROP), fibrosis following eye surgery (glaucoma
surgery, cataract
surgery, LASIK surgery).
-17-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0084] In some embodiments, described herein are methods for the treatment or
prevention of
fibrosis of the eye of a subject, the methods comprising the administration of
an autotaxin
inhibitor to the subject. In some instances, administration of an autotaxin
inhibitor to the subject
attenuates, delays or inhibits the progression of ocular fibrosis In some
cases, administration of
an autotaxin inhibitor results in the attenuation, delay or prevention of a
sign, symptom and/or
complication of ocular fibrosis. In some instances, administration of an
autotaxin inhibitor
reduces the accumulation of extracellular matrix or the rate of accumulation
of extracellular
matrix in the eye. In some cases, ocular fibrosis is the result of acute or
chronic, sustained injury
to eye tissue.
[0085] In some embodiments, following administration of an autotaxin inhibitor
to a subject
having ocular fibrosis, the extent of fibrosis of the eye decreases. For
example, administration of
an autotaxin inhibitor decreases fibrosis of the bleb following trabeculectomy
surgery and
reduces the failure rate of the bleb due to fibrosis by about 5%, 10%, 20%,
30%, 40% or 50% as
compared to patients without treatment with an autotaxin inhibitor.
[0086] In some embodiments, described herein are methods for the reversal of
fibrosis or
fibrosis regression of the eye of a subject, the methods comprising
administration of an autotaxin
inhibitor to the subject.
[0087] In some embodiments, any method provided herein comprising the
administration of an
autotaxin inhibitor, further comprises the administration of one or more
additional fibrosis
and/or eye disease therapies. Eye fibrosis therapies include, without
limitation, administration of
mitomycin, 5-fluorouracil, corticosteroids, antibiotics, anti-transforming
growth factor beta
antibodies, or a combination thereof.
[0088] In some embodiments, the fibrotic condition is a fibrotic condition of
the peritoneum. In
some embodiments, described herein are methods for the treatment or prevention
of fibrosis of
the peritoneum a subject, the methods comprising the administration of an
autotaxin inhibitor to
the subject. In some instances, administration of an autotaxin inhibitor to
the subject attenuates,
delays or inhibits the progression of peritoneal fibrosis. In some cases,
administration of an
autotaxin inhibitor results in the attenuation, delay or prevention of a sign,
symptom and/or
complication of peritoneal fibrosis. In some instances, administration of an
autotaxin inhibitor
reduces the accumulation of extracellular matrix or the rate of accumulation
of extracellular
matrix in the peritoneum.
[0089] In some embodiments, fibrosis of the peritoneum is caused by long-term
peritoneal
dialysis. In some embodiments, an autotaxin inhibitor is administered to a
subject having
peritonitis. In some embodiments, peritoneal fibrosis is caused by one or more
of the following
insults: bioincompatible dialysates, peritonitis, uremia, and/or chronic
inflammation.
-18-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[0090] In some cases, described herein are methods for the reversal of
fibrosis or fibrosis
regression of the peritoneum of a subject, the methods comprising
administration of an autotaxin
inhibitor to the subject.
[0091] In some embodiments, any method provided herein comprising the
administration of an
autotaxin inhibitor, further comprises the administration of an anti-
inflammatory agent or an
immunosuppressant.
[0092] In some embodiments, the fibrotic condition is a fibrotic condition of
the
gastrointestinal tract. In some embodiments, the fibrotic condition is chosen
from one or more of
fibrosis associated with scleroderma; radiation induced gut fibrosis; fibrosis
associated with a
foregut inflammatory disorder such as Barrett's esophagus and chronic
gastritis, and/or fibrosis
associated with a hindgut inflammatory disorder, such as inflammatory bowel
disease (MD),
ulcerative colitis and Crohn's disease.
[0093] In some embodiments, the fibrotic condition is a fibrotic condition of
the lung. In some
embodiments, the fibrotic condition of the lung is chosen from one or more of:
pulmonary
fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis
(UIP), interstitial
lung disease, cryptogenic fibrosing alveolitis (CFA), bronchiolitis
obliterans, or bronchiectasis.
In some embodiments, the fibrosis of the lung is secondary to a disease, a
toxin, an insult, a
medical treatment, or a combination thereof. In some embodiments, fibrosis of
the lung is
associated with one or more of: a disease process such as asbestosis and
silicosis; an
occupational hazard; an environmental pollutant; cigarette smoking; an
autoimmune connective
tissue disorders (e.g., rheumatoid arthritis, scleroderma and systemic lupus
erythematosus
(SLE)); a connective tissue disorder such as sarcoidosis; an infectious
disease, e.g., infection,
particularly chronic infection; a medical treatment, including but not limited
to, radiation
therapy, and drug therapy, e.g., chemotherapy (e.g., treatment with as
bleomycin, methotrexate,
amiodarone, busulfan, and/or nitrofurantoin). In some embodiments, the
fibrotic condition of the
lung treated with the methods of the invention is associated with (e.g.,
secondary to) a cancer
treatment, e.g., treatment of a cancer (e.g. squamous cell carcinoma,
testicular cancer, Hodgkin's
disease with bleomycin).
[0094] In some embodiments, the fibrotic condition is a fibrotic condition of
the heart. In
certain embodiments, the fibrotic condition of the heart is myocardial
fibrosis (e.g., myocardial
fibrosis associated with radiation myocarditis, a surgical procedure
complication (e.g.,
myocardial post-operative fibrosis), infectious diseases (e.g., Chagas
disease, bacterial,
trichinosis or fungal myocarditis)); granulomatous, metabolic storage
disorders (e.g.,
cardiomyopathy, hemochromatosis); developmental disorders (e.g., endocardial
fibroelastosis);
arteriosclerotic, or exposure to toxins or irritants (e.g., drug induced
cardiomyopathy, drug
-19-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
induced cardiotoxicity, alcoholic cardiomyopathy, cobalt poisoning or
exposure). In some
embodiments, the myocardial fibrosis is associated with an inflammatory
disorder of cardiac
tissue (e.g., myocardial sarcoidosis).
[0095] In some embodiments, the fibrotic condition is adhesions. In some
embodiments, the
adhesions are chosen from one or more of: abdominal adhesions, peritoneal
adhesions, pelvic
adhesions, pericardial adhesions, peridural adhesions, peritendinous or
adhesive capsulitis.
[0096] In some embodiments, the fibrotic condition is a fibrotic condition of
the eye. In some
embodiments, the fibrotic condition of the eye involves diseases of the
anterior segment of the
eye such as glaucoma and corneal opacification; in some embodiments, the
fibrotic condition of
the eye involves disease of the posterior segment of the eye such as age-
related macular
degeneration, diabetic retinopathy, retinopathy of prematurity and neovascular
glaucoma; in
some embodiments, the fibrotic condition of the eye results from fibrosis
following ocular
surgery.
[0097] In some embodiments, the fibrotic condition is a fibrotic condition of
the bone marrow
or a hematopoietic tissue. In some embodiments, the fibrotic condition of the
bone marrow is an
intrinsic feature of a chronic myeloproliferative neoplasm of the bone marrow,
such as primary
myelofibrosis (also referred to herein as agnogenic myeloid metaplasia or
chronic idiopathic
myelofibrosis). In some embodiments, the bone marrow fibrosis is associated
with (e.g., is
secondary to) a malignant condition or a condition caused by a clonal
proliferative disease. In
some embodiments, the bone marrow fibrosis is associated with a hematologic
disorder (e.g., a
hematologic disorder chosen from one or more of polycythemia vera, essential
thrombocythemia, myelodysplasia, hairy cell leukemia, lymphoma (e.g., Hodgkin
or non-
Hodgkin lymphoma), multiple myeloma or chronic myelogeneous leukemia (CML)).
In some
embodiments, the bone marrow fibrosis is associated with (e.g., secondary to)
a non-
hematologic disorder (e.g., a non-hematologic disorder chosen from solid tumor
metastasis to
bone marrow, an autoimmune disorder (e.g., systemic lupus erythematosus,
scleroderma, mixed
connective tissue disorder, or polymyositis), an infection (e.g.,
tuberculosis), or secondary
hyperparathyroidism associated with vitamin D deficiency.
Colitis
[0098] In some embodiments, disclosed herein are methods of treating colitis
with an autotaxin
inhibitor. In some embodiments, disclosed herein are methods of preventing
colitis with an
autotaxin inhibitor. In some embodiments, disclosed herein are methods of
attenuating,
reversing, or inhibiting a sign or symptom of colitis.
[0099] In some embodiments, disclosed herein are methods comprising the
administration of an
autotaxin inhibitor to a subject having colitis. In some embodiments,
disclosed herein are
-20-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
methods comprising the administration of an autotaxin inhibitor to a subject
susceptible to
colitis.
[00100] In some embodiments, disclosed herein are methods of reducing colitis
in a tissue, the
methods comprising contacting a tissue with an autotaxin inhibitor, in an
amount sufficient to
decrease or inhibit the colitis. In some cases, the amount sufficient to
decrease and/or inhibit
colitis is a therapeutically effective amount.
[00101] "Colitis," as used herein, refers to an inflammation of colon tissue.
Colitis includes
acute, self-limited and chronic colitis. Colitis includes autoimmune colitis,
idiopathic colitis,
latrogenic colitis, vascular disease and infectious colitis. Autoimmune types
of colitis include
inflammatory bowel disease and ulcerative colitis. Idiopathic types of colitis
include
microscopic colitis, lymphocytic colitis and collagenous colitis. Latrogenic
types of colitis
include diversion colitis and chemical colitis. Colitis caused by vascular
disease includes
ischemic colitis. Infectious colitis includes colitis caused by Clostridium
difficile, Shigella
dysenteriae or Shigatoxigenic group of Escherichia coli. In some embodiments,
colitis comprises
ulcerative colitis.
[00102] In some embodiments, disclosed herein are methods of treating colitis
in a subject by
administering an autotaxin inhibitor to the subject. In some embodiments, one
or more signs or
symptoms of colitis are reduced in a subject after administration of an
autotaxin inhibitor. Signs
or symptoms of colitis include, without limitation, abdominal pain, loss of
appetite, fatigue,
diarrhea, mucus in the stool, cramping, urgency, bloating, abdominal
tenderness, weight loss,
changes in bowel habits such as increased frequency, fever, bleeding, bloody
stool, distension,
colonic mucosal erythema and ulcers.
[00103] In some embodiments, following administration of an autotaxin
inhibitor to a subject
having colitis, the subject shows improvement in colitis clinical signs,
symptoms or
histopathology. In one example, following autotaxin inhibitor administration,
colon
inflammation is decreased. In another example, following autotaxin inhibitor
administration,
tissue damage is reversed. In another example, following autotaxin inhibitor
administration,
tissue damage progression is attenuated. In yet another example, following
autotaxin inhibitor
administration, tissue damage is inhibited. Tissue damage can be visualized,
for example, by
histology using a stain such as trichrome stain (Masson).
[00104] In some embodiments, following autotaxin inhibitor administration to a
subject having
ulcerative colitis, ulcer area is decreased, for example, by at least about
1%, 2%, 3%, 4%, 5%,
10%, 15%, 20%, 50%, 90%, 99% of its size prior to autotaxin inhibitor
administration. In
another example, following autotaxin inhibitor administration, ulcer area is
at least about 2-fold,
-21-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
3-fold or 5-fold smaller in size than prior to autotaxin inhibitor
administration or as compared to
administration of a control.
[00105] In some embodiments, following autotaxin inhibitor administration to a
subject having
colitis, the subject's body weight does not increase or decrease by more than
about 2%, 5% or
10%.
[00106] In some embodiments, following autotaxin inhibitor administration to a
subject having
colitis, the subject has an increase in stool consistency.
[00107] In some embodiments, a subject having colitis is treated by
administration of an
autotaxin inhibitor and one or more additional treatments. Addition treatments
include hydration
therapy and administration of a steroid, anti-inflammatory agent, and/or
immunosuppressant. In
one example, the additional treatment is cyclosporin A (CsA). In another
example, the additional
treatment is sulfasalazine.
[00108] In some embodiments, an animal model induced with colitis (e.g., DSS-
induced colitis
or DNBS-induced colitis) is administered (prophylactically or therapeutically)
an autotaxin
inhibitor; wherein following autotaxin inhibitor administration, the animal
exhibits an increase
in colon length, an increase in colon weight, or both an increase in colon
length and weight. For
example, following administration of an autotaxin inhibitor to a mouse or rat
induced with
colitis, the colon length increases by at least about 0.1 cm, 0.2 cm, 0.3 cm,
0.4 cm, 0.5 cm, 1 cm,
2 cm or 3 cm as compared to administration of a vehicle or control. In another
example,
following administration of an autotaxin inhibitor to a mouse or rat induced
with colitis, the
colon weight increases by at least about 0.05g as compared to administration
of a vehicle or
control. In some embodiments, following autotaxin inhibitor treatment of a
mouse or rat induced
with colitis, the mouse or rat has a reduction in ulcer area by at least about
10%, 20%, 50% or
90% as compared to ulcer area prior to administration. In some embodiments,
following
autotaxin inhibitor treatment of a mouse or rat induced with colitis, the
mouse or rat has an ulcer
area less than about 90%, 80%, 70%, 50%, 20%, or 10% of ulcer area size in an
untreated or
control mouse or rat having induced colitis.
Pruritus
[00109] In some embodiments, disclosed herein are methods of treating pruritus
with an
autotaxin inhibitor. In some embodiments, disclosed herein are methods of
preventing pruritus
with an autotaxin inhibitor. In some embodiments, disclosed herein are methods
of attenuating,
reversing or inhibiting at least one sign or symptom of pruritus.
[00110] In some embodiments, disclosed herein are methods comprising the
administration of an
autotaxin inhibitor to a subject having pruritus. In some embodiments,
disclosed herein are
-22-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
methods comprising the administration of an autotaxin inhibitor to a subject
susceptible to
pruritus.
[00111] In some embodiments, disclosed herein are methods of reducing pruritus
in a tissue, the
methods comprising contacting a tissue with an autotaxin inhibitor, in an
amount sufficient to
decrease or inhibit the pruritus.
[00112] Pruritus is a condition involving localized or general itching that is
a common and
distressing symptom in a variety of diseases. Although usually occurring in
the skin, pruritus can
also occur in non-cutaneous sites such as mucous membranes. Pruritus is a
frequent
manifestation of localized skin disorders caused by hypersensitivity reactions
such as allergic
reactions to insect bites or to environmental allergens, urticaria, dermatoses
of fungal and
bacterial origins, ectoparasite infections, and hemorrhoids. In some
embodiments, disclosed
herein are method of treating pruritus caused by systemic diseases, including,
for example,
hypothyroidism, thyrotoxicosis, mucocandiasis in diabetes mellitus, and
Hodgkin's disease. In
some embodiments, disclosed herein are methods of treating bouts of persistent
or recurrent
pruritus associated with many systemic diseases and skin disorders. Pruritus
includes, without
limitation, renal pruritus, cholestatic pruritus, hematologic pruritus and
endocrine pruritus.
[00113] In some embodiments, disclosed herein are methods of treating pruritus
associated with
liver diseases and intrahepatic or posthepatic cholestasis. Hepatic diseases
leading to pruritus
include primary biliary cirrhosis, B and C viral hepatitis, primary sclerosing
cholangitis,
carcinoma of bile ducts, alcoholic cirrhosis, autoimmune hepatitis and others.
[00114] In some embodiments, disclosed herein are methods of treating pruritus
arising from a
variety of causes such as xerosis, skin conditions (such as psoriasis, eczema,
sunburn, athlete's
foot), insect bites, poisonous plants (such as poison ivy, poison oak, poison
sumac), Hodgkin's
disease, jaundice, polycythemia, scabies, lice, worms, thyroid illness,
diabetes mellitus,
dandruff, iron deficiency anemia, parasitic infections, medications,
cholestasis, pruritus related
to pregnancy, HIV infection, other causes of itching or pruritus, or
combinations thereof.
[00115] In some embodiments, disclosed herein are methods of treating or
preventing pruritus in
a subject in need thereof, the methods comprising the administration of an
autotaxin inhibitor to
the subject. In some embodiments, administration of an autotaxin inhibitor
reduces pruritus by at
least about 10%, 20%, 30%, 50%, or 90%.
[00116] In some embodiments, following autotaxin inhibitor administration to a
subject having
pruritus, the subject has a decrease in total number of scratch movements as
compared to scratch
number before autotaxin inhibitor administration. For example, scratch
movements decrease by
at least about 10%, 20%, 50%, or 90%. In some embodiments, pruritus is
prevented or treated by
the administration of an autotaxin inhibitor and one or more additional
pruritus therapies or
-23-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
therapeutic agents. Pruritus therapies include, without limitation, use of
skin creams and lotions
to prevent skin dryness and use of an antihistamine, steroid or antibiotic.
Pruritus therapeutic
agents include, doxepin, mirtazapine, gabapentin, aprepitant, capsaicin,
tacrolimus, gamma
linolenic acid, cholestyramine, rifampin, an opioid antagonist, ondansetron,
and activated
charcoal.
[00117] In some embodiments, described herein are methods for the prevention
or treatment of
renal pruritus in a subject, the methods comprising administration of an
autotaxin inhibitor to the
subject. In some embodiments, described herein are methods for the prevention
or treatment of
cholestatic pruritus in a subject, the methods comprising administration of an
autotaxin inhibitor
to the subject. In some embodiments, described herein are methods for the
prevention or
treatment of hematologic pruritus in a subject, the methods comprising
administration of an
autotaxin inhibitor to the subject. In some embodiments, described herein are
methods for the
prevention or treatment of endocrine pruritus in a subject, the methods
comprising
administration of an autotaxin inhibitor to the subject.
Neurological Disease
[00118] In some embodiments, disclosed herein are methods of treating a
neurological disease,
condition or disorder with an autotaxin inhibitor. In some embodiments,
disclosed herein are
methods of preventing a neurological disease, condition or disorder with an
autotaxin inhibitor.
In some embodiments, disclosed herein are methods of attenuating, reversing or
inhibiting a sign
or symptom of a neurological disease, condition or disorder.
[00119] In some embodiments, disclosed herein are methods comprising the
administration of an
autotaxin inhibitor to a subject having a neurological disease, condition or
disorder. In some
embodiments, disclosed herein are methods comprising the administration of an
autotaxin
inhibitor to a subject susceptible to having a neurological disease, condition
or disorder.
[00120] In some embodiments, the neurological disease is multiple sclerosis.
In some instances,
the neurological disease is caused by a genetic disorder. In some instances,
the neurological
disease is developmental, for example, spina bifida. In some instances, the
neurological disease
is a degenerative disease, for example, Parkinson's disease or Alzheimer's
disease. In some
instances, the neurological disease results from a stroke. Neurological
diseases, conditions and
disorders or characteristics of neurological diseases, conditions and
disorders suitable for
treatment with an ATX inhibitor include, without limitation, Amyotrophic
lateral sclerosis
(ALS), Arteriovenous malformations (AVMs), brain aneurysm, brain tumor, Dural
arteriovenous fistulae, epilepsy, headache, memory disorders, Parkinson's
disease, peripheral
neuropathy, post-herpefic neuralgia, spinal cord tumor and stroke. In certain
instances, autotaxin
-24-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
activity is increased in CSF (cerebrospinal fluid) and serum of
relapse/remitting multiple
sclerosis patients compared to patients with other neurological diseases.
[00121] In some embodiments, the mutiple sclerosis is relapsing-remitting
multiple sclerosis,
relapsing multiple sclerosis, primary-progressive multiple sclerosis, or
secondary-progressive
multiple sclerosis.
[00122] In some embodiments, the mutiple sclerosis is relapsing-remitting
multiple sclerosis
(RRMS). People with this type of MS have clearly defined attacks of worsening
neurologic
function. These attacks are followed by partial or complete recovery periods
called remissions.
During remission, symptoms often improve and there is no apparent worsening or
progression of
disease. About 85% of people with MS are initially diagnosed with RRMS.
[00123] In some embodiments, the mutiple sclerosis is relapsing multiple
sclerosis (RMS). RMS
includes several forms of MS that have relapsing features, including relapsing-
remitting MS,
progressive-relapsing MS, and secondary-progressive MS.
[00124] In some embodiments, the mutiple sclerosis is primary-progressive
multiple sclerosis
(PPMS). This form has a steady worsening of neurologic functioning, but
without any distinct
relapses or periods of remission. A person's rate of progression may vary over
time - with
occasional plateaus or temporary improvements - but the progression is
continuous. 10% of
people are diagnosed with this type of MS.
[00125] In some embodiments, the mutiple sclerosis is secondary-progressive
multiple sclerosis
(SPMS). Following an initial period of relapsing-remitting MS (RRMS), many
people transition
to SPMS. The disease begins to worsen more steadily, with or without
occasional relapses,
remissions, or plateaus.
[00126] In some embodiments, disclosed herein are methods of treating a
nervous system injury
in a subject, for example, injury to the brain, spinal cord and/or nerve
tissue, the methods
comprising the administration of an autotaxin inhibitor to the subject.
[00127] In some embodiments, disclosed herein are methods for the treatment of
a cancer
affecting the nervous system of a subject, the methods comprising the
administration of an
autotaxin inhibitor to the subject. In some examples, the cancer is brain
cancer.
[00128] In some embodiments, disclosed herein are methods of treating injury-
induced
demyelination in a subject, the methods comprising the administration of an
autotaxin inhibitor
to the subject.
[00129] In some embodiments, disclosed herein are methods of treating an
infection of the
nervous system in a subject, the methods comprising the administration of an
autotaxin inhibitor
to the subject. In some examples, the nervous system infection includes
meningitis.
-25-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00130] In some embodiments, disclosed herein are methods of treating a
neurological disease,
disorder or condition in a subject, the methods comprising administration of
an autotaxin
inhibitor to the subject in need thereof. In some embodiments, disclosed
herein are methods of
treating multiple sclerosis in a subject, the methods comprising administering
an autotaxin
inhibitor to the subject. In some embodiments, treatment includes the
inhibition or reversal of
demyelination. Inhibition of demyelination includes a decrease in rate of
demyelination as
compared to the absence of autotaxin inhibitor treatment, where a decrease in
rate is a decrease
of at least 5%, 10%, 20%, 30%, 40%, 50%, 80% or 90% demyelination. In some
instances,
administration of an autotaxin inhibitor prevents, delays and and/or
attenuates demyelination.
[00131] In some embodiments, disclosed herein are methods of preventing or
treating a sign,
symptom and/or complication of a neurological disease, disorder or condition,
the methods
comprising administration of an autotaxin inhibitor. In some embodiments,
disclosed herein are
methods of preventing or treating a sign, symptom and/or complication of
multiple sclerosis in a
subject, the methods comprising administering an autotaxin inhibitor to the
subject. Signs and
symptoms of multiple sclerosis include, without limitation, numbness or
weakness in one or
more limbs, partial or complete loss of vision, double vision, blurring of
vision, tingling
sensation, electric-shock sensations, tremors, lack of coordination, unsteady
gait, slurred speech,
fatigue, dizziness, and changes in bowel and/or bladder function. Examples of
multiple sclerosis
complications include, without limitation, muscle stiffness, muscle spasms,
paralysis, mental
changes such as forgetfulness and mood swings, depression and epilepsy.
[00132] In some embodiments, disclosed herein are methods of decreasing the
frequency,
severity and/or duration of a relapse of a neurological disease, disorder or
condition, the
methods comprising administration of an autotaxin inhibitor. In some
embodiments, disclosed
herein are methods of decreasing the frequency, severity and/or duration of a
relapse of multiple
sclerosis, the methods comprising administration of an autotaxin inhibitor. In
some instances,
administration of an autotaxin inhibitor decreases or stops the progression of
one or more
symptoms in a patient having multiple sclerosis. In some instances,
administration of an
autotaxin inhibitor prevents or delays the onset of multiple sclerosis
symptoms.
[00133] In some instances, a neurological disorder such as multiple sclerosis
is treated with a
combination of an autotaxin inhibitor and one or more additional treatments.
Addition
treatments include, without limitation, plasma exchange, physical therapy,
muscle relaxants,
exercise, rest, and administration of one or more of the following:
corticosteroids, beta
interferons, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide,
natalizumab,
mitoxantrone; and combinations thereof.
-26-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00134] Neurological diseases, conditions and disorders or characteristics of
neurological
diseases, conditions and disorders suitable for treatment with an autotaxin
inhibitor include,
without limitation, absence of the septum pellucidum, acid lipase disease,
acid maltase
deficiency, acquired epileptiform aphasia, acute disseminated
encephalomyelitis, ADHD, Adie's
pupil, Adie's syndrome, adrenoleukodystrophy, agenesis of the corpus callosum,
agnosia, aicardi
syndrome, neurological complications from AIDS, Alexander disease, Alpers'
disease,
alternating hemiplegia, Alzheimer's disease, amyotrophic lateral sclerosis
(ALS), anencephaly,
aneurysm, angelman syndrome, angiomatosis, anoxia, antiphospholipid syndrome,
aphasia,
apraxia, arachnoid cysts, arachnoiditis, Arnold-Chiari malformation,
arteriovenous
malformation, Asperger syndrome, ataxia, stroke, Barth syndrome, batten
disease, Becker's
myotonia, Behcet's disease, Bell's palsy, benign essential blepharospasm,
benign focal
amyotrophy, benign intracranial hypertension, Bernhardt-Roth syndrome,
Binswanger's disease,
blepharospasm, Bloch-Sulzberger syndrome, brachial plexus injuries, Bradbury-
Eggleston
syndrome, brain aneurysm, brain injury, Brown-Sequard syndrome, CADASIL,
canavan
disease, causalgia, cavernomas, cavernous angioma, cavernous malformation,
central cord
syndrome, central pain syndrome, central pontine myelinolysis, cephalic
disorders, ceramidase
deficiency, cerebellar degeneration, cerebellar hypoplasia, cerebral
aneurysms, cerebral
arteriosclerosis, cerebral atrophy, cerebral beriberi, cerebral cavernous
malformation, cerebral
gigantism, cerebral hypoxia, cerebral palsy, cerebro-oculo-facio-skeletal
syndrome, chiari
malformation, chorea, choreoacanthocytosis, chronic inflammatory demyelinating
polyneuropathy (CIDP), chronic orthostatic intolerance, cockayne syndrome type
II, Coffin
Lowry syndrome, colpocephaly, coma, complex regional pain syndrome, congenital
facial
diplegia, congenital myasthenia, congenital myopathy, congenital vascular
cavernous
malformations, corticobasal degeneration, cranial arteritis, craniosynostosis,
cree encephalitis,
Creutzfeldt-Jakob disease, cumulative trauma disorders, Cushing's syndrome,
cytomegalic
inclusion body disease, cytomegalovirus infection, Dandy-Walker syndrome,
Dawson disease,
De Morsier's syndrome, Dejerine-Klumpke palsy, dementia, dentate cerebellar
ataxia,
dentatorubral atrophy, dermatomyositis, developmental dyspraxia, Devic's
syndrome, diabetic
neuropathy, diffuse sclerosis, dravet syndrome, dysautonomia, dysgraphia,
dysphagia,
dyspraxia, dyssynergia cerebellaris, dystonias, bulbospinal muscular atrophy,
encephalopathy,
empty sella syndrome, encephalitis, encephaloceles, encephalotrigeminal
angiomatosis,
epilepsy, Erb-Duchenne and Dejerine-Klumpke Palsies, Erb's palsy, extrapontine
myelinolysis,
fabry disease, Fahr's syndrome, familial dysautonomia, familial hemangioma,
familial idiopathic
basal ganglia calcification, familial periodic paralyses, familial spastic
paralysis, Farber's
-27-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Disease, febrile seizures, fibromuscular dysplasia, fisher syndrome,
Friedreich's ataxia, and
frontotemporal dementia.
Inflammation and Inflammatory Disorders
[00135] In some embodiments, disclosed herein are methods of treating an
inflammatory
condition, disease, or disorder with an autotaxin inhibitor. In some
embodiments, disclosed
herein are methods of reducing inflammation in a tissue of a subject, the
method comprising
administering to the subject an autotaxin inhibitor. In some instances, the
tissue is colon tissue.
[00136] As used in the present disclosure, "inflammation" refers to the well-
known localized
response to various types of injury or infection, which is characterized by
redness, heat,
swelling, and pain, and often also including dysfunction or reduced mobility.
[00137] The methods described herein, in some embodiments, include methods for
the
treatment, reduction of risk, and delaying onset of other inflammatory
conditions or diseases
with an autotaxin inhibitor, such as (a) ocular inflammation associated with
corneal ulcers, giant
papillary conjunctivitis, blepharitis, chelazion, uveitis, dry eye, post-
surgical inflammation, and
contact lens associated inflammation; (b) allergic diseases such as hay fever,
rhinitis, seasonal
allergic conjunctivitis, vernal conjunctivitis and other eosinophil-mediated
conditions; (c) skin
diseases such as psoriasis, contact dermatitis, eczema, infectious skin
ulcers, open wounds, and
cellulitis; (d) infectious diseases including sepsis, septic shock,
encephalitis, infectious arthritis,
endotoxic shock, gram negative shock, Jarisch-Herxheimer reaction, shingles,
toxic shock,
cerebral malaria, bacterial meningitis, acute respiratory distress syndrome
(ARDS), lyme
disease, and HIV infection; (e) wasting diseases such as cachexia secondary to
cancer and HIV;
(f) inflammation due to organ, tissue or cell transplantation (e.g., bone
marrow, cornea, kidney,
lung, liver, heart, skin, pancreatic islets) including transplant rejection,
and graft versus host
disease; (g) adverse effects from drug therapy, including adverse effects from
amphotericin B
treatment, adverse effects from immunosuppressive therapy, e.g., interleukin-2
treatment,
adverse effects from OKT3 treatment, adverse effects from GM-CSF treatment,
adverse effects
of cyclosporine treatment, and adverse effects of aminoglycoside treatment,
stomatitis, and
mucositis due to immunosuppression; (h) cardiovascular conditions including
circulatory
diseases induced or exasperated by an inflammatory response, such as ischemia,
atherosclerosis,
peripheral vascular disease, restenosis following angioplasty, inflammatory
aortic aneurysm,
vasculitis, stroke, spinal cord injury, congestive heart failure, hemorrhagic
shock,
ischemia/reperfusion injury, vasospasm following subarachnoid hemorrhage,
vasospasm
following cerebrovascular accident, pleuritis, pericarditis, and the
cardiovascular complications
of diabetes; (i) dialysis, including pericarditis, due to peritoneal dialysis;
(j) gout; and (k)
chemical or thermal-induced inflammation due to burns, acid, alkali and the
like.
-28-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Autoimmune Diseases
[00138] The methods described herein, in some embodiments, include methods for
the
treatment, reduction of risk, and delaying of onset of an autoimmune disease
or disorder with an
autotaxin inhibitor. Examples of autoimmune diseases include, but are not
limited to, Alopecia
Areata, Lupus, Ankylosing Spondylitis, Meniere's Disease, Antiphospholipid
Syndrome, Mixed
Connective Tissue Disease, Autoimmune Addison's Disease, Autoimmune Hemolytic
Anemia,
Myasthenia Gravis, Autoimmune Hepatitis, Pemphigus Vulgaris, Behcet's Disease,
Pernicious
Anemia, Bullous Pemphigoid, Polyarthritis Nodosa, Cardiomyopathy,
Polychondritis, Celiac
Sprue-Dermatitis, Polyglandular Syndromes, Chronic Fatigue Syndrome (CFIDS),
Polymyalgia
Rheumatica, Chronic Inflammatory Demyelinating, Polymyositis and
Dermatomyositis, Chronic
Inflammatory Polyneuropathy, Primary Agammaglobulinemia, Churg-Strauss
Syndrome,
Primary Biliary Cirrhosis, Cicatricial Pemphigoid, Psoriasis, CREST Syndrome,
Raynaud's
Phenomenon, Cold Agglutinin Disease, Reiter's Syndrome, Crohn's Disease,
Rheumatic Fever,
Discoid Lupus, Multiple Sclerosis, Rheumatoid Arthritis, Essential Mixed,
Cryoglobulinemia
Sarcoidosis, Fibromyalgia, Scleroderma, Grave's Disease, Sjogren's Syndrome,
Guillain-Barre,
Stiff-Man Syndrome, Hashimoto's Thyroiditis, Takayasu Arteritis, Idiopathic
Pulmonary
Fibrosis, Temporal Arteritis/Giant Cell Arteritis, Idiopathic Thrombocytopenia
Purpura (ITP),
Ulcerative Colitis, IgA Nephropathy, Uveitis, Insulin Dependent Diabetes (Type
I), Diabetes
(Type II), Vasculitis, Lichen Planus, and Vitiligo.
[00139] In some embodiments, the methods for the treatment, reduction of risk,
and delaying the
onset of an autoimmune disease or disorder further comprise the administration
of an
immunosuppressant. Immunosuppressants include, without limitation,
glucocorticoids,
cytostatics, antibodies and drugs that act on immunophilins. Examples of
glucocorticoids
include cortisol, cortisone, prednisone, prednisolone, methylprednisolone,
dexamethasone,
betamethasone, triamcinolone, beclometasone, fludrocortisone,
deoxycorticosterone, and
aldosterone. Examples of cytostatics include alkylating agents (e.g., nitrogen
mustards such as
cyclophosphamide, nitrosoureas, platinum compounds) and antimetabolites (e.g.,
folic acid
analogues such as methotrexate, purine analogues such as azathioprine and
mercaptopurine,
pyrimidine analogues such as fluorouracil, protein synthesis inhibitors).
Examples of drugs for
use in the methods described include ciclosporin, tacrolimus, sirolimus,
interferons, opioids,
TNF binding proteins, mycophenolate, and fingolimod. Examples of antibodies
useful for co-
administration with an autotaxin inhibitor in a method described herein
include Antithymocyte
globulin, 1D09C3, Adalimumab/D2E7 (Humira; Trudexa), Afelimomab,
Afutuzumab/GA101
(type II), Alemtuzumab/Campath-1H (MabCampath), Apolizumab/HulD10, Aselizumab,
Atlizumab, Basiliximab (Simulect), Bectumomab/IIVIMU-LL2, Belimumab (Benlysta,
-29-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
LymphoStat-B), Bertilimumab, BL22/CAT-3888, Brentuximab/cAC10/SGN-35,
Briakinumab/ABT-874, Canakinumab/ACZ885 (Ilaris), Certolizumab pegol/CDP870
(Cimzia),
Clenoliximab, Dacetuzumab/SGN-40, Daclizumab (Zenapax), Eculizumab/5G1.1
(Soliris),
Efalizumab (Raptiva, formerly Xanelim), Epratuzumab/hLL2/LVIMU-102
(LymphocydeC),
Fontolizumab, Fresolimumab/GC-1008, Galiximab/IDEC-114, Gavilimomab/ABX-CBL,
Gemtuzumab, Golimumab/CNT0148 (Simponi), HL2434P (IMMU-114), Ibritumomab
tiuxetan
(MXDPTA)/IDEC Y2B8 (Zevalin), Infliximab/chimeric A2 (cA2) (Remicade),
Inolimomab/BT563, Inotuzumab, Keliximab/IDEC CE9.1, Lerdelimumab/CAT-152,
Lintuzumab/HuM195 (Zamyl), LMB-2, Lorvotuzumab mertansine, Lumiliximab/IDEC-
152,
Lym-1 (Oncolym), MDX-060, Mepolizumab/SB-240563, Metelimumab/CAT-192,
Mogamulizumab/KW-0761/AMG-761, Moxetumomab pasudotox/CAT-8015/HA22,
Muromonab-CD3 (Orthoclone OKT3), Natalizumab (Tysabri, Antegren),
Nerelimomab/CDP571, Ocrelizumab/PRO70769 (type I), Odulimomab,
Ofatumumab/2F2/HuMax-CD20 (Arzerra) (type I), Omalizumab (Xolair),
Otelixizumab/TRX4,
Pascolizumab/SB 240683, Reslizumab/SCH 55700 (Cinquil), Rituximab/chimeric 2B8
(IDEC-
C2B8) (Rituxan, MabThera) (type I), Ruplizumab (Antova), SAR-3419,
Secukinumab/AIN-457,
SGN30, Siplizumab/MEDI-507, Teplizumab/MGA031/hOKT371(Ala-Ala), Tocilizumab
(Actemra), Tositumomab (type II), Ustekinumab/CNTO 1275 (Stelara),
Vedolizumab/MNL-
0002, Veltuzumab/IMMU-106/hA20 (type I), Visilizumab (Nuvion),
Zanolimumab/HuMax-
CD4, Zolimomab aritox/H65, Abatacept/CTLA4-Ig/BMS-188667 (Orencia),
Belatacept/LEA29Y, Atacicept/BLyS/APREL-Ig, Etanercept/TNFR-Ig (Enbrel),
Pegsunercept/pegylated TNFR-Ig, Alefacept (Amevive), and Rilonacept
(Arcalyst).
Immunosuppressive antibodies include antibodies that target complement-
dependent proteins
and interleukins.
Angiogenesis
[00140] In some embodiments, described herein are methods for the treatment or
prevention of
angiogenesis in a subject comprising the administration of an autotaxin
inhibitor to the subject.
Angiogenesis includes sprouting angiogenesis and intussusceptive angiogenesis.
In some
instances, the methods further comprise the administration of an angiogenesis
inhibitor, for
example, a VEGF inhibitor (bevacizumab), sorafenib sunitinib, pazopanib,
everolimus, or a
combination thereof.
Cancer
[00141] Autotaxin has been demonstrated to increase cell motility,
neovascularization,
proliferation and aggressiveness of tumors. It is upregulated in numerous
tumor lineages, such as
breast, renal, liver, glioblastoma, ovarian and prostate cancer.
-30-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00142] In some embodiments, disclosed herein are methods of treating cancer
with an autotaxin
inhibitor.
[00143] Autotaxin is a prometastatic enzyme initially isolated from the
conditioned medium of
human melanoma cells In addition, autotaxin overexpression is frequently
observed in
malignant tumor tissues such as breast cancer, renal cancer, Hodgkin lymphoma,
hepatocellular
carcinoma, pancreatic cancer and glioblastoma. LPA also contributes to
tumorigenesis by
increasing motility and invasiveness of cells
[00144] The term "cancer" as used herein, refers to an abnormal growth of
cells that tend to
proliferate in an uncontrolled way and, in some cases, to metastasize
(spread). Types of cancer
include, but are not limited to, solid tumors (such as those of the bladder,
bowel, brain, breast,
endometrium, heart, kidney, lung, liver, uterus, lymphatic tissue (lymphoma),
ovary, pancreas or
other endocrine organ (thyroid), prostate, skin (melanoma or basal cell
cancer) or hematological
tumors (such as the leukemias and lymphomas) at any stage of the disease with
or without
metastases.
[00145] Non- limiting examples of cancers include, acute lymphoblastic
leukemia, acute
myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer,
astrocytomas,
atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer,
bladder cancer, bone
cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma,
brain tumors,
brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt
lymphoma, cervical
cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon
cancer, colorectal
cancer, craniopharyngioma, cutaneous T-Cell lymphoma, desmoid tumors,
embryonal tumors,
endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, ewing
sarcoma
family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric
(stomach) cancer,
gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST),
gastrointestinal stromal
cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck
cancer, hepatocellular
(liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma,
islet cell
tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell
histiocytosis,
laryngeal cancer, leukemia, Acute lymphoblastic leukemia, acute myeloid
leukemia, chronic
lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, liver
cancer, non-
small cell lung cancer, small cell lung cancer, Burkitt lymphoma, cutaneous T-
cell lymphoma,
Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom
macroglobulinemia,
medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer,
chronic
myelogenous leukemia, myeloid leukemia, multiple myeloma, nasopharyngeal
cancer,
neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer,
oropharyngeal
cancer, osteosarcoma, malignant fibrous histiocytoma of bone, ovarian cancer,
ovarian epithelial
-31-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
cancer, ovarian germ cell tumor, ovarian low malignant potential tumor,
pancreatic cancer,
papillomatosis, parathyroid cancer, penile cancer, pharyngeal cancer, pineal
parenchymal tumors
of intermediate differentiation, pineoblastoma and supratentorial primitive
neuroectodermal
tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma,
pleuropulmonary blastoma,
primary central nervous system lymphoma, prostate cancer, rectal cancer, renal
cell (kidney)
cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma,
Sezary syndrome,
skin cancer, small cell lung cancer, small intestine cancer, soft tissue
sarcoma, squamous cell
carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal
tumors, T-cell
lymphoma, testicular cancer, throat cancer, thymoma and thymic carcinoma,
thyroid cancer,
urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar
cancer, Waldenstrom
macroglobulinemia, and Wilms tumor.
[00146] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in the treatment of ovarian cancer, prostate cancer, breast
cancer, lung cancer,
melanoma, head and neck cancer, bowel cancer (colorectal cancer), thyroid
cancer,
glioblastoma, follicular lymphoma, renal cancer, Hodgkin lymphoma,
hepatocellular carcinoma,
pancreatic cancer or melanoma.
[00147] In some embodiments, an autotaxin inhibitor disclosed herein, or a
pharmaceutically
acceptable salt thereof, is used in the treatment of bone metastases.
[00148] In some embodiments, an autotaxin inhibitor disclosed herein, or a
pharmaceutically
acceptable salt thereof, is used in the treatment of oral cancer, prostate
cancer, rectal cancer,
non-small cell lung cancer, lip and oral cavity cancer, liver cancer, lung
cancer, anal cancer,
kidney cancer, vulvar cancer, breast cancer, oropharyngeal cancer, nasal
cavity and paranasal
sinus cancer, nasopharyngeal cancer, urethra cancer, small intestine cancer,
bile duct cancer,
bladder cancer, ovarian cancer, laryngeal cancer, hypopharyngeal cancer,
gallbladder cancer,
colon cancer, colorectal cancer, head and neck cancer, parathyroid cancer,
penile cancer, vaginal
cancer, thyroid cancer, pancreatic cancer, esophageal cancer, Hodgkin's
lymphoma, leukemia-
related disorders, mycosis fungoides, or myelodysplastic syndrome.
[00149] In some embodiments, an autotaxin inhibitor disclosed herein, or a
pharmaceutically
acceptable salt thereof, is used in the treatment of non-small cell lung
cancer, pancreatic cancer,
breast cancer, ovarian cancer, colorectal cancer, or head and neck cancer.
[00150] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in the treatment of a carcinoma, a tumor, a neoplasm, a
lymphoma, a melanoma,
a glioma, a sarcoma, or a blastoma.
[00151] In some embodiments, the carcinoma is selected from the group
consisting of:
carcinoma, adenocarcinoma, adenoid cystic carcinoma, adenosquamous carcinoma,
-32-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
adrenocortical carcinoma, well differentiated carcinoma, squamous cell
carcinoma, serous
carcinoma, small cell carcinoma, invasive squamous cell carcinoma, large cell
carcinoma, islet
cell carcinoma, oat cell carcinoma, squamous carcinoma, undifferentiatied
carcinoma, verrucous
carcinoma, renal cell carcinoma, papillary serous adenocarcinoma, merkel cell
carcinoma,
hepatocellular carcinoma, soft tissue carcinomas, bronchial gland carcinomas,
capillary
carcinoma, bartholin gland carcinoma, basal cell carcinoma, carcinosarcoma,
papilloma/carcinoma, clear cell carcinoma, endometrioid adenocarcinoma,
mesothelial,
metastatic carcinoma, mucoepidermoid carcinoma, cholangiocarcinoma, actinic
keratoses,
cystadenoma, and hepatic adenomatosis.
[00152] In some embodiments, the tumor is selected from the group consisting
of: astrocytic
tumors, malignant mesothelial tumors, ovarian germ cell tumor, supratentorial
primitive
neuroectodermal tumors, Wilm's tumor, pituitary tumors, extragonadal germ cell
tumor,
gastrinoma, germ cell tumors, gestational trophoblastic tumor, brain tumors,
pineal and
supratentorial primitive neuroectodermal tumors, pituitary tumor, somatostatin-
secreting tumor,
endodermal sinus tumor, carcinoids, central cerebral astrocytoma, glucagonoma,
hepatic
adenoma, insulinoma, medulloepithelioma, plasmacytoma, vipoma, and
pheochromocytoma.
[00153] In some embodiments, the neoplasm is selected from the group
consisting of:
intaepithelial neoplasia, multiple myeloma/plasma cell neoplasm, plasma cell
neoplasm,
interepithelial squamous cell neoplasia, endometrial hyperplasia, focal
nodular hyperplasia,
hemangioendothelioma, lymphangioleio myomatosis and malignant thymoma.
[00154] In some embodiments, the lymphoma is selected from the group
consisting of: nervous
system lymphoma, AIDS-related lymphoma, cutaneous T-cell lymphoma, non-
Hodgkin's
lymphoma, mantle cell lymphoma, follicular lymphoma and Waldenstrom's
macroglobulinemia.
[00155] In some embodiments, the melanoma is selected from the group
consisting of: acral
lentiginous melanoma, superficial spreading melanoma, uveal melanoma, lentigo
maligna
melanomas, melanoma, intraocular melanoma, adenocarcinoma nodular melanoma,
and
hemangioma.
[00156] In some embodiments, the sarcoma is selected from the group consisting
of: adenomas,
adenosarcoma, chondosarcoma, endometrial stromal sarcoma, Ewing's sarcoma,
Kaposi's
sarcoma, leiomyosarcoma, rhabdomyosarcoma, sarcoma, uterine sarcoma,
osteosarcoma, and
pseudosarcoma.
[00157] In some embodiments, the glioma is selected from the group consisting
of: glioma,
brain stem glioma, and hypothalamic and visual pathway glioma.
-33-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00158] In some embodiments, the blastoma is selected from the group
consisting of: pulmonary
blastoma, pleuropulmonary blastoma, retinoblastoma, neuroblastoma,
medulloblastoma,
glioblastoma, and hemangiblastomas.
Airway diseases
[00159] Inflammatory conditions, diseases, and disorders, which can be treated
with an
autotaxin inhibitor, include airway diseases comprising pulmonary
inflammation, such as
chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma.
COPD is comprised
primarily of two related diseases: chronic bronchitis and emphysema. In both
diseases, there is
chronic obstruction of the flow of air through the airways and out of the
lungs, and the
obstruction generally is permanent and progressive over time.
[00160] Asthma is a chronic disease of the airways of the lungs, characterized
by inflammation
and paradoxical narrowing of the bronchi. Asthma includes asthmatic conditions
mediated via
T-cell action, including extrinsic asthma (allergic asthma), intrinsic asthma
(non-allergic
asthma), mixed asthma (extrinsic and intrinsic asthma), occupational asthma
induced by agents
such as toluene diisocyanate, polyvinyl chloride, phthalic anhydride,
trimellitic anhydride,
plicatic acid (Western Red Cedar trees) or metal salts such as platinum or
nickel), drug-induced
asthma (including aspirin-induced asthma or asthma induced by non-steroidal
anti-inflammatory
drugs (NSAlDs)), exercise-induced asthma, and cough variant asthma. In some
embodiments,
the asthma is an allergic or non-allergic asthmatic condition mediated by T-
cell function.
[00161] In some embodiments, disclosed herein are methods of treating asthma
with an
autotaxin inhibitor. In an asthmatic individual, the release of normal repair
mediators, including
LPA, is exaggerated or the actions of the repair mediators are inappropriately
prolonged leading
to inappropriate airway remodeling. Major structural features of the remodeled
airway observed
in asthma include a thickened lamina reticularis (the basement membrane-like
structure just
beneath the airway epithelial cells), increased numbers and activation of
myofibroblasts,
thickening of the smooth muscle layer, increased numbers of mucus glands and
mucus
secretions, and alterations in the connective tissue and capillary bed
throughout the airway wall.
In some embodiments, autotaxin and/or LPA contribute to these structural
changes in the
airway. In some embodiments, autotaxin and/or LPA are involved in acute airway
hyperresponsiveness in asthma. The lumen of the remodeled asthmatic airway is
narrower due to
the thickening of the airway wall, thus decreasing airflow. In some
embodiments, LPA
contributes to the long-term structural remodeling and the acute
hyperresponsiveness of the
asthmatic airway. In some embodiments, LPA contributes to the hyper-
responsiveness that is a
primary feature of acute exacerbations of asthma.
-34-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00162] In some embodiments, disclosed herein are methods of treating or
preventing COPD
with an autotaxin inhibitor. The term "chronic obstructive pulmonary disease
(COPD)" refers to
a group of lung diseases, including chronic bronchitis, emphysema and
obliterative bronchiolitis.
The most common of these diseases are chronic bronchitis and emphysema.
Although a person
with COPD may have either chronic bronchitis or emphysema, he or she will
often have a
mixture of the symptoms of these two conditions. Although emphysema usually
results from
damage to the lungs caused by environmental insult, usually as a result of
long-term smoking,
emphysema may also be caused by congenital absence of al-antitrypsin in the
lungs; this type of
emphysema is usually inherited.
[00163] In some embodiments, disclosed herein are methods of treating chronic
bronchitis with
an autotaxin inhibitor. Chronic bronchitis (CB) is inflammation of one or more
bronchi, usually
secondary to infection, and is characterized by excessive production of mucus
in the bronchi,
accompanied by a recurrent cough which persists for at least three months of
the year during at
least two successive years. CB is the major non-asthmatic disease of the lung.
Many different
factors initiate CB, including cigarette smoking, environmental pollution,
chronic infections and
various genetic abnormalities. Of these factors, cigarette smoking is the most
prevalent.
Pathological changes in the lung include: (1) hypertrophy and hyperplasia of
mucus-secreting
glands in the bronchi, (2) increase in goblet cells, (3) disappearance or
damage of cilia, and (4)
chronic inflammatory changes and narrowing of small airways.
[00164] In some embodiments, disclosed herein are methods of treating
emphysema with an
autotaxin inhibitor. Emphysema is a lung condition which results from damage
to the alveolar
sacs in the lungs, usually caused by long-term smoking. This damage leads to a
pathological
accumulation of air in the tissues.
[00165] Administration of LPA in vivo induces airway hyperresponsiveness, itch-
scratch
responses, infiltration and activation of eosinophils and neutrophils,
vascular remodeling, and
nociceptive flexor responses. LPA also induces histamine release from mouse
and rat mast cells.
In an acute allergic reaction, histamine induces various responses, such as
contraction of smooth
muscle, plasma exudation, and mucus production. Plasma exudation is important
in the airway,
because the leakage and subsequent airway-wall edema contribute to the
development of airway
hyperresponsiveness. In some embodiments, disclosed herein are methods of
reducing plasma
exudation due to an acute allergic reaction with an autotaxin inhibitor.
Obesity
[00166] In some embodiments, disclosed herein are methods of treating obesity
and/or diabetes
with an autotaxin inhibitor.
-35-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00167] Autotaxin is responsible for the lysoPLD activity released by
adipocytes and exerts a
paracrine control on preadipocyte growth via an LPA-dependent mechanism. In
addition,
autotaxin is up-regulated during adipocyte differentiation and in genetic
obesity. In certain
instances, autotaxin mRNA is up-regulated in adipocytes from db/db mice
suggesting that the
up-regulation of autotaxin is related to the severe type 2 diabetes phenotype
and adipocyte
insulin resistance. In some instances, up-regulation of autotaxin in
adipocytes is associated with
type 2 diabetes.
[00168] "Obesity," as used herein, refers to a medical condition in which
excess body fat has
accumulated to the extent that it may have an adverse effect on health,
leading to increased
health problems. In some embodiments, "obesity" refers to a weight increase,
which is at least
5% of the total body weight. In some embodiments, disclosed herein are methods
of treating
postmenopausal obesity and/or visceral obesity with an autotaxin inhibitor.
Metabolic Disorders
[00169] In some embodiments, disclosed herein are methods of treating
metabolic disorders, and
conditions associated with metabolic disorders, comprising administering an
autotaxin inhibitor.
As used herein, a "metabolic disorder" refers to any pathological condition
resulting from an
alteration in a subject's metabolism. Such disorders include those resulting
from an alteration in
glucose homeostasis and/or insulin dysfunction. Metabolic disorders, include
but are not limited
to, metabolic syndrome, elevated blood glucose levels, insulin resistance,
glucose intolerance,
type 2 diabetes, type 1 diabetes, pre-diabetes, non-alcoholic fatty liver
disease, nonalcoholic
steatohepatitis, and obesity.
[00170] Metabolic disorders are inter-related and can result in disorders
across various systems.
Addressing the core metabolic disorder can reduce the severity of related
conditions in a patient,
including, for example, cardiovascular disorders (including, e.g., ischemic
heart disease, angina
and myocardial infarction, congestive heart failure, high blood pressure,
abnormal cholesterol
levels, deep vein thrombosis, and pulmonary embolism), neurological disorders
(including, e.g.,
stroke, meralgia paresthetica, migraines, idiopathic, and intracranial
hypertension, depression
and social stigmatism), rheumatological and orthopedic disorders (including,
e.g., gout, poor
mobility, osteoarthritis, and lower back pain), dermatological disorders
(including, e.g., stretch
marks, acanthosis nigricans, lymphedema, cellulitis), gastrointestinal
disorders (including, e.g.,
gastroesophageal reflux disease (GERD) and cholelithiasis (gallstones)),
respiratory disorders
(including, e.g., obstructive sleep apnea, obesity hypoventilation syndrome,
asthma, and
increased complications during general anaesthesia), urology and nephrology
disorders
(including, e.g., erectile dysfunction, urinary incontinence, chronic renal
failure, and
hypogonadism).
-36-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00171] In some embodiments, described herein are methods for treating
metabolic disorders. In
some embodiments, administering an autotaxin inhibitor to an individual with a
metabolic
disorder has a variety of desirable outcomes which include, but are not
limited to, reducing
blood glucose levels, decreasing plasma lysophosphatidic acid levels,
improving insulin
sensitivity, increasing insulin secretion, improving glucose tolerance, and
decreasing adipose
tissue expansion. Any of these outcomes can treat, delay or prevent the onset
of a metabolic
disorder, wherein such metabolic disorders include, but are not limited to,
metabolic syndrome,
elevated blood glucose levels, insulin resistance, glucose intolerance, type 2
diabetes, type 1
diabetes, pre-diabetes, non-alcoholic fatty liver disease, nonalcoholic
steatohepatitis, and
obesity.
[00172] In some embodiments, described herein are methods of administering an
autotaxin
inhibitor for reducing fasting blood glucose levels in a mouse fed a high fat
diet. A mouse fed a
high fat diet, as illustrated herein, has higher fasting blood glucose levels
than a mouse fed a
normal diet. The administration of an autotaxin inhibitor to a mouse fed a
high fat diet reduced
fasting blood glucose levels thereby allowing fasting blood glucose levels to
approach those
levels observed in a mouse fed a normal diet.
[00173] In some embodiments, methods disclosed herein comprise administering
an autotaxin
inhibitor to a subject with elevated blood glucose levels. In some
embodiments, the autotaxin
inhibitor is used to treat an underlying metabolic disorder. In some
embodiments, the metabolic
disorder is treated by reducing blood glucose levels. In some embodiments, the
subject is
overweight or obese. In some embodiments, the subject has type 2 diabetes. In
some
embodiments, the subject has non-alcoholic fatty liver disease and/or
nonalcoholic
steatohepatitis. In some embodiments, the subject does not have a metabolic
disorder. In some
embodiments, the autotaxin inhibitor delays or prevents the onset of the
metabolic disorder by
reducing elevated blood glucose levels.
[00174] In some embodiments, methods disclosed herein comprise reducing plasma
lysophosphatidic acid levels in an individual by administering an autotaxin
inhibitor. In some
embodiments, the plasma lysophosphatidic acid levels in the individual are
elevated relative to a
control. In some embodiments, the control is a person without a metabolic
disorder. In some
embodiments, the elevated plasma lysophosphatidic acid levels in the
individual contribute to or
increase the risk for developing a metabolic disorder.
[00175] In some embodiments, disclosed herein are methods comprising
administering an
autotaxin inhibitor to a subject with elevated plasma lysophosphatidic acid
levels relative to a
control. In some embodiments, disclosed herein are methods for improving
insulin sensitivity
comprising administering an autotaxin inhibitor to an individual sensitive to
insulin. In some
-37-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
embodiments, disclosed herein are methods comprising the administration of an
autotaxin
inhibitor to a subject with insulin resistance. In some embodiments, disclosed
herein are
methods comprising the administration of an autotaxin inhibitor to improve
insulin secretion in
an individual. In some embodiments, disclosed herein are methods comprising
the
administration of an autotaxin inhibitor to improve glucose tolerance in an
individual with
impaired glucose tolerance. In some embodiments, disclosed herein are methods
for decreasing
adipose tissue expansion in a subject comprising administering to the subject
an autotaxin
inhibitor. In some embodiments, disclosed herein are methods for the treatment
of a metabolic
disorder in a subject that is overweight or obese comprising administering to
the subject an
autotaxin inhibitor.
Drug Induced Hyperglycemia
[00176] In some embodiments, disclosed herein are methods of treating drug
induced
hyperglycemia in a subject comprising administering to the subject an
autotaxin inhibitor. In
some embodiments, administration of an autotaxin inhibitor to a subject
treats, prevents, or
ameliorates the symptoms of drug induced hyperglycemia. In some embodiments,
administration of an autotaxin inhibitor to a subject treats, prevents, or
ameliorates the
symptoms of drug induced hyperglycemia by reducing blood glucose levels.
Pharmacological
agents can affect glucose homeostasis that can result in hyperglycemia. In
some embodiments,
the hyperglycemia occurs in the absence of a diagnosis of diabetes. If left
untreated, the elevated
blood glucose levels can lead to a medical emergency. Symptoms include, but
are not limited to
fatigue, weakness, fruity odor of the breath, confusion, lack of
concentration, shortness of
breath, nausea, vomiting, dry skin, and flushing of the skin. Common drug
categories that are
associated with contributing to hyperglycemia include, but are not limited to:
antibiotics, such as
fluoroquinolones including gatifloxacin; beta-blockers, such as propranolol,
metoprolol or
atenolol; thiazide, such as hydrochlorothiazide, and thiazide-like diuretics,
and thiazide-like
drugs (metolazone); second-generation antipsychotics (SGAs) or "atypical
antipsychotics" such
as olanzapine or clozapine; corticosteroids; calcinuerin inhibitors such as
cyclosporine, sirolimus
or tarcrolimus; and protease inhibitors such as ritonavir.
Stress Induced Hyperglycemia
[00177] In some embodiments, disclosed herein are methods of treating stress
induced
hyperglycemia in a subject comprising administering to the subject an
autotaxin inhibitor. In
some embodiments, administration of an autotaxin inhibitor to a subject treats
or prevents or
delays the onset of stress induced hyperglycemia. In some embodiments,
administration of an
autotaxin inhibitor to a subject treats or prevents or delays the onset of
stress induced
hyperglycemia by reducing blood glucose levels. Stressed induced hyperglycemia
(SIB) is a
-38-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
transient increase in plasma glucose levels higher than 200 mg/dL which occurs
during an acute
illness or injury. In some embodiments, the hyperglycemia occurs in the
absence of a diagnosis
of diabetes. The SIH results from an excess of glucose production relative
glucose clearance.
SIR has been associated with conditions including, but not limited to,
myocardial infarction,
stroke, and trauma. SIR has been associated with increase mortality and a
higher incidence of
congestive heart failure and cardiogenic shock in patients after myocardial
infarction. Stroke
victims have higher mortality associated with SIR and worse odds of desirable
neurological
outcomes as glucose levels increase with SIR. Hyperglycemia was also shown to
be a predictor
of infectious complications in the form of pneumonia, urinary tract
infections, wound infections
and bacteria. Overall, published studies have consistently shown higher
morbidity and higher
mortality rates in those patients that present with SIR.
Intraocular Pressure
[00178] In some embodiments, disclosed herein are methods of treating elevated
intraocular
pressure associated with glaucoma in a subject, the methods comprising
administration of an
autotaxin inhibitor to the subject.
[00179] Glaucoma is one of the leading causes of blindness and is
characterized by elevated
intraocular pressure (TOP). TOP is a primary risk factor for developing
glaucoma and the risk of
developing glaucoma decreases when IOP is reduced. Ocular hypotensive therapy
is the
mainstay of glaucoma treatment. Elevated IOP results from diminished aqueous
humor (AH)
drainage through the trabecular pathway and autotaxin activity is an abundant
protein in human
AH. Autotaxin is secreted by human trabecular meshwork cells and autotaxin
activity is
significantly elevated from glaucoma patients. Inhibition of autotaxin
activity in AH by topical
and intracameral delivery of a small molecule inhibitor leads to decreased TOP
in rabbits.
Neuropathic Pain
[00180] In some embodiments, disclosed herein are methods of treating
neuropathic pain with
an autotaxin inhibitor.
[00181] LPA induces neuropathic pain as well as demyelination and pain-related
protein
expression changes via LPAL In some instances, autotaxin heterozygous knockout
mice show
about 50% recovery of nerve injury- induced neuropathic pain compared to wild
type mice.
Lysophosphatidylcholine (LPC), is known to induce neuropathic pain. In certain
instances, LPC-
induced neuropathic pain is partially reduced in autotaxin heterozygous
knockout mice.
[00182] Neuropathic pain results from injury to a nerve. In contrast to
immediate pain caused by
tissue injury, in some embodiments, neuropathic pain develops days or months
after a traumatic
injury. In addition, neuropathic pain frequently is long-lasting or chronic
and can occur
spontaneously or as a result of stimulation that normally is not painful.
-39-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Autotaxin Inhibitor Compounds
[00183] In some embodiments, the autotaxin inhibitor contemplated for use in
any of the
embodiments described herein is a small molecule inhibitor.
[00184] In some embodiments, the autotaxin inhibitor is a small molecule
inhibitor that is
characterized as having one or more of the following properties:
-a molecular weight of at most 700
-capability of at least 50% inhibition (at 1 micromolar) of autotaxin
conversion of
lysophosphatidyl choline to lysophosphatidic acid in a suitable in vitro assay
that measures such
activity
-selective inhibition of autotaxin activity
-suitable for administration to human at therapeutically relevant doses with
at least 50%
inhibition of autotaxin at trough
[00185] In some embodiments, the autotaxin inhibitor has the structure of
Compound A:
0
OH
S
\ 4
CI
F
N-N
Compound A
[00186] In some embodiments, Compound A is used as the free acid. In some
embodiments,
Compound A is used as a pharmaceutically acceptable salt. In some embodiments,
Compound A
is used as the sodium salt.
[00187] In some embodiments, the autotaxin inhibitor has the structure of
Compound B:
0
OH
S
\ CI
CI
F
-N
Compound B
-40-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00188] In some embodiments, Compound B is used as the free acid. In some
embodiments,
Compound B is used as a pharmaceutically acceptable salt. In some embodiments,
Compound B
is used as the sodium salt.
[00189] In some embodiments, the autotaxin inhibitor has the structure of
Compound C:
0
N
\
110
Compound C
[00190] In some embodiments, Compound C is used as the free amine. In some
embodiments,
Compound C is used as a pharmaceutically acceptable salt. In some embodiments,
Compound C
is used as the hydrochloride salt.
[00191] In some embodiments, the autotaxin inhibitor has the structure of
Compound D:
H
NQ
\
1110
Compound D
[00192] In some embodiments, Compound D is used as the free amine. In some
embodiments,
Compound D is used as a pharmaceutically acceptable salt. In some embodiments,
Compound D
is used as the hydrochloride salt.
[00193] Additional autotaxin inhibitors include compounds with the following
structure:
-41-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
NH NH
0 0
1\1.--0
I I\A'0
CI NN N
110
, F
NH ('NH
0 0
\ 0
0
CI N
, or F ; or a
pharmaceutically
acceptable salt thereof
[00194] In some embodiments, the 4-fluorobenzyl group of any the preceding
compounds is
replaced with 4-chlorobenzyl; 3-chlorobenzyl; 3-fluorobenzyl; 3,5-
difluorobenzyl; 2,4-
difluorobenzyl; 3,5-dichlorobenzyl; 2-chloropyridin-5-ylmethyl; 2-
methoxypyridin-5-ylmethyl;
2-trifluoromethylthiazol-5-ylmethyl; phenylprop-3-y1; thien-2-ylmethyl; or 5-
chlorothien-2-
ylmethyl.
[00195] In some embodiments, the autotaxin inhibitor has the structure of
Compound E:
0
OH
S
\ CI
CI N
F
N-N
Compound E
[00196] In some embodiments, Compound E is used as the free acid. In some
embodiments,
Compound E is used as a pharmaceutically acceptable salt. In some embodiments,
Compound E
is used as the sodium salt.
[00197] In some embodiments, the autotaxin inhibitor has the structure of
Compound F:
-42-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
0
OH
N_
S\/
\ CI
CI 1101 N
F
N N
Compound F
[00198] In some embodiments, Compound F is used as the free acid. In some
embodiments,
Compound F is used as a pharmaceutically acceptable salt. In some embodiments,
Compound F
is used as the sodium salt.
[00199] In some embodiments, the autotaxin inhibitor has the structure of
Compound G:
0
OH
S \N-/
\ci
CI
F
N-N
Compound G
[00200] In some embodiments, Compound G is used as the free acid. In some
embodiments,
Compound G is used as a pharmaceutically acceptable salt. In some embodiments,
Compound G
is used as the sodium salt.
[00201] In some embodiments, the autotaxin inhibitor has the structure of
Compound H:
0
OH
S
c,
CI
F
N_N
-43-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Compound H
[00202] In some embodiments, Compound H is used as the free acid. In some
embodiments,
Compound H is used as a pharmaceutically acceptable salt. In some embodiments,
Compound H
is used as the sodium salt
[00203] In some embodiments, the autotaxin inhibitor has the structure of
Compound I:
0
OH
S
I.
\ CI
CI
F
N-N
Compound I
[00204] In some embodiments, Compound I is used as the free acid. In some
embodiments,
Compound I is used as a pharmaceutically acceptable salt. In some embodiments,
Compound I
is used as the sodium salt.
[00205] In some embodiments, the autotaxin inhibitor for use in any of the
embodiments
described herein is a compound described in international patent application
no.
PCT/US2014/066706 filed November 20, 2014, published as WO/2015/077503, which
is herein
incorporated by reference for such compounds.
[00206] In some embodiments, the autotaxin inhibitor for use in any of the
embodiments
described herein is a compound described in international patent application
no.
PCT/US2014/066705 filed November 20, 2014, published as WO/2015/077502, which
is herein
incorporated by reference for such compounds.
[00207] In one aspect, autotaxin inhibitors are in the form of
pharmaceutically acceptable salts.
As well, active metabolites of these compounds having the same type of
activity are included in
the scope of the present disclosure. In addition, the autotaxin inhibitors can
exist in unsolvated
as well as solvated forms with pharmaceutically acceptable solvents such as
water, ethanol, and
the like. The solvated forms of the compounds presented herein are also
considered to be
disclosed herein.
[00208] "Pharmaceutically acceptable," as used herein, refers a material, such
as a carrier or
diluent, which does not abrogate the biological activity or properties of the
compound, and is
relatively nontoxic, i.e., the material is administered to an individual
without causing
-44-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
undesirable biological effects or interacting in a deleterious manner with any
of the components
of the composition in which it is contained.
[00209] The term "pharmaceutically acceptable salt" refers to a form of a
therapeutically active
agent that consists of a cationic form of the therapeutically active agent in
combination with a
suitable anion, or in alternative embodiments, an anionic form of the
therapeutically active agent
in combination with a suitable cation. Handbook of Pharmaceutical Salts:
Properties, Selection
and Use. International Union of Pure and Applied Chemistry, Wiley-VCH 2002.
S.M. Berge,
L.D. Bighley, D.C. Monkhouse, J. Pharm. Sci. 1977, 66, 1-19. P. H. Stahl and
C. G. Wermuth,
editors, Handbook of Pharmaceutical Salts: Properties, Selection and Use,
Weinheim/Thrich:Wiley-VCH/VHCA, 2002. Pharmaceutical salts typically are more
soluble
and more rapidly soluble in stomach and intestinal juices than non-ionic
species and so are
useful in solid dosage forms. Furthermore, because their solubility often is a
function of pH,
selective dissolution in one or another part of the digestive tract is
possible and this capability
can be manipulated as one aspect of delayed and sustained release behaviors.
Also, because the
salt-forming molecule can be in equilibrium with a neutral form, passage
through biological
membranes can be adjusted.
[00210] In some embodiments, pharmaceutically acceptable salts are obtained by
reacting an
autotaxin inhibitor with an acid. In some embodiments, the autotaxin inhibitor
(i.e. free base
form) is basic and is reacted with an organic acid or an inorganic acid.
Inorganic acids include,
but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid,
phosphoric acid, nitric
acid, and metaphosphoric acid. Organic acids include, but are not limited to,
1-hydroxy-2-
naphthoic acid; 2,2-dichloroacetic acid; 2-hydroxyethanesulfonic acid; 2-
oxoglutaric acid; 4-
acetamidobenzoic acid; 4-aminosalicylic acid; acetic acid; adipic acid;
ascorbic acid (L);
aspartic acid (L); benzenesulfonic acid; benzoic acid; camphoric acid (+);
camphor-10-sulfonic
acid (+); capric acid (decanoic acid); caproic acid (hexanoic acid); caprylic
acid (octanoic acid);
carbonic acid; cinnamic acid; citric acid; cyclamic acid; dodecylsulfuric
acid; ethane-1,2-
disulfonic acid; ethanesulfonic acid; formic acid; fumaric acid; galactaric
acid; gentisic acid;
glucoheptonic acid (D); gluconic acid (D); glucuronic acid (D); glutamic acid;
glutaric acid;
glycerophosphoric acid; glycolic acid; hippuric acid; isobutyric acid; lactic
acid (DL);
lactobionic acid; lauric acid; maleic acid; malic acid (- L); malonic acid;
mandelic acid (DL);
methanesulfonic acid; naphthalene-1,5-disulfonic acid; naphthalene-2-sulfonic
acid; nicotinic
acid; oleic acid; oxalic acid; palmitic acid; pamoic acid; phosphoric acid;
proprionic acid;
pyroglutamic acid (- L); salicylic acid; sebacic acid; stearic acid; succinic
acid; sulfuric acid;
tartaric acid (+ L); thiocyanic acid; toluenesulfonic acid (p); and
undecylenic acid.
-45-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00211] In some embodiments, an autotaxin inhibitor is prepared as a chloride
salt, sulfate salt,
bromide salt, mesylate salt, maleate salt, citrate salt or phosphate salt. In
some embodiments, an
autotaxin inhibitor is prepared as a hydrochloride salt.
[00212] In some embodiments, pharmaceutically acceptable salts are obtained by
reacting an
autotaxin inhibitor with a base. In some embodiments, the autotaxin inhibitor
is acidic and is
reacted with a base. In such situations, an acidic proton of the autotaxin
inhibitor is replaced by
a metal ion, e.g., lithium, sodium, potassium, magnesium, calcium, or an
aluminum ion. In some
cases, autotaxin inhibitors coordinate with an organic base, such as, but not
limited to,
ethanolamine, diethanolamine, triethanolamine, tromethamine, meglumine, N-
methylglucamine,
dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, autotaxin
inhibitors form
salts with amino acids such as, but not limited to, arginine, lysine, and the
like. Acceptable
inorganic bases used to form salts with compounds that include an acidic
proton, include, but are
not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide,
sodium
carbonate, potassium carbonate, sodium hydroxide, lithium hydroxide, and the
like. In some
embodiments, the compounds provided herein are prepared as a sodium salt,
calcium salt,
potassium salt, magnesium salt, meglumine salt, N-methylglucamine salt or
ammonium salt. In
some embodiments, the compounds provided herein are prepared as a sodium salt.
[00213] It should be understood that a reference to a pharmaceutically
acceptable salt includes
the solvent addition forms. In some embodiments, solvates contain either
stoichiometric or non-
stoichiometric amounts of a solvent, and are formed during the process of
crystallization with
pharmaceutically acceptable solvents such as water, ethanol, and the like.
Hydrates are formed
when the solvent is water, or alcoholates are formed when the solvent is
alcohol. Solvates of
autotaxin inhibitors are conveniently prepared or formed during the processes
described herein.
In addition, the compounds provided herein optionally exist in unsolvated as
well as solvated
forms.
[00214] The methods and formulations described herein include the use of N-
oxides (if
appropriate), crystalline forms (also known as polymorphs), or
pharmaceutically acceptable salts
of autotaxin inhibitors, as well as active metabolites of these compounds
having the same type
of activity.
[00215] In some embodiments, sites on the organic radicals (e.g. alkyl groups,
aromatic rings) of
autotaxin inhibitors are susceptible to various metabolic reactions.
Incorporation of appropriate
substituents on the organic radicals will reduce, minimize or eliminate this
metabolic pathway.
In specific embodiments, the appropriate substituent to decrease or eliminate
the susceptibility
of the aromatic ring to metabolic reactions is, by way of example only, a
halogen, deuterium, an
alkyl group, a haloalkyl group, or a deuteroalkyl group.
-46-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00216] In another embodiment, the autotaxin inhibitors are labeled
isotopically (e.g. with a
radioisotope) or by another other means, including, but not limited to, the
use of chromophores
or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[00217] Autotaxin inhibitors include isotopically-labeled compounds, which are
identical to
those recited in the various formulae and structures presented herein, but for
the fact that one or
more atoms are replaced by an atom having an atomic mass or mass number
different from the
atomic mass or mass number usually found in nature. Examples of isotopes that
can be
incorporated into the present compounds include isotopes of hydrogen, carbon,
nitrogen,
oxygen, fluorine and chlorine, such as, for example, 2H, 3H, 13C, 14C, 15N,
180, 170, 35s, 18F, 36C1.
In one aspect, isotopically-labeled autotaxin inhibitors, for example those
into which radioactive
isotopes such as 3H and 14C are incorporated, are useful in drug and/or
substrate tissue
distribution assays. In one aspect, substitution with isotopes such as
deuterium affords certain
therapeutic advantages resulting from greater metabolic stability, such as,
for example, increased
in vivo half-life or reduced dosage requirements.
[00218] In some embodiments, the autotaxin inhibitors possess one or more
stereocenters and
each stereocenter exists independently in either the R or S configuration. The
compounds
presented herein include all diastereomeric, enantiomeric, atropisomers, and
epimeric forms as
well as the appropriate mixtures thereof The compounds and methods provided
herein include
all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as
the appropriate
mixtures thereof.
[00219] Individual stereoisomers are obtained, if desired, by methods such as,
stereoselective
synthesis and/or the separation of stereoisomers by chiral chromatographic
columns. In certain
embodiments, autotaxin inhibitors are prepared as their individual
stereoisomers by reacting a
racemic mixture of the compound with an optically active resolving agent to
form a pair of
diastereoisomeric compounds/salts, separating the diastereomers and recovering
the optically
pure enantiomers. In some embodiments, resolution of enantiomers is carried
out using covalent
diastereomeric derivatives of the autotaxin inhibitors. In another embodiment,
diastereomers are
separated by separation/resolution techniques based upon differences in
solubility. In other
embodiments, separation of steroisomers is performed by chromatography or by
the forming
diastereomeric salts and separation by recrystallization, or chromatography,
or any combination
thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates
and
Resolutions", John Wiley And Sons, Inc., 1981. In some embodiments,
stereoisomers are
obtained by stereoselective synthesis.
[00220] In some embodiments, autotaxin inhibitors are prepared as prodrugs. A
"prodrug" refers
to an agent that is converted into the parent drug in vivo. Prodrugs are often
useful because, in
-47-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
some situations, they are easier to administer than the parent drug. They are,
for instance,
bioavailable by oral administration whereas the parent is not. Further or
alternatively, the
prodrug also has improved solubility in pharmaceutical compositions over the
parent drug. In
some embodiments, the design of a prodrug increases the effective water
solubility. An example,
without limitation, of a prodrug is an autotaxin inhibitor, which is
administered as an ester (the
"prodrug") but then is metabolically hydrolyzed to provide the active entity.
A further example
of a prodrug is a short peptide (polyaminoacid) bonded to an acid group where
the peptide is
metabolized to reveal the active moiety. In certain embodiments, upon in vivo
administration, a
prodrug is chemically converted to the biologically, pharmaceutically or
therapeutically active
form of the compound. In certain embodiments, a prodrug is enzymatically
metabolized by one
or more steps or processes to the biologically, pharmaceutically or
therapeutically active form of
the compound.
[00221] Prodrugs of the autotaxin inhibitors include, but are not limited to,
esters, ethers,
carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives,
quaternary
derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid
conjugates, phosphate
esters, and sulfonate esters. See for example Design of Prodrugs, Bundgaard,
A. Ed., Elseview,
1985 and Method in Enzymology, Widder, K. et al., Ed.; Academic, 1985, vol.
42, p. 309-396;
Bundgaard, H. "Design and Application of Prodrugs" in A Textbook of Drug
Design and
Development, Krosgaard-Larsen and H. Bundgaard, Ed., 1991, Chapter 5, p. 113-
191; and
Bundgaard, H., Advanced Drug Delivery Review, 1992, 8, 1-38, each of which is
incorporated
herein by reference. In some embodiments, a hydroxyl group in the compounds
disclosed herein
is used to form a prodrug, wherein the hydroxyl group is incorporated into an
acyloxyalkyl ester,
alkoxycarbonyloxyalkyl ester, alkyl ester, aryl ester, phosphate ester, sugar
ester, ether, and the
like. In some embodiments, a hydroxyl group in the compounds disclosed herein
is a prodrug
wherein the hydroxyl is then metabolized in vivo to provide a carboxylic acid
group. In some
embodiments, a carboxyl group is used to provide an ester or amide (i.e. the
prodrug), which is
then metabolized in vivo to provide a carboxylic acid group. In some
embodiments, autotaxin
inhibitors are prepared as alkyl ester prodrugs.
[00222] Prodrug forms of the herein described compounds, wherein the prodrug
is metabolized
in vivo to produce an autotaxin inhibitor as set forth herein are included
within the scope of the
claims. In some cases, some of the herein-described compounds is a prodrug for
another
derivative or active compound.
[00223] In additional or further embodiments, the autotaxin inhibitors are
metabolized upon
administration to an organism in need to produce a metabolite that is then
used to produce a
desired effect, including a desired therapeutic effect.
-48-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00224] A "metabolite" of an autotaxin inhibitor is a derivative of that
compound that is formed
when the compound is metabolized. The term "active metabolite" refers to a
biologically active
derivative of a compound that is formed when the compound is metabolized. The
term
"metabolized," as used herein, refers to the sum of the processes (including,
but not limited to,
hydrolysis reactions and reactions catalyzed by enzymes) by which a particular
substance is
changed by an organism. Thus, enzymes may produce specific structural
alterations to a
compound For example, cytochrome P450 catalyzes a variety of oxidative and
reductive
reactions while uridine diphosphate glucuronyltransferases catalyze the
transfer of an activated
glucuronic-acid molecule to aromatic alcohols, aliphatic alcohols, carboxylic
acids, amines and
free sulphydryl groups. Metabolites of the compounds disclosed herein are
optionally identified
either by administration of compounds to a host and analysis of tissue samples
from the host, or
by incubation of compounds with hepatic cells in vitro and analysis of the
resulting compounds.
Certain Terminology
[00225] Unless otherwise stated, the following terms used in this application
have the definitions
given below. The use of the term "including" as well as other forms, such as
"include",
"includes," and "included," is not limiting. The section headings used herein
are for
organizational purposes only and are not to be construed as limiting the
subject matter described.
[00226] The term "acceptable" with respect to a formulation, composition or
ingredient, as used
herein, means having no persistent detrimental effect on the general health of
the subject being
treated.
[00227] The term "modulate" as used herein, means to interact with a target
either directly or
indirectly so as to alter the activity of the target, including, by way of
example only, to enhance
the activity of the target, to inhibit the activity of the target, to limit
the activity of the target, or
to extend the activity of the target.
[00228] The term "modulator" as used herein, refers to a molecule that
interacts with a target
either directly or indirectly. The interactions include, but are not limited
to, the interactions of an
agonist, partial agonist, an inverse agonist, antagonist, degrader, or
combinations thereof In
some embodiments, a modulator is an antagonist. In some embodiments, a
modulator is a
degrader.
[00229] The terms "administer," "administering", "administration," and the
like, as used herein,
refer to the methods that may be used to enable delivery of compounds or
compositions to the
desired site of biological action. These methods include, but are not limited
to oral routes,
intraduodenal routes, parenteral injection (including intravenous,
subcutaneous, intraperitoneal,
intramuscular, intravascular or infusion), topical and rectal administration.
Those of skill in the
art are familiar with administration techniques that can be employed with the
compounds and
-49-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
methods described herein. In some embodiments, the compounds and compositions
described
herein are administered orally.
[00230] The terms "co-administration" or the like, as used herein, are meant
to encompass
administration of the selected therapeutic agents to a single patient, and are
intended to include
treatment regimens in which the agents are administered by the same or
different route of
administration or at the same or different time.
[00231] The terms "effective amount" or "therapeutically effective amount," as
used herein,
refer to a sufficient amount of an agent or a compound being administered,
which will relieve to
some extent one or more of the symptoms of the disease or condition being
treated. The result
includes reduction and/or alleviation of the signs, symptoms, or causes of a
disease, or any other
desired alteration of a biological system. For example, an "effective amount"
for therapeutic
uses is the amount of the composition comprising a compound as disclosed
herein required to
provide a clinically significant decrease in disease symptoms. An appropriate
"effective"
amount in any individual case is optionally determined using techniques, such
as a dose
escalation study.
[00232] The terms "enhance" or "enhancing," as used herein, means to increase
or prolong
either in potency or duration a desired effect. Thus, in regard to enhancing
the effect of
therapeutic agents, the term "enhancing" refers to the ability to increase or
prolong, either in
potency or duration, the effect of other therapeutic agents on a system. An
"enhancing-effective
amount," as used herein, refers to an amount adequate to enhance the effect of
another
therapeutic agent in a desired system.
[00233] The term "pharmaceutical combination" as used herein, means a product
that results
from the mixing or combining of more than one active ingredient and includes
both fixed and
non-fixed combinations of the active ingredients. The term "fixed combination"
means that the
active ingredients, e.g. an autotaxin inhibitor, or a pharmaceutically
acceptable salt thereof, and
a co-agent, are both administered to a patient simultaneously in the form of a
single entity or
dosage. The term "non-fixed combination" means that the active ingredients,
e.g. an autotaxin
inhibitor, or a pharmaceutically acceptable salt thereof, and a co-agent, are
administered to a
patient as separate entities either simultaneously, concurrently or
sequentially with no specific
intervening time limits, wherein such administration provides effective levels
of the two
compounds in the body of the patient. The latter also applies to cocktail
therapy, e.g. the
administration of three or more active ingredients.
[00234] The terms "kit" and "article of manufacture" are used as synonyms.
[00235] The term "subject" or "patient" encompasses mammals. Examples of
mammals include,
but are not limited to, any member of the Mammalian class: humans, non-human
primates such
-50-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
as chimpanzees, and other apes and monkey species; farm animals such as
cattle, horses, sheep,
goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory
animals including
rodents, such as rats, mice and guinea pigs, and the like. In one aspect, the
mammal is a human.
[00236] The terms "treat," "treating" or "treatment," as used herein, include
alleviating, abating
or ameliorating at least one symptom of a disease or condition, preventing
additional symptoms,
inhibiting the disease or condition, e.g., arresting the development of the
disease or condition,
relieving the disease or condition, causing regression of the disease or
condition, relieving a
condition caused by the disease or condition, or stopping the symptoms of the
disease or
condition either prophylactically and/or therapeutically.
Autotaxin Inhibition
[00237] Provided herein, in various aspects, are methods for the prevention or
treatment of a
disease, disorder or condition in a subject that would benefit from the
inhibition or reduction of
autotaxin activity comprising administering to the subject an autotaxin
inhibitor. In some
embodiments, provided herein are methods for reducing plasma autotaxin
activity in a subject in
need thereof, comprising administering a therapeutically effective amount of
an autotaxin
inhibitor to the subject in need thereof In some embodiments, the subject in
need thereof is
suffereing from a disease, disorder or condition associated with autotaxin
activity. Non-limiting
examples of diseases, disorders and conditions are described herein.
[00238] In some embodiments, described herein are methods for the treatment of
one or more
conditions, diseases, and/or disorders in a human comprising administering an
autotaxin
inhibitor, wherein in the autottaxin inhibitor is suitable for administration
to a human at
therapeutically relevant doses with at least 50% inhibition of autotaxin at
trough.
[00239] In some embodiments, described herein are methods for the treatment of
one or more
conditions, diseases, and/or disorders in a subject, the method comprising the
administration of a
non-competitive autotaxin inhibitor.Non-limiting examples of non-competitive
autotaxin
inhibitors include Compound A and Compound B.
[00240] In some embodiments, described herein are methods for the treatment of
one or more
conditions, diseases and/or disorders in a subject comprising the
administration of an autotaxin
inhibitor to the subject, wherein the autotaxin inhibitor has an in vitro
autotaxin inhibition ICso
of less than about 100 nM, 50 nM, 40 nM, 30 nM, 20 nM or 10 nM. In some
examples, an in
vitro autotaxin inhibition assay includes an assay described as described in
the Examples.
[00241] In some embodiments, described herein are methods for the treatment of
one or more
conditions, diseases, and/or disorders in a subject, the method comprising the
administration of
an autotaxin inhibitor, wherein the autotaxin inhibitor preferentially
inhibits autotaxin acitivity
as compared to ENPP1, ENPP3, ENPP6, and/or ENPP7. In some embodiments, an
autotaxin
-51-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
inhibitor useful in the methods of treatment described herein has an IC50 for
the inhibition of
ENPP1, ENPP3, ENPP6, or ENPP7 greater than about 10, 20, or 100 [IM in an in
vitro assay
that measures such activity. In on such in vitro assay, Compound A and
Compound B exhibited
an IC50 greater than 1011M for ENPP 1, 3, 6, and 7.
[00242] In some embodiments, described herein are methods for the treatment of
one or more
conditions, diseases, and/or disorders in a subject, the method comprising the
administration of
an autotaxin inhibitor, wherein the autotaxin inhibitor is at least 80%, 90%,
95%, 96%, 97%,
98%, or 99% bound to plasma.
[00243] In some embodiments, described herein are methods for the prevention
or treatment of
one or more conditions, diseases, and/or disorders in a subject, the method
comprising the
administration of an autotaxin inhibitor, wherein the autotaxin inhibitor
cause acute or chronic
liver toxicity. In some embodiments, liver toxicity can be assessed in
suitable in vivo assays. In
some embodiments, liver toxicity is assessed by monitoring any increases in
the levels of liver
markers ALT, AST, AlkP and bilirubin. For example, in a suitable dog liver
toxicity study,
Compound A exhibited undesired elevated liver markers whereas Compound B did
not exhibit
the same effects. In some embodiments, no increases in liver markers ALT, AST,
AlkP and
bilirubin were observed for Compound B when dosed at 100mpk for 5 days.
Pharmaceutical Compositions
[00244] In some embodiments, the autotaxin inhibitors are formulated into
pharmaceutical
compositions. Pharmaceutical compositions are formulated in a conventional
manner using one
or more pharmaceutically acceptable inactive ingredients that facilitate
processing of the active
compounds into preparations that are used pharmaceutically. Proper formulation
is dependent
upon the route of administration chosen. A summary of pharmaceutical
compositions described
herein is found, for example, in Remington: The Science and Practice of
Pharmacy, Nineteenth
Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's
Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975;
Liberman, H.A. and
Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y.,
1980; and
Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott
Williams &
Wilkins1999), herein incorporated by reference for such disclosure.
[00245] In some embodiments, the autotaxin inhibitors are administered either
alone or in
combination with pharmaceutically acceptable carriers, excipients or diluents,
in a
pharmaceutical composition. Administration of the autotaxin inhibitors and
compositions
described herein can be effected by any method that enables delivery of the
compounds to the
site of action. These methods include, though are not limited to delivery via
enteral routes
(including oral, gastric or duodenal feeding tube, rectal suppository and
rectal enema), parenteral
-52-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
routes (injection or infusion, including intraarterial, intracardiac,
intradermal, intraduodenal,
intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal,
intravascular,
intravenous, intravitreal, epidural and subcutaneous), inhalational,
transdermal, transmucosal,
sublingual, buccal and topical (including epicutaneous, dermal, enema, eye
drops, ear drops,
intranasal, vaginal) administration, although the most suitable route may
depend upon for
example the condition and disorder of the recipient. By way of example only,
autotaxin
inhibitors can be administered locally to the area in need of treatment, by
for example, local
infusion during surgery, topical application such as creams or ointments,
injection, catheter, or
implant. The administration can also be by direct injection at the site of a
diseased tissue or
organ.
[00246] In some embodiments, pharmaceutical compositions suitable for oral
administration are
presented as discrete units such as capsules, cachets or tablets each
containing a predetermined
amount of the active ingredient; as a powder or granules; as a solution or a
suspension in an
aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion
or a water-in-oil
liquid emulsion. In some embodiments, the active ingredient is presented as a
bolus, electuary or
paste.
[00247] Pharmaceutical compositions which can be used orally include tablets,
push-fit capsules
made of gelatin, as well as soft, sealed capsules made of gelatin and a
plasticizer, such as
glycerol or sorbitol. Tablets may be made by compression or molding,
optionally with one or
more accessory ingredients. Compressed tablets may be prepared by compressing
in a suitable
machine the active ingredient in a free-flowing form such as a powder or
granules, optionally
mixed with binders, inert diluents, or lubricating, surface active or
dispersing agents. Molded
tablets may be made by molding in a suitable machine a mixture of the powdered
compound
moistened with an inert liquid diluent. In some embodiments, the tablets are
coated or scored
and are formulated so as to provide slow or controlled release of the active
ingredient therein.
All formulations for oral administration should be in dosages suitable for
such administration.
The push-fit capsules can contain the active ingredients in admixture with
filler such as lactose,
binders such as starches, and/or lubricants such as talc or magnesium stearate
and, optionally,
stabilizers. In soft capsules, the active compounds may be dissolved or
suspended in suitable
liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
In some embodiments,
stabilizers are added. Dragee cores are provided with suitable coatings. For
this purpose,
concentrated sugar solutions may be used, which may optionally contain gum
arabic, talc,
polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or
pigments may be
-53-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
added to the tablets or Dragee coatings for identification or to characterize
different
combinations of active compound doses.
[00248] In some embodiments, pharmaceutical compositions are formulated for
parenteral
administration by injection, e.g., by bolus injection or continuous infusion.
Formulations for
injection may be presented in unit dosage form, e.g., in ampoules or in multi-
dose containers,
with an added preservative. The compositions may take such forms as
suspensions, solutions or
emulsions in oily or aqueous vehicles, and may contain formulatory agents such
as suspending,
stabilizing and/or dispersing agents. The compositions may be presented in
unit-dose or multi-
dose containers, for example sealed ampoules and vials, and may be stored in
powder form or in
a freeze-dried (lyophilized) condition requiring only the addition of the
sterile liquid carrier, for
example, saline or sterile pyrogen-free water, immediately prior to use.
Extemporaneous
injection solutions and suspensions may be prepared from sterile powders,
granules and tablets
of the kind previously described.
[00249] Pharmaceutical compositions for parenteral administration include
aqueous and non-
aqueous (oily) sterile injection solutions of the active compounds which may
contain
antioxidants, buffers, bacteriostats and solutes which render the formulation
isotonic with the
blood of the intended recipient; and aqueous and non-aqueous sterile
suspensions which may
include suspending agents and thickening agents. Suitable lipophilic solvents
or vehicles include
fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl
oleate or triglycerides,
or liposomes. Aqueous injection suspensions may contain substances which
increase the
viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol,
or dextran.
Optionally, the suspension may also contain suitable stabilizers or agents
which increase the
solubility of the compounds to allow for the preparation of highly
concentrated solutions.
[00250] Pharmaceutical compositions may also be formulated as a depot
preparation. Such long
acting formulations may be administered by implantation (for example
subcutaneously or
intramuscularly) or by intramuscular injection. Thus, for example, the
compounds may be
formulated with suitable polymeric or hydrophobic materials (for example, as
an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly soluble derivatives,
for example, as a
sparingly soluble salt.
[00251] For buccal or sublingual administration, the compositions may take the
form of tablets,
lozenges, pastilles, or gels formulated in conventional manner. Such
compositions may comprise
the active ingredient in a flavored basis such as sucrose and acacia or
tragacanth.
[00252] Pharmaceutical compositions may also be formulated in rectal
compositions such as
suppositories or retention enemas, e.g., containing conventional suppository
bases such as cocoa
butter, polyethylene glycol, or other glycerides.
-54-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00253] Pharmaceutical compositions may be administered topically, that is by
non-systemic
administration. This includes the application of an autotaxin inhibitor of the
present invention
externally to the epidermis or the buccal cavity and the instillation of such
an autotaxin inhibitor
into the ear, eye and nose, such that the compound does not significantly
enter the blood stream.
In contrast, systemic administration refers to oral, intravenous,
intraperitoneal and intramuscular
administration.
[00254] Pharmaceutical compositions suitable for topical administration
include liquid or semi-
liquid preparations suitable for penetration through the skin to the site of
inflammation such as
gels, liniments, lotions, creams, ointments or pastes, and drops suitable for
administration to the
eye, ear or nose. The active ingredient may comprise, for topical
administration, from 0.001% to
10% w/w, for instance from 1% to 2% by weight of the formulation.
[00255] Pharmaceutical compositions for administration by inhalation are
conveniently
delivered from an insufflator, nebulizer pressurized packs or other convenient
means of
delivering an aerosol spray. Pressurized packs may comprise a suitable
propellant such as
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane,
carbon dioxide or
other suitable gas In the case of a pressurized aerosol, the dosage unit may
be determined by
providing a valve to deliver a metered amount. Alternatively, for
administration by inhalation or
insufflation, pharmaceutical preparations may take the form of a dry powder
composition, for
example a powder mix of the compound and a suitable powder base such as
lactose or starch.
The powder composition may be presented in unit dosage form, in for example,
capsules,
cartridges, gelatin or blister packs from which the powder may be administered
with the aid of
an inhalator or insufflator.
[00256] It should be understood that in addition to the ingredients
particularly mentioned above,
the autotaxin inhibitors and compositions described herein may include other
agents
conventional in the art having regard to the type of formulation in question,
for example those
suitable for oral administration may include flavoring agents.
Methods of Dosing and Treatment Regimens
[00257] In one embodiment, the autotaxin inhibitors, or a pharmaceutically
acceptable salt
thereof, are used in the preparation of medicaments for the treatment of
diseases or conditions in
a mammal that would benefit from inhibition or reduction of autotaxin
activity. Methods for
treating any of the diseases or conditions described herein in a mammal in
need of such
treatment, involves administration of pharmaceutical compositions that include
at least one
autotaxin inhibitor or a pharmaceutically acceptable salt, active metabolite,
prodrug, or
pharmaceutically acceptable solvate thereof, in therapeutically effective
amounts to said
mammal.
-55-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00258] In certain embodiments, the compositions containing the compound(s)
described herein
are administered for prophylactic and/or therapeutic treatments. In certain
therapeutic
applications, the compositions are administered to a patient already suffering
from a disease or
condition, in an amount sufficient to cure or at least partially arrest at
least one of the symptoms
of the disease or condition. Amounts effective for this use depend on the
severity and course of
the disease or condition, previous therapy, the patient's health status,
weight, and response to the
drugs, and the judgment of the treating physician. Therapeutically effective
amounts are
optionally determined by methods including, but not limited to, a dose
escalation and/or dose
ranging clinical trial.
[00259] In prophylactic applications, compositions containing the autotaxin
inhibitors are
administered to a patient susceptible to or otherwise at risk of a particular
disease, disorder or
condition. Such an amount is defined to be a "prophylactically effective
amount or dose." In this
use, the precise amounts also depend on the patient's state of health, weight,
and the like. When
used in patients, effective amounts for this use will depend on the severity
and course of the
disease, disorder or condition, previous therapy, the patient's health status
and response to the
drugs, and the judgment of the treating physician. In one aspect, prophylactic
treatments include
administering to a mammal, who previously experienced at least one symptom of
the disease
being treated and is currently in remission, a pharmaceutical composition
comprising an
autotaxin inhibitor, or a pharmaceutically acceptable salt thereof, in order
to prevent a return of
the symptoms of the disease or condition.
[00260] In certain embodiments wherein the patient's condition does not
improve, upon the
doctor's discretion the administration of autotaxin inhibitors are
administered chronically, that
is, for an extended period of time, including throughout the duration of the
patient's life in order
to ameliorate or otherwise control or limit the symptoms of the patient's
disease or condition.
[00261] In certain embodiments wherein a patient's status does improve, the
dose of drug being
administered is temporarily reduced or temporarily suspended for a certain
length of time (i.e., a
"drug holiday"). In specific embodiments, the length of the drug holiday is
between 2 days and 1
year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6
days, 7 days, 10 days,
12 days, 15 days, 20 days, 28 days, or more than 28 days. The dose reduction
during a drug
holiday is, by way of example only, by 10%-100%, including by way of example
only 10%,
15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%,
95%, and 100%.
[00262] Once improvement of the patient's conditions has occurred, a
maintenance dose is
administered if necessary. Subsequently, in specific embodiments, the dosage
or the frequency
of administration, or both, is reduced, as a function of the symptoms, to a
level at which the
-56-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
improved disease, disorder or condition is retained. In certain embodiments,
however, the
patient requires intermittent treatment on a long-term basis upon any
recurrence of symptoms.
[00263] The amount of a given agent that corresponds to such an amount varies
depending upon
factors such as the particular autotaxin inhibitor, disease condition and its
severity, the identity
(e.g., weight, sex) of the subject or host in need of treatment, but
nevertheless is determined
according to the particular circumstances surrounding the case, including,
e.g., the specific agent
being administered, the route of administration, the condition being treated,
and the subject or
host being treated.
[00264] In general, however, doses employed for adult human treatment are
typically in the
range of 0.01 mg-5000 mg per day. In one aspect, doses employed for adult
human treatment are
from about 1 mg to about 1000 mg per day. In one embodiment, the desired dose
is conveniently
presented in a single dose or in divided doses administered simultaneously or
at appropriate
intervals, for example as two, three, four or more sub-doses per day.
[00265] In one embodiment, the daily dosages appropriate for the autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, are from about 0.01 to about 50
mg/kg per body
weight. In some embodiments, the daily dosage or the amount of active in the
dosage form are
lower or higher than the ranges indicated herein, based on a number of
variables in regard to an
individual treatment regime. In various embodiments, the daily and unit
dosages are altered
depending on a number of variables including, but not limited to, the activity
of the autotaxin
inhibitor used, the disease or condition to be treated, the mode of
administration, the
requirements of the individual subject, the severity of the disease or
condition being treated, and
the judgment of the practitioner.
[00266] Toxicity and therapeutic efficacy of such therapeutic regimens are
determined by
standard pharmaceutical procedures in cell cultures or experimental animals,
including, but not
limited to, the determination of the LD50 and the ED50. The dose ratio between
the toxic and
therapeutic effects is the therapeutic index and it is expressed as the ratio
between LD50 and
ED50. In certain embodiments, the data obtained from cell culture assays and
animal studies are
used in formulating the therapeutically effective daily dosage range and/or
the therapeutically
effective unit dosage amount for use in mammals, including humans. In some
embodiments, the
daily dosage amount of the autotaxin inhibitors lies within a range of
circulating concentrations
that include the ED50 with minimal toxicity. In certain embodiments, the daily
dosage range
and/or the unit dosage amount varies within this range depending upon the
dosage form
employed and the route of administration utilized.
[00267] In any of the aforementioned aspects are further embodiments in which
the effective
amount of the autotaxin inhibitor, or a pharmaceutically acceptable salt
thereof, is: (a)
-57-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
systemically administered to the mammal; and/or (b) administered orally to the
mammal; and/or
(c) intravenously administered to the mammal; and/or (d) administered by
injection to the
mammal; and/or (e) administered topically to the mammal; and/or (f)
administered non-
systemically or locally to the mammal
[00268] In any of the aforementioned aspects are further embodiments
comprising single
administrations of the effective amount of the autotaxin inhibitor, including
further
embodiments in which (i) the autotaxin inhibitor is administered once a day;
or (ii) the autotaxin
inhibitor is administered to the mammal multiple times over the span of one
day.
[00269] In any of the aforementioned aspects are further embodiments
comprising multiple
administrations of the effective amount of the autotaxin inhibitor, including
further
embodiments in which (i) the autotaxin inhibitor is administered continuously
or intermittently:
as in a single dose; (ii) the time between multiple administrations is every 6
hours; (iii) the
autotaxin inhibitor is administered to the mammal every 8 hours; (iv) the
autotaxin inhibitor is
administered to the mammal every 12 hours; (v) the autotaxin inhibitor is
administered to the
mammal every 24 hours. In further or alternative embodiments, the method
comprises a drug
holiday, wherein the administration of the autotaxin inhibitor is temporarily
suspended or the
dose of the autotaxin inhibitor being administered is temporarily reduced; at
the end of the drug
holiday, dosing of the autotaxin inhibitor is resumed. In one embodiment, the
length of the drug
holiday varies from 2 days to 1 year.
[00270] In some embodiments, administration of a therapeutically effective
dose of an autotaxin
inhibitor does not cause hepatobiliary damage. In some embodiments,
administration of an
autotaxin inhibitor does not cause an increase or does not cause a significant
increase in serum
levels of one or more liver proteins. Liver proteins include, without
limitation, aspartate
transaminase (AST), bilirubin, and alkaline phosphatase (ALP). As an example,
a significant
increase is an increase of at least about 50%, 100%, 200% or higher of serum
protein levels after
administration of a prophylactic or therapeutic dose of an autotaxin inhibitor
as compared to
serum protein levels prior to autotaxin inhibitor administration. Measurement
of liver enzymes
after administration includes the measurement of liver enzymes after
completion of a therapeutic
regimen. Measurement of liver enzymes after administration includes the
measurement of liver
enzymes during the course of a therapeutic regimen.
[00271] In some embodiments, administration of a therapeutically effect dose
of an autotaxin
inhibitor does not cause an elevation in serum aspartate transaminase (AST)
levels as compared
to serum AST levels prior to the administration. In some embodiments,
administration of a
therapeutically effective dose of an autotaxin inhibitor causes less than a 10-
fold, 5-fold, 3-fold,
or 2-fold increase in serum AST levels as compared to serum AST levels prior
to the
-58-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
administration In some embodiments, following administration of a
therapeutically effective
dose of an autotaxin inhibitor to a subject, serum AST levels of the subject
are between about 8
and about 200 U/L, between about 8 and 100 U/L, between about 8 and 80 U/L or
between
about 8 and 60 U/L
[00272] In some embodiments, administration of a therapeutically effective
dose of an autotaxin
inhibitor to a subject does not cause an elevation in bilirubin levels in the
subject as compared to
bilirubin levels prior to the administration. In some embodiments, the
bilirubin levels are not
significantly increased within 1 or more days, weeks, months or years after
initial administration
of an autotaxin inhibitor. A significant increase includes, at least a 2-fold,
3-fold, 4-fold, or 5-
fold increase in bilirubin level after administration of an autotaxin
inhibitor.
[00273] In some embodiments, administration of a therapeutically effective
dose of an autotaxin
inhibitor to a subject does not cause an elevation in alkaline phosphatase
(ALP) levels in the
subject as compared to ALP levels prior to the administration. In some
embodiments, the ALP
level is not significantly increased within 1 or more days, weeks, months or
years after initial
administration of an autotaxin inhibitor. A significant increase includes, at
least a 2-fold, 3-fold,
4-fold, or 5-fold increase in ALP level after administration of an autotaxin
inhibitor.
[00274] In some embodiments, administration of a therapeutically effective
dose of an autotaxin
inhibitor to a subject does not cause an increase in bile staining in a liver
sample from the
subject as compared to bile staining prior to the administration. In some
embodiments, bile
staining is not significantly increased within 1 or more days, weeks, months
or years after initial
administration of an ATX inhibitor.
[00275] In some embodiments, following the administration of a therapeutically
effective dose
of an autotaxin inhibitor to a subject, the no observed adverse effect level
(NOAEL) is at least 1,
10, 20, 50, 100, 500 or 1000 milligrams of autotaxin inhibitor per kilogram of
body weight
(mpk). In some examples, the 7-day NOAEL for a rat administered an autotaxin
inhibitor is at
least about 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500 or 2000 mpk. In
some examples,
the 7-day NOAEL for a dog administered an autotaxin inhibitor is at least
about 10, 20, 30, 40,
50, 60, 70, 80, 90, 100, 200, 500 mpk. In some examples, the 5-day NOAEL for a
dog
administered an autotaxin inhibitor is at least about 10, 20, 30, 40, 50, 60,
70, 80, 90, 100, 200,
500 mpk.
Combination Treatments
[00276] In certain instances, it is appropriate to administer at least one
autotaxin inhibitor, or a
pharmaceutically acceptable salt thereof, in combination with one or more
other therapeutic
agents. In embodiments, the pharmaceutical composition further comprises one
or more anti-
cancer agents.
-59-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00277] In one embodiment, the therapeutic effectiveness of one of the
autotaxin inhibitors is
enhanced by administration of an adjuvant (i.e., by itself the adjuvant has
minimal therapeutic
benefit, but in combination with another therapeutic agent, the overall
therapeutic benefit to the
patient is enhanced). Or, in some embodiments, the benefit experienced by a
patient is increased
by administering one of the autotaxin inhibitors with another agent (which
also includes a
therapeutic regimen) that also has therapeutic benefit.
[00278] In one specific embodiment, an autotaxin inhibitor, or a
pharmaceutically acceptable
salt thereof, is co-administered with a second therapeutic agent, wherein the
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, and the second therapeutic
agent modulate
different aspects of the disease, disorder or condition being treated, thereby
providing a greater
overall benefit than administration of either therapeutic agent alone.
[00279] In any case, regardless of the disease, disorder or condition being
treated, the overall
benefit experienced by the patient is simply be additive of the two
therapeutic agents or the
patient experiences a synergistic benefit.
[00280] In certain embodiments, different therapeutically-effective dosages of
autotaxin
inhibitors will be utilized in formulating pharmaceutical composition and/or
in treatment
regimens when the autotaxin inhibitors are administered in combination with
one or more
additional agent, such as an additional therapeutically effective drug, an
adjuvant or the like.
Therapeutically-effective dosages of drugs and other agents for use in
combination treatment
regimens is optionally determined by means similar to those set forth
hereinabove for the actives
themselves. Furthermore, the methods of prevention/treatment described herein
encompasses the
use of metronomic dosing, i.e., providing more frequent, lower doses in order
to minimize toxic
side effects. In some embodiments, a combination treatment regimen encompasses
treatment
regimens in which administration of an autotaxin inhibitor, or a
pharmaceutically acceptable salt
thereof, is initiated prior to, during, or after treatment with a second agent
described herein, and
continues until any time during treatment with the second agent or after
termination of treatment
with the second agent. It also includes treatments in which an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, and the second agent being used in
combination are
administered simultaneously or at different times and/or at decreasing or
increasing intervals
during the treatment period. Combination treatment further includes periodic
treatments that
start and stop at various times to assist with the clinical management of the
patient.
[00281] It is understood that the dosage regimen to treat, prevent, or
ameliorate the condition(s)
for which relief is sought, is modified in accordance with a variety of
factors (e.g. the disease,
disorder or condition from which the subject suffers; the age, weight, sex,
diet, and medical
-60-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
condition of the subject) Thus, in some instances, the dosage regimen actually
employed varies
and, in some embodiments, deviates from the dosage regimens set forth herein.
[00282] For combination therapies described herein, dosages of the co-
administered compounds
vary depending on the type of co-drug employed, on the specific drug employed,
on the disease
or condition being treated and so forth. In additional embodiments, when co-
administered with
one or more other therapeutic agents, the autotaxin inhibitor is administered
either
simultaneously with the one or more other therapeutic agents, or sequentially.
[00283] In combination therapies, the multiple therapeutic agents (one of
which is one of the
autotaxin inhibitors) are administered in any order or even simultaneously. If
administration is
simultaneous, the multiple therapeutic agents are, by way of example only,
provided in a single,
unified form, or in multiple forms (e.g., as a single pill or as two separate
pills).
[00284] The autotaxin inhibitors, or a pharmaceutically acceptable salt
thereof, as well as
combination therapies, are administered before, during or after the occurrence
of a disease or
condition, and the timing of administering the composition containing an
autotaxin inhibitor
varies. Thus, in one embodiment, the autotaxin inhibitors are used as a
prophylactic and are
administered continuously to subjects with a propensity to develop conditions
or diseases in
order to prevent the occurrence of the disease or condition. In another
embodiment, the
autotaxin inhibitors and compositions are administered to a subject during or
as soon as possible
after the onset of the symptoms. In specific embodiments, an autotaxin
inhibitor is administered
as soon as is practicable after the onset of a disease or condition is
detected or suspected, and for
a length of time necessary for the treatment of the disease. In some
embodiments, the length
required for treatment varies, and the treatment length is adjusted to suit
the specific needs of
each subject. For example, in specific embodiments, an autotaxin inhibitor or
a formulation
containing the autotaxin inhibitor is administered for at least 2 weeks, about
1 month to about 5
years.
Exemplary Agents for use in Combination Therapy
[00285] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is administered in combination with chemotherapy, hormone blocking
therapy, radiation
therapy, monoclonal antibodies, or combinations thereof.
[00286] In certain embodiments, the at least one additional therapy is
administered at the same
time as the autotaxin inhibitor. In certain embodiments, the at least one
additional therapy is
administered less frequently than the autotaxin inhibitor. In certain
embodiments, the at least one
additional therapy is administered more frequently than the autotaxin
inhibitor. In certain
embodiments, the at least one additional therapy is administered prior to
administration of the
-61-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
autotaxin inhibitor. In certain embodiments, the at least one additional
therapy is administered
after administration of the autotaxin inhibitor.
[00287] Hormone blocking therapy includes the use of agents that block the
production of
estrogens or block the estrogen receptors. In some embodiments, hormone
blocking therapy
includes the use of estrogen receptor modulators and/ aromatase inhibitors.
Estrogen receptor
modulators include triphenylethylene derivatives (e.g. tamoxifen, toremifene,
droloxifene, 3-
hydroxytamoxifen, idoxifene, TAT-59 (a phosphorylated derivative of 4-
hydroxytamoxifen)
and GW5638 (a carboxylic acid derivative of tamoxifen)); non-steroidal
estrogen receptor
modulators (e.g. raloxifene, LY353381 (SERM3) and LY357489); steroidal
estrogen receptor
modulators (e.g. ICI-182,780). Aromatase inhibitors include steroidal
aromatase inhibitors and
non-steroidal aromatase inhibitors. Steroidal aromatase inhibitors include,
but are not limited to,
such exemestane. Non-steroidal aromatase inhibitors include, but are not
limited to, as
anastrozole, and letrozole.
[00288] Chemotherapy includes the use of anti-cancer agents.
[00289] In some embodiments, anti-cancer agents for use in combination with an
autotaxin
inhibitor, or a pharmaceutically acceptable salt thereof, include one or more
of the following:
abiraterone; abarelix; abraxane, adriamycin; actinomycin; acivicin;
aclarubicin; acodazole
hydrochloride; acronine; adozelesin; aldesleukin; alemtuzumab; allopurinol;
alitretinoin;
altretamine; ametantrone acetate; aminoglutethimide; aminolevulinic acid;
amifostine;
amsacrine; anastrozole; anthramycin; aprepitant; arsenic trioxide;
asparaginase; asperlin;
azacitidine; azetepa; azotomycin; batimastat; bendamustine hydrochloride;
benzodepa;
bevacizumab; bexarotene; bicalutamide; bisantrene hydrochloride; bisnafide
dimesylate;
bizelesin; bleomycin; bleomycin sulfate; bortezomib; brequinar sodium;
bropirimine; busulfan;
cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine;
carubicin
hydrochloride; carzelesin; capecitabine; cedefingol; cetuximab; chlorambucil;
cirolemycin;
cisplatin; cladribine; clofarabine; crisnatol mesylate; cyclophosphamide;
cytarabine;
dacarbazine; dasatinib; daunorubicin hydrochloride; dactinomycin; darbepoetin
alfa; decitabine;
degarelix; denileukin diftitox; dexormaplatin; dexrazoxane hydrochloride;
dezaguanine;
dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin
hydrochloride;
droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin;
edatrexate;
eflornithine hydrochloride; elsamitrucin; eltrombopag olamine; enloplatin;
enpromate;
epipropidine; epirubicin hydrochloride; epoetin alfa; erbulozole; erlotinib
hydrochloride;
esorubicin hydrochloride; estramustine; estramustine phosphate sodium;
etanidazole; etoposide;
etoposide phosphate; etoprine; everolimus; exemestane; fadrozole
hydrochloride; fazarabine;
fenretinide; filgrastim; floxuridine; fludarabine phosphate; fluorouracil;
flurocitabine;
-62-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
fosquidone; fostriecin sodium; fulvestrant; gefitinib; gemcitabine;
gemcitabine hydrochloride;
gemcitabine ¨cisplatin; gemtuzumab ozogamicin; goserelin acetate; histrelin
acetate;
hydroxyurea; idarubicin hydrochloride; ifosfamide; iimofosine; ibritumomab
tiuxetan;
idarubicin; ifosfamide; imatinib mesylate; imiquimod; interleukin II
(including recombinant
interleukin II, or r1L2), interferon alfa-2a; interferon alfa-2b; interferon
alfa-n1; interferon alfa-
n3; interferon beta-1 a; interferon gamma-1 b; iproplatin; irinotecan
hydrochloride; ixabepilone;
lanreotide acetate; lapatinib; lenalidomide; letrozole; leuprolide acetate;
leucovorin calcium;
leuprolide acetate; levamisole; liposomal cytarabine; liarozole hydrochloride;
lometrexol
sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine;
mechlorethamine
hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
mercaptopurine;
methotrexate; methotrexate sodium; methoxsalen; metoprine; meturedepa;
mitindomide;
mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin C; mitosper;
mitotane; mitoxantrone
hydrochloride; mycophenolic acid; nandrolone phenpropionate; nelarabine;
nilotinib;
nocodazoie; nofetumomab; nogalamycin; ofatumumab; oprelvekin; ormaplatin;
oxaliplatin;oxisuran; paclitaxel; palifermin; palonosetron hydrochloride;
pamidronate;
pegfilgrastim; pemetrexed di sodium; pentostatin; panitumumab; pazopanib
hydrochloride;
pemetrexed disodium; plerixafor; pralatrexate; pegaspargase; peliomycin;
pentamustine;
peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone
hydrochloride;
plicamycin; plomestane; pomalidomide, porfimer sodium; porfiromycin;
prednimustine;
procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin;
quinacrine;
raloxifene hydrochloride; rasburicase; recombinant HPV bivalent vaccine;
recombinant HPV
quadrivalent vaccine; riboprine; rogletimide; rituximab; romidepsin;
romiplostim; safingol;
safingol hydrochloride; sargramostim; semustine; simtrazene; sipuleucel-T;
sorafenib; sparfosate
sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin;
streptonigrin;
streptozocin; sulofenur; sunitinib malate; talisomycin; tamoxifen citrate;
tecogalan sodium;
tegafur; teloxantrone hydrochloride; temozolomide; temoporfin; temsirolimus;
teniposide;
teroxirone; testolactone; thalidomide; thiamiprine; thioguanine; thi otepa;
tiazofurin;
tirapazamine; topotecan hydrochloride; toremifene; tositumomab and I 131Iodine
tositumomab;
trastuzumab; trestolone acetate; tretinoin; triciribine phosphate;
trimetrexate; trimetrexate
glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa;
valrubicin;
vapreotide; verteporfin; vinblastine; vinblastine sulfate; vincristine
sulfate; vindesine; vindesine
sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate;
vinorelbine tartrate;
vinrosidine sulfate; vinzolidine sulfate; vorinostat; vorozole; zeniplatin;
zinostatin; zoledronic
acid; and zorubicin hydrochloride.
-63-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00290] Monoclonal antibodies include, but are not limited to, trastuzumab
(Herceptin) and
rituximab (Rituxan).
[00291] In some embodiments, the at least one additional chemotherapeutic
agent is selected
from, by way of example only, alemtuzumab, arsenic trioxide, asparaginase
(pegylated or non-),
bevacizumab, cetuximab, platinum-based compounds such as cisplatin,
cladribine,
daunorubicin/doxorubicin/idarubicin, irinotecan, fludarabine, 5-fluorouracil,
gemtuzumab,
methotrexate, taxol, temozolomide, thioguanine, or classes of drugs including
hormones (an
antiestrogen, an antiandrogen, or gonadotropin releasing hormone analogues,
interferons such as
alpha interferon, nitrogen mustards such as busulfan or melphalan or
mechlorethamine, retinoids
such as tretinoin, topoisomerase inhibitors such as irinotecan or topotecan,
tyrosine kinase
inhibitors such as gefinitinib or imatinib, or agents to treat signs or
symptoms induced by such
therapy including allopurinol, filgrastim,
granisetron/ondansetron/palonosetron, dronabinol.
[00292] In one aspect, the autotaxin inhibitor, or a pharmaceutically
acceptable salt thereof, is
administered or formulated in combination with one or more anti-cancer agents.
In some
embodiments, one or more of the anti-cancer agents are proapoptotic agents.
Examples of anti-
cancer agents include, but are not limited to, any of the following: gossypol,
genasense,
polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor
necrosis factor-
related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans
retinoic acid,
doxorubicin, vincristine, etoposide, gemcitabine, imatinib, geldanamycin, 17-N-
Allylamino-17-
Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib,
carfilzomib,
trastuzumab, BAY 11-7082, PKC412, or PD184352, paclitaxel, and analogs of
paclitaxel.
Compounds that have the basic taxane skeleton as a common structure feature,
have also been
shown to have the ability to arrest cells in the G2-M phases due to stabilized
microtubules and
are optionally useful for treating cancer in combination with the autotaxin
inhibitors.
[00293] Further examples of anti-cancer agents for use in combination with an
autotaxin
inhibitor, or a pharmaceutically acceptable salt thereof, include inhibitors
of mitogen-activated
protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-
142886,
SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR
inhibitors; activin inhibitors, PKM2 inhibitors, c-fms inhibitors and histone
deacetylase
inhibitors. Further examples of anti-cancer agents for use in combination with
an autotaxin
inhibitor, or a pharmaceutically acceptable salt thereof, include aromatase
inhibitors. Aromatase
inhibitors include steroidal aromatase inhibitors and non-steroidal aromatase
inhibitors.
Steroidal aromatase inhibitors include, but are not limited to, exemestane.
Non-steroidal
aromatase inhibitors include, but are not limited to, anastrozole, and
letrozole.
-64-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00294] Yet other anticancer agents for use in combination with an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, include alkylating agents,
antimetabolites, natural
products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine,
cyclophosphamide,
chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g.,
carmustine, lomusitne,
ete.), or triazenes (decarbazine, etc.). Examples of antimetabolites include
but are not limited to
folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g.,
Cytarabine), purine analogs
(e.g., mercaptopurine, thioguanine, pentostatin).
[00295] Examples of natural products for use in combination with an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, include but are not limited to vinca
alkaloids (e.g.,
vinblastin, vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics
(e.g., daunorubicin,
doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological
response modifiers (e.g.,
interferon alpha).
[00296] Examples of alkylating agents for use in combination with an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, include, but are not limited to,
nitrogen mustards (e.g.,
mechloroethamine, cyclophosphamide, chlorambucil, meiphalan, etc.),
ethylenimine and
methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g.,
busulfan),
nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or
triazenes
(decarbazine, ete.).
[00297] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used to treat cancer in combination with: an antiestrogen (e.g.,
tamoxifen), an
antiandrogen (e.g., bicalutamide, flutamide), a gonadotropin releasing hormone
analog (e.g.,
leuprolide).
[00298] Other agents that are optionally used in the methods and compositions
described herein
for the treatment or prevention of cancer include platinum coordination
complexes (e.g.,
cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted
urea (e.g.,
hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical
suppressant (e.g.,
mitotane, aminoglutethimide).
[00299] Examples of anti-cancer agents which act by arresting cells in the G2-
M phases due to
stabilized microtubules include without limitation the following marketed
drugs and drugs in
development: Erbulozole, Dolastatin 10, Mivobulin isethionate, Vincristine,
NSC-639829,
Discodermolide, ABT-751, Altorhyrtins (such as Altorhyrtin A and Altorhyrtin
C),
Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3,
Spongistatin 4,
Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and
Spongistatin 9), Cemadotin
hydrochloride, Epothilones (such as Epothilone A, Epothilone B, Epothilone C,
Epothilone D,
Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-
epothilone B,
-65-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
21-aminoepothilone B, 21-hydroxyepothilone D, 26-fluoroepothilone, Auristatin
PE, Soblidotin,
Vincristine sulfate, Cryptophycin 52, Vitilevuamide, Tubulysin A, Canadensol,
Centaureidin,
Oncocidin Al Fijianolide B, Laulimalide, Narcosine, Nascapine, Hemiasterlin,
Vanadocene
acetylacetonate, Indanocine Eleutherobins (such as Desmethyleleutherobin,
Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Carib aeoside,
Caribaeolin,
Halichondrin B, Diazonamide A, Taccalonolide A, Diozostatin, (-)-
Phenylahistin, Myoseverin
B, Resverastatin phosphate sodium.
[00300] In one aspect, an autotaxin inhibitor, or a pharmaceutically
acceptable salt thereof, is co-
administered with thrombolytic agents (e.g., alteplase anistreplase,
streptokinase, urokinase, or
tissue plasminogen activator), heparin, tinzaparin, warfarin, dabigatran
(e.g., dabigatran
etexilate), factor Xa inhibitors (e.g., fondaparinux, draparinux, rivaroxaban,
DX-9065a,
otamixaban, LY517717, or YM150), ticlopidine, clopidogrel, CS-747 (prasugrel,
LY640315),
ximelagatran, or BIBR 1048.
[00301] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in combination with anti-emetic agents to treat nausea or
emesis, which result
from the use of an autotaxin inhibitor, or a pharmaceutically acceptable salt
thereof, anti-cancer
agent(s) and/or radiation therapy.
[00302] Anti-emetic agents include, but are not limited to: neurokinin-1
receptor antagonists,
5HT3 receptor antagonists (such as ondansetron, granisetron, tropisetron,
palonosetron, and
zatisetron), GABAB receptor agonists (such as baclofen), corticosteroids (such
as
dexamethasone, prednisone, prednisolone, or others), dopamine antagonists
(such as, but not
limited to, domperidone, droperidol, haloperidol, chlorpromazine,
promethazine,
prochlorperazine, metoclopramide), antihistamines (H1 histamine receptor
antagonists, such as
but not limited to, cyclizine, diphenhydramine, dimenhydrinate, meclizine,
promethazine,
hydroxyzine), cannabinoids (such as but not limited to, cannabis, marinol,
dronabinol), and
others (such as, but not limited to, trimethobenzamide; ginger, emetrol,
propofol).
[00303] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in combination with an agent useful in the treatment of
anemia. Such an anemia
treatment agent is, for example, a continuous eythropoiesis receptor activator
(such as epoetin-
a).
[00304] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in combination with an agent useful in the treatment of
neutropenia. Examples of
agents useful in the treatment of neutropenia include, but are not limited to,
a hematopoietic
growth factor which regulates the production and function of neutrophils such
as a human
granulocyte colony stimulating factor, (G-CSF). Examples of a G-CSF include
filgrastim.
-66-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00305] In one aspect, an autotaxin inhibitor, or a pharmaceutically
acceptable salt thereof, is
administered in combination with one or more immunosuppressants.
Immunosuppressive
therapy is clinically used to treat or prevent the rejection of transplanted
organs and tissues (e.g.
bone marrow, heart, kidney, liver); treatment of autoimmune diseases or
diseases that are most
likely of autoimmune origin (e.g. rheumatoid arthritis, myasthenia gravis,
systemic lupus
erythematosus, Crohn's disease, and ulcerative colitis); and treatment of some
other non-
autoimmune inflammatory diseases (e.g. long term allergic asthma control), and
in the treatment
of fibrotic conditions. Immunosuppressants include, without limitation,
glucocorticoids,
cytostatics, antibodies and drugs that act on immunophilins. Examples of
glucocorticoids
include cortisol, cortisone, prednisone, prednisolone, methylprednisolone,
dexamethasone,
betamethasone, triamcinolone, beclometasone, fludrocortisone,
deoxycorticosterone, and
aldosterone. Examples of cytostatics include alkylating agents (e.g., nitrogen
mustards such as
cyclophosphamide, nitrosoureas, platinum compounds) and antimetabolites (e.g.,
folic acid
analogues such as methotrexate, purine analogues such as azathioprine and
mercaptopurine,
pyrimidine analogues such as fluorouracil, protein synthesis inhibitors).
Examples of drugs for
use in the methods described include ciclosporin, tacrolimus, sirolimus,
interferons, opioids,
TNF binding proteins, mycophenolate, and fingolimod. Examples of antibodies
useful for co-
administration with an autotaxin inhibitor in a method described herein
include Antithymocyte
globulin, 1D09C3, Adalimumab/D2E7 (Humira; Trudexa), Afelimomab,
Afutuzumab/GA101
(type II), Alemtuzumab/Campath-1H (MabCampath), Apolizumab/HulD10, Aselizumab,
Atlizumab, Basiliximab (Simulect), Bectumomab/WIMU-LL2, Belimumab (Benlysta,
LymphoStat-B), Bertilimumab, BL22/CAT-3888, Brentuximab/cAC10/SGN-35,
Briakinumab/ABT-874, Canakinumab/ACZ885 (Ilaris), Certolizumab pegol/CDP870
(Cimzia),
Clenoliximab, Dacetuzumab/SGN-40, Daclizumab (Zenapax), Eculizumab/5G1.1
(Soliris),
Efalizumab (Raptiva, formerly Xanelim), Epratuzumab/hLL2/IIVIMU-102
(Lymphocyde0),
Fontolizumab, Fresolimumab/GC-1008, Galiximab/IDEC-114, Gavilimomab/ABX-CBL,
Gemtuzumab, Golimumab/CNT0148 (Simponi), HL2434P (IIVIMU-114), Ibritumomab
tiuxetan
(MXDPTA)/IDEC Y2B8 (Zevalin), Infliximab/chimeric A2 (cA2) (Remicade),
Inolimomab/BT563, Inotuzumab, Keliximab/IDEC CE9.1, Lerdelimumab/CAT-152,
Lintuzumab/HuM195 (Zamyl), LMB-2, Lorvotuzumab mertansine, Lumiliximab/IDEC-
152,
Lym-1 (Oncolym), MDX-060, Mepolizumab/SB-240563, Metelimumab/CAT-192,
Mogamulizumab/KW-0761/AMG-761, Moxetumomab pasudotox/CAT-8015/HA22,
Muromonab-CD3 (Orthoclone OKT3), Natalizumab (Tysabri, Antegren),
Nerelimomab/CDP571, Ocrelizumab/PRO70769 (type I), Odulimomab,
Ofatumumab/2F2/HuMax-CD20 (Arzerra) (type I), Omalizumab (Xolair),
Otelixizumab/TRX4,
-67-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Pascolizumab/SB 240683, Reslizumab/SCH 55700 (Cinquil), Rituximab/chimeric 2B8
(DEC-
C2B8) (Rituxan, MabThera) (type I), Ruplizumab (Antova), SAR-3419,
Secukinumab/AIN-457,
SGN30, Siplizumab/MEDI-507, Teplizumab/MGA031/hOKT371(Ala-Ala), Tocilizumab
(Actemra), Tositumomab (type II), Ustekinumab/CNTO 1275 (Stelara),
Vedolizumab/MNL-
0002, Veltuzumab/IMMU-106/hA20 (type I), Visilizumab (Nuvion),
Zanolimumab/HuMax-
CD4, Zolimomab aritox/H65, Abatacept/CTLA4-Ig/BMS-188667 (Orencia),
Belatacept/LEA29Y, Atacicept/BLyS/APRIL-Ig, Etanercept/TNFR-Ig (Enbrel),
Pegsunercept/pegylated TNFR-Ig, Alefacept (Amevive), and Rilonacept
(Arcalyst).
Immunosuppressive antibodies include antibodies that target complement-
dependent proteins
and interleukins.
[00306] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is administered with a corticosteroid. In some embodiments, an
autotaxin inhibitor, or a
pharmaceutically acceptable salt thereof, is administered with an a
therapeutic agent selected
from among: Calcineurin inhibitors (such as, but not limited to, cyclosporin,
tacrolimus); mTOR
inhibitors (such as, but not limited to, sirolimus, everolimus); anti-
proliferatives (such as, but not
limited to, azathioprine, mycophenolic acid), corticosteroids (such as, but
not limited to,
prednisone, cortisone acetate, prednisolone, methylprednisolone,
dexamethasone,
betamethasone, triamcinolone, beclometasone, fludrocortisone acetate,
deoxycorticosterone
acetate, aldosterone, hydrocortisone); antibodies (such as, but not limited
to, monoclonal anti-
IL-2Ra receptor antibodies (basiliximab, daclizumab), polyclonal anti-T-cell
antibodies (anti-
thymocyte globulin (ATG), anti-lymphocyte globulin (ALG)), B-cell antagonists,
rituximab,
natalizumab.
[00307] Other therapeutic agents useful for combination with an autotaxin
inhibitor as described
herein include, but are not limited to: cyclophosphamide, penicillamine,
cyclosporine,
nitrosoureas, cisplatin, carboplatin, oxaliplatin, methotrexate, azathioprine,
mercaptopurine,
pyrimidine analogues, protein synthesis inhibitors, dactinomycin,
anthracyclines, mitomycin C,
bleomycin, mithramycin, Atgam(R), Thymoglobuline , OKT3 , basiliximab,
daclizumab,
cyclosporin, tacrolimus, sirolimus, Interferons (IFN-13, IFN-7), opioids, TNF
binding proteins
(infliximab, etanercept, adalimumab, golimumab), leflunomide, gold
thioglucose, gold
thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline,
rapamicin, mycophenolic
acid, mycophenolate mofetil, FTY720, as well as those listed in US 7,060,697.
[00308] In one embodiment, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is administered in combination with Cyclosporin A (CsA) or tacrolimus
(FK506). In one
embodiment, an autotaxin inhibitor, or a pharmaceutically acceptable salt
thereof, is
administered to a mammal in combination with an anti-inflammatory agent
including, but not
-68-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
limited to, non-steroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase-
4 inhibitors
JNK kinase inhibitors and corticosteroids (glucocorticoids).
[00309] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is administered with corticosteroids. Corticosteroids, include, but
are not limited to:
betamethasone, prednisone, alclometasone, aldosterone, amcinonide,
beclometasone,
betamethasone, budesonide, ciclesonide, clobetasol, clobetasone, clocortolone,
cloprednol,
cortisone, cortivazol, deflazacort, deoxycorticosterone, desonide,
desoximetasone,
desoxycortone, dexamethasone, diflorasone, diflucortolone, difluprednate,
fluclorolone,
fludrocortisone, fludroxycortide, flumetasone, flunisolide, fluocinolone
acetonide, fluocinonide,
fluocortin, fluocortolone, fluorometholone, fluperolone, fluprednidene,
fluticasone, formocortal,
halcinonide, halometasone, hydrocortisone/cortisol, hydrocortisone aceponate,
hydrocortisone
buteprate, hydrocortisone butyrate, loteprednol, medrysone, meprednisone,
methylprednisolone,
methylprednisolone aceponate, mometasone furoate, paramethasone,
prednicarbate,
prednisone/prednisolone, rimexolone, tixocortol, triamcinolone, and
ulobetasol.
[00310] In one embodiment, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is administered to a mammal in combination with a non-steroidal anti-
inflammatory
drug (NSAID). NSAIDs include, but are not limited to: aspirin, salicylic acid,
gentisic acid,
choline magnesium salicylate, choline salicylate, choline magnesium
salicylate, choline
salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen,
fenoprofen, fenoprofen
calcium, flurobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac
tromethamine,
naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin,
meclofenamate,
meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, COX-2 specific
inhibitors
(such as, but not limited to, celecoxib, rofecoxib, valdecoxib, parecoxib,
etoricoxib, lumiracoxib,
CS-502, JTE-522, L-745,337 and NS398).
[00311] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is co-administered with an analgesic.
[00312] In some embodiments, an autotaxin inhibitor, or a pharmaceutically
acceptable salt
thereof, is used in combination with radiation therapy (or radiotherapy).
Radiation therapy is the
treatment of cancer and other diseases with ionizing radiation. Radiation
therapy is optionally
used to treat localized solid tumors, such as cancers of the skin, tongue,
larynx, brain, breast,
prostate, colon, liver, uterus and/or cervix. It is also optionally used to
treat leukemia and
lymphoma (cancers of the blood-forming cells and lymphatic system,
respectively).
[00313] A technique for delivering radiation to cancer cells is to place
radioactive implants
directly in a tumor or body cavity. This is called internal radiotherapy
(brachytherapy, interstitial
irradiation, and intracavitary irradiation are types of internal
radiotherapy.) Using internal
-69-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
radiotherapy, the radiation dose is concentrated in a small area, and the
patient stays in the
hospital for a few days. Internal radiotherapy is frequently used for cancers
of the tongue, uterus,
prostate, colon, and cervix.
[00314] The term "radiotherapy" or "ionizing radiation" include all forms of
radiation, including
but not limited to a, (3, and 7 radiation and ultraviolet light.
[00315] In some embodiments, an autotaxin inhibitor is administered with a
glucose-lowering
agent. In some embodiments, the glucose-lowering agent is selected from among
a peroxisome
proliferator activated receptor (PPAR) agonist (gamma, dual, or pan), a
dipeptidyl peptidase
(IV) inhibitor, a glucagon-like peptide-1 (GLP-I) analog, insulin or an
insulin analog, an insulin
secretagogue, a sodium glucose co-transporter 2 (SGLT2) inhibitor, a
glucophage, a human
amylin analog, a biguanide, an alpha-glucosidase inhibitor, a meglitinide, a
thiazolidinedione,
and sulfonylurea. In some embodiments, an autotaxin inhibitor is administered
with metformin,
sitagliptin, saxaglitpin, repaglinide, nateglinide, exenatide, liraglutide,
insulin lispro, insulin
aspart, insulin glargine, insulin detemir, insulin isophane, and glucagon-like
peptide 1, or any
combination thereof In some embodiments, an autotaxin inhibitor is
administered with a lipid-
lowering agent.
[00316] In some embodiments, an autotaxin inhibitor is administered in
combination with at
least one additional therapy used to treat cardiovascular disease. In some
embodiments, the
therapy used to treat cardiovascular disease is an angiotensin-converting
enzyme (ACE)
inhibitor, angiotensin II receptor blocker (ARB), beta-blocker, diuretic,
calcium channel blocker,
inhibitor of renin-angiotensin system (RAS), blood-thinning medication, a
statin, and a fibrate,
and any combination thereof.
Kits and Articles of Manufacture
[00317] Described herein are kits for treating a condition, disease or
disorder associated with
autotaxin activity comprising administering to said individual an autotaxin
inhibitor.
[00318] For use in the therapeutic applications described herein, kits and
articles of manufacture
are also described herein. In some embodiments, such kits include a carrier,
package, or
container that is compartmentalized to receive one or more containers such as
vials, tubes, and
the like, each of the container(s) including one of the separate elements to
be used in a method
described herein. Suitable containers include, for example, bottles, vials,
syringes, and test tubes.
The containers can be formed from a variety of materials such as glass or
plastic.
[00319] The articles of manufacture provided herein contain packaging
materials. Examples of
pharmaceutical packaging materials include, but are not limited to, blister
packs, bottles, tubes,
inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging
material suitable
for a selected formulation and intended mode of administration and treatment.
A wide array of
-70-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
formulations of the compounds and compositions provided herein are
contemplated as are a
variety of treatments for any disorder that benefit by inhibition of
autotaxin, or in which
autotaxin is a mediator or contributor to the symptoms or cause.
[00320] The container(s) optionally have a sterile access port (for example
the container is an
intravenous solution bag or a vial having a stopper pierceable by a hypodermic
injection needle).
Such kits optionally comprise a compound with an identifying description or
label or
instructions relating to its use in the methods described herein.
[00321] A kit will typically include one or more additional containers, each
with one or more of
various materials (such as reagents, optionally in concentrated form, and/or
devices) desirable
from a commercial and user standpoint for use of a compound described herein.
Non-limiting
examples of such materials include, but not limited to, buffers, diluents,
filters, needles,
syringes; carrier, package, container, vial and/or tube labels listing
contents and/or instructions
for use, and package inserts with instructions for use. A set of instructions
will also typically be
included.
[00322] In some embodiments, a label is on or associated with the container. A
label can be on a
container when letters, numbers or other characters forming the label are
attached, molded or
etched into the container itself; a label can be associated with a container
when it is present
within a receptacle or carrier that also holds the container, e.g., as a
package insert. A label can
be used to indicate that the contents are to be used for a specific
therapeutic application. The
label can also indicate directions for use of the contents, such as in the
methods described
herein.
[00323] In certain embodiments, a pharmaceutical composition comprising the
autotaxin
inhibitor is presented in a pack or dispenser device which can contain one or
more unit dosage
forms. The pack can for example contain metal or plastic foil, such as a
blister pack. The pack or
dispenser device can be accompanied by instructions for administration. The
pack or dispenser
can also be accompanied with a notice associated with the container in form
prescribed by a
governmental agency regulating the manufacture, use, or sale of
pharmaceuticals, which notice
is reflective of approval by the agency of the form of the drug for human or
veterinary
administration. Such notice, for example, can be the labeling approved by the
U.S. Food and
Drug Administration for prescription drugs, or the approved product insert.
Compositions
containing a compound provided herein formulated in a compatible
pharmaceutical carrier can
also be prepared, placed in an appropriate container, and labeled for
treatment of an indicated
condition.
-71-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
EXAMPLES
[00324] The following examples are provided for illustrative purposes only and
not to limit the
scope of the claims provided herein.
Example 1: Synthesis of 34(6-Chloro-2-cyclopropy1-1-(1-ethyl-1H-pyrazol-4-y1)-
7-fluoro-
1H-indol-3-yl)thio)-2-fluorobenzoic acid (Compound A):
Route 1
o
1.1
Aid,, BCI3,
Chloroacetonitrile, ,.._
101 CI
CyclopropylMgBr ).- I* \ 4
Cl NH, CH2Cl2, reflux, Cl NH2 toluene,
CI N
F 14 h; 3N HCI, reflux, 3 h F 0 C-RT,1 h
F H
1 2 3
F C 02Et
Br--C l>1 F co2Et
S 110
4 N,....._
Ns -'' 6
NN'-d imethyl I101 \ 4 101 \ 4
ethylenediamine, CI N NCS, CH2Cl2,
.. CI ________________________________________________ N
K3PO4, Cul, F h RT, 16 h F h
toluene, 140 C, 16 h
N-N
N-N
c C
7
F
CO2Na F CO2H
S lit S
NaOH
le\ 4
\ 4
CI N CI 14" N
Fh F h
N-N N-N
c c
Cornpound A sodium salt Compound A
F F PMBSH F F
Br 40 CO2H Et0H, H2804 Br 0 ..2. Pd2(dba)3, Xantphos pmErS 0 co2Et -rpA
,. HS 40 CO2Et
Reflux, 24 h DIPEA, 1,4-dioxane 80 C, 12
h
Al A2 A3 6
Step 1: Synthesis of 1-(2-amino-4-chloro-3-fluoropheny1)-2-chloroethan-1-one
(2):
[00325] To a stirred solution of A1C13 (10.0 g, 75.01 mmol) and BC13 (1M in n-
hexane) (74 mL,
75.01 mmol) in CH2C12 (80 mL) was added 3-chloro-2-fluoroaniline 1 (9.0 g,
6.18 mmol)
followed by a solution of chloroacetonitrile (11.6 g, 153.64 mmol) in CH2C12
(20 mL) at 0 C
under inert atmosphere. The reaction mixture was allowed to stir at RT for 30
minutes; heated to
reflux temperature and maintained for additional 14 h. The reaction mixture
was then cooled to
0 C, added aqueous 3N HC1 solution (100 mL) and raised the temperature to
reflux and stirred
for 3 h. After completion of the reaction by TLC, the reaction mixture was
cooled RT, diluted
-72-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
with water (50 mL) and extracted with CH2C12 (2 x 150 mL). The combined
organic extracts
were dried over Na2SO4, filtered and concentrated under reduced pressure to
obtain the crude.
The crude was purified by triturating with n-pentane to afford compound 2 (4.5
g, 33%) as an
off-white solid. 111 NMR (500 MHz, DMSO-d6): 6 7.61 (d, J = 9.0 Hz, 1H), 7.35
(br s, 2H),
6.72 (d, J = 9.0 Hz, 1H), 5.06 (s, 2H).
Step 2: Synthesis of 6-ehloro-2-cyclopropy1-7-fluoro-1H-indole (3):
[00326] To a stirred solution of compound 2 (4.5 g, 20.3 mmol) in toluene (50
mL) was added
cyclopropyl magnesium bromide (0.5 M in THF; 102.0 mL, 50.9 mmol) at 0 C
under inert
atmosphere. The reaction mixture was stirred at 0 C for 15 min and then
warmed to RT and
stirring was continued for additional 1 h. After completion of the reaction by
TLC, the reaction
mixture was quenched with saturated ammonium chloride solution (10 mL) and
extracted with
Et0Ac (3 x 75 mL). The combined organic extracts were dried over Na2SO4,
filtered and
concentrated under reduced pressure to obtain the crude. The crude was
purified (silica gel
chromatography; 1% Et0Ac/Hexanes) to afford compound 3 (2.7 g, 63%) as an off-
white solid.
111 NMR (500 MHz, DMSO-d6): 6 11.55 (s, 1H), 7.18 (d, J = 8.5 Hz, 1H), 6.97
(dd, J = 8.5, 6.5
Hz, 1H), 6.16 (s, 1H), 2.03-1.99 (m, 1H), 0.99-0.96 (m, 2H), 0.83-0.80 (m,
2H); LC-MS (ES!):
91.6%; m/z 208.1 (M - H+); (column: X Select CSH C-18, 50 >< 3.0 mm, 3.5 lam);
RT 4.32 min;
mM NH40Ac: ACN; 0.8 mL/min).
Step 3: Synthesis of 4-bromo-1-ethy1-1H-pyrazole (4):
[00327] To a stirred solution of NaH (34.0 g, 0.85 mol; 60% in mineral oil) in
THF (400 mL)
was added a solution of 4-bromo-1H-pyrazole (50 g, 0.34 mol) in THF (100 mL)
at 0 C under
inert atmosphere. The reaction mixture was warmed to RT and maintained at same
temperature
for 1 h. The reaction mixture was cooled again to 0 C and added EtI (63.67 g,
0.408 mol)
slowly for 5 min. The resultant solution was allowed to warm to RT and then
stirred for 16 h.
After completion of the reaction (monitored by TLC), the reaction mixture was
quenched with
ice-cold water (100 mL) and extracted with Et0Ac (3 x 250 mL). The combined
organic
extracts were dried over Na2SO4, filtered and concentrated under reduced
pressure to obtain the
crude. The crude was purified (silica gel chromatography; 4-6% Et0Ac/Hexanes)
to afford
compound 4 (43 g, 72%) as a pale yellow liquid. 1-14 NMR (500 MHz, CDC13): 6
7.45 (s, 1H),
7.41 (s, 1H), 4.15 (q, J = 7.5 Hz, 2H), 1.47 (t, J = 7.5 Hz, 3H); MS (ES!):
m/z 175.0 (M + H+).
Step 4: Synthesis of 6-chloro-2-cyclopropy1-1-(1-ethyl-1H-pyrazol-4-y1)-7-
fluoro-M-indole
[00328] To a solution of compound 3 (4.3 g, 20.5 mmol) in toluene (50 mL) were
added 4-
bromo-1-ethy1-1H-pyrazole 4(4.0 g, 22.8 mmol), potassium phosphate (11.0 g,
51.2 mmol),
N,N'-dimethylethylenediamine (722 mg, 8.2 mmol) and Cu(I)I (390 mg, 2.0 mmol)
at RT under
-73-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
inert atmosphere. The reaction solution was purged with argon for 15 min and
then sealed the
tube. The reaction mixture was heated to 140 C and stirred for 16 h. After
completion of the
reaction by TLC, the reaction mixture was cooed to RT, diluted with Et0Ac (50
mL) and
filtered. The filtrate was washed with water (40 mL), brine (40 mL), dried
over Na2SO4, filtered
and concentrated under reduced pressure to obtain the crude. The crude was
purified (silica gel
chromatography; 9% Et0Ac/Hexanes) to afford compound 5 (3.9 g, 63%) as a pale
brown solid.
111 NMR (400 MHz, CDC13): 6 7.64 (s, 1H), 7.60 (s, 1H), 7.16 (d, J = 8.4 Hz,
1H), 7.01 (dd, J =
8.4, 6.4 Hz, 1H), 6.12 (s, 1H), 4.25 (q, J = 7.2 Hz, 2H), 1.69-1.62 (m, 1H),
1.56 (t, J = 7.2 Hz,
3H), 0.92-0.87 (m, 2H), 0.76-0.72 (m, 2H); LC-MS (ESI): 98.6%; m/z 304.3 (M +
H+);
(column: X Select C-18, 50 x 3.0 mm, 3.5 [tm); RT 4.23 min; 5 mM NH40Ac: ACN;
0.8
mL/min).
Step 5: Synthesis of ethyl 3-bromo-2-fluorobenzoate (A2):
[00329] To a stirred solution of 3-bromo-2-fluorobenzoic acid Al (25.0 g,
114.15 mmol) in
ethanol (400 mL) was added conc. H2 SO4 (3 mL) at RT and stirred at reflux
temperature for 24
h. The reaction was monitored by LC-MS; after completion of the reaction, the
reaction mixture
was concentrated to obtain the residue. The residue was diluted with Et0Ac
(500 mL), washed
with water (300 mL), brine (300 mL), dried over Na2SO4, filtered and
concentrated under
reduced pressure to afford compound A2 (26.0 g, 92%) as a light yellow liquid.
114 NMR (400
MHz, CDC13): 6 7.88-7.84 (m, 1H), 7.72-7.69 (m, 1H), 7.08-7.04 (m, 1H), 4.39
(q, J = 7.2 Hz,
2H), 1.39 (t, J = 7.2 Hz, 3H).
Step 6: Synthesis of ethyl 2-fluoro-3((4-methoxybenzyl)thio)benzoate (A3):
[00330] 1,4-dioxane (250 mL) was degassed by purging with N2 gas for 30 min
and to this, were
added a solution of compound A2 (13.2 g, 53.4 mmol) in 1,4-dioxane (50 mL;
degassed), (4-
methoxyphenyl)methanethiol (PMBSH) (8.2 g, 53.4 mmol), xantphos (1.54 g, 2.66
mmol),
diisopropyl ethyl amine (19.6 mL, 106.8 mmol) and Pd2(dba)3 (1.22 g, 1.33
mmol) at RT. The
reaction mixture was heated to 90 C and stirred for 2 h. The reaction was
monitored by TLC;
after completion of the reaction, the reaction mixture was diluted with hexane
(450 mL) and
stirred at RT for 15 min. The resultant solution was filtered through celite
and washed with
hexane (100 mL). The filtrate was washed water (250 mL) dried over Na2SO4,
filtered and
concentrated under reduced pressure to obtain the crude. The crude was
purified through silica
gel column chromatography using 3-4% Et0Ac/Hexanes to afford compound A3 (15
g, 88%) as
pale yellow solid. 1H NMR (500 MHz, CDC13): 6 7.78-7.74 (m, 1H), 7.43-7.39 (m,
1H), 7.19
(d, J = 8.0 Hz, 2H), 7.07-7.04 (m, 1H), 6.80 (d, J = 8.0 Hz, 2H), 4.41 (q, J =
7.2 Hz, 2H), 4.08 (s,
2H), 3.78 (s, 3H), 1.41 (t, J = 7.2 Hz, 3H). LC-MS (ES!): 89.7%; m/z 318.9 (M-
H+); (column:
X Select CSH C-18, 50 x 3.0 mm, 3.5 p.m); RT 4.22 min; 5 mM NH40Ac: ACN; 0.8
mL/min).
-74-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Step 7: Synthesis of ethyl 2-fluoro-3-mercaptobenzoate (6):
[00331] A stirred solution of compound A3 (30.0 g, 93.75 mmol) in TFA (54.5
mL) was heated
to 80 C and stirred for 12 h under inert atmosphere. The reaction was
monitored by TLC; after
completion of the reaction, the volatiles were removed under reduced pressure.
The residue was
dissolved in ice-cold water (100 mL), basified with solid sodium bicarbonate
and extracted with
Et0Ac (2 x 200 mL). The combined organic extracts were dried over Na2SO4,
filtered and
concentrated under reduced pressure to obtain the crude. The crude was
purified through silica
gel column chromatography using 3% Et0Ac/Hexanes to afford compound 6 (11.7 g,
62%) as a
pale brown syrup. 1H NMR (500 MHz, CDC13): 6 7.70-7.66 (m, 1H), 7.48-7.44 (m,
1H), 7.08-
7.04 (m, 1H), 4.20 (q, J = 7.5 Hz, 2H), 3.67 (s, 1H), 1.40 (t, J = 7.5 Hz,
3H); LC-MS (ES!):
91.8%; m/z 199.0 (M- H+); (column: X Select CSH C-18, 50 x 3.0 mm, 3.5 [tm);
RT 2.60 min;
mM NH40Ac: ACN; 0.8 mL/min).
Step 8: Synthesis of ethyl 34(6-chloro-2-cyclopropy1-1-(1-ethy1-1H-pyrazol-4-
y1)-7-fluoro-
1H-indol-3-yl)thio)-2-fluorobenzoate (7):
[00332] To a stirred solution of ethyl 2-fluoro-3-mercaptobenzoate 6 (2.8 g,
14.0 mmol) in
CH2C12 (30 mL) under inert atmosphere was added NCS (1.9 g, 14.0 mmol) at RT
and allowed
to stir for 2 h. To this, compound 5 (3.9 g, 12.8 mmol) in CH2C12 (10 mL) was
added at RT and
stirred for 16 h. After completion of the reaction by TLC, the reaction
mixture was diluted with
water (100 mL) and extracted with CH2C12 (2 x 80 mL). The combined organic
extracts were
washed with water (2 x 200 mL), dried over Na2SO4, filtered and concentrated
under reduced
pressure to obtain the crude. The crude was purified by triturating with n-
pentane (2 X 50 mL)
to afford 7 (5.2 g, 81%) as a pale yellow solid. 1H NMR (400 MHz, CDC13): 6
7.66-7.7.60 (m,
3H), 7.18 (d, J = 8.4 Hz, 1H), 7.08 (dd, J = 8.4, 6.5 Hz, 1H), 6.93 (t, J =
8.4 Hz, 1H), 6.79-6.75
(m, 1H), 4.40 (q, J = 7.2 Hz, 2H), 4.26 (q, J = 7.6 Hz, 2H), 1.74-1.68 (m,
1H), 1.56 (t, J = 7.2
Hz, 3H), 1.41 (t, J = 7.6 Hz, 3H), 1.08-1.04 (m, 2H), 0.89-0.84 (m, 2H); MS
(ES!): m/z 502.5
(M + H+); HPLC: 97.5%; (column: Acquity BEH C-18 (50 x 2.1 mm, 1.7 [t); RT
3.44 min;
ACN: 0.025% TFA (aq); 0.5 mL/min.
Step 9: Synthesis of 3-((6-chloro-2-cyclopropv1-1-(1-ethy1-1H-pyrazol-4-y1)-7-
fluoro-1H-
indo1-3-yl)thio)-2-fluorobenzoic acid sodium salt (8):
[00333] 1.0 M NaOH (10.25 mL, 10.2 mmol) was added to a solution of compound
7(5.14 g,
10.2 mmol) in THF/Me0H (3 : 1)(56 mL). The mixture was heated at 65 C for 1.5
h.
Additional 1.0 M NaOH (0.23 mL, 0.2 mmol) was added to the reaction and heated
at 65 C for
0.5 h. The mixture was concentrated under reduced pressure to afford the crude
acid sodium salt
(5.12 g, 100 %) as a pale pink solid. The crude solid (600 mg) in THF/Et0H (4:
1) (6 mL) and a
few drops of water. The mixture filtered and concentrated under reduced
pressure and
-75-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
precipitants formed. The solids filtered off and washed with THE/Et0H (9 : 1)
to afford 3-((6-
chloro-2-cyclopropy1-1-(1-ethy1-1H-pyrazol-4-y1)-7-fluoro-1H-indo1-3-yl)thio)-
2-fluorobenzoic
acid sodium salt (Compound A sodium salt; 449 mg) as an off white solid. 1H
NMR (300
MHz, DMSO-d6): 6 8.26 (s, 1H), 7.79 (m, 1H), 7.18-7.13 (m, 3H), 6.81 (t, 1H),
6.43-6.38 (m,
1H), 4.21 (q, 2H), 1.84-1.72 (m, 1H), 1.42 (t, 3H), 0.96-0.93 (m, 2H), 0.84-
0.80 (m, 2H); LC-
MS: 474 (M+)
34(6-Chloro-2-cyclopropy1-1-(1-ethyl-1H-pyrazol-4-y1)-7-fluoro-1H-indol-3-
y1)thio)-2-
fluorobenzoic acid (Compound A):
[00334] To compound A sodium salt (50 mg, 0.10 mmol) suspended in CH2C12 (1
mL) and
water (1 mL) was added sat. citric acid until pH 3. The suspension stirred
until clear solution.
The organic layer was separated, washed with brine, dried over Na2SO4,
filtered, and
concentrated under reduced pressure to obtain the crude material to afford
compound B as a
white solid (33 mg, 70%) 1H NMR (300 MHz, DMSO-d6): 6 13.39 (s, 1H), 8.24 (s,
1H), 7.79
(s, 1H), 7.57 (t, 1H), 7.22-7.06 (m, 3H), 6.80 (t, 1H), 4.21 (q, 2H), 1.84-
1.72 (m, 1H), 1.42 (t,
3H), 0.96-0.88 (m, 2H), 0.86-0.80 (m, 2H); LC-MS: 474 (M+)
Alternative route to intermediate 7:
CO2Et
4 \- N F CO2Et
S
N N,IV-dimethyl
ethylene diamine, CI 1.1 N HS j6
CI F NCS, CH2Cl2 N
K3PO4, Cul, NBS,
CCI4
8
toluene N--"N F
9 C
N-N
c
CO2Et CO2Et
S 1>-13(OH)2 s
\ Br Pd(OAc)2, FCY3 \ 4
CI N
3PO4, toluene ClC
F F
N-N N-N
11 C 7 C
Step 1: Synthesis of 6-chloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-fluoro-1H-indole
(9):
[00335] To a stirred solution of 6-chloro-7-fluoro-1H-indole 8 (400 mg, 2.36
mmol) in toluene
(10 mL) were added 4-bromo-1-ethyl-1H-pyrazole 4 (Step 3 above; 414 mg, 2.36
mmol),
potassium phosphate (1.25 g, 5.91 mmol), N,N'-dimethylethylenediamine (84 mg,
0.95 mmol)
and Cu(I)I (45 mg, 0.24 mmol) at RT under inert atmosphere. The resulted
solution was purged
with argon and sealed the tube. The reaction mixture was then heated to 140 C
for 16 h. After
completion of the reaction (monitored by TLC), the reaction mixture was cooled
to RT, diluted
-76-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
with hexane (10 mL) and filtered through a short pad of celite. The filtrate
was washed with
water (2x10 mL), dried over Na2SO4, filtered and concentrated under reduced
pressure to obtain
the crude. The crude was purified (silica gel chromatography; 8-10%
Et0Ac/Hexanes) to afford
compound 9 (224 mg, 36%) as a light brown thick liquid. 111 NMR (500 MHz,
CDC13): 6 7.64
(s, 1H), 7.61 (s, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.12-7.07 (m, 2H), 6.60-6.59
(m, 1H), 4.22 (q, J =
7.5 Hz, 2H), 1.55 (t, J = 7.5 Hz, 3H); LC-MS (ER): 94.7%; m/z 264.1 (M + H+);
(column: X
Select C-18, 50 x 3.0 mm, 3.5 [tm); RT 3.87 min; 5 mM NH40Ac: ACN; 0.8
mL/min).
Step 2: Synthesis of ethyl 3-((6-chloro-1-(1-ethyl-1H-pyrazo1-4-y1)-7-fluoro-
1H-indol-3-
yl)thio)-2-fluorobenzoate (10):
[00336] To a stirred solution of ethyl 2-fluoro-3-mercaptobenzoate 6 (Step 7
above; 212 mg,
1.06 mmol) in CH2C12 (4 mL) under inert atmosphere was added NCS (156 mg, 1.16
mmol) at 0
C and allowed to stir at RT for 1 h. The reaction mixture was cooled to 0 C
and compound 3
(280 mg, 1.06 mmol) in CH2C12 (1 mL) was added slowly and stirred at RT for 16
h. After
completion of the reaction by TLC, the reaction mixture was diluted with
CH2C12 (15 mL) and
washed with water (2 x 20 mL), dried over Na2SO4, filtered and concentrated
under reduced
pressure to obtain the crude. The crude was purified (silica gel
chromatography; 8-10%
Et0Ac/Hexanes) to afford compound 10 (300 mg, 61%) as a pale brown solid. 11-1
NMR (500
MHz, CDC13): 6 7.69-7.64 (m, 3H), 7.44 (s, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.16
(dd, J = 8.5, 6.0
Hz, 1H), 7.01-6.94 (m, 2H), 4.39 (q, J = 7.5 Hz, 2H), 4.24 (q, J = 7.0 Hz,
2H), 1.57 (t, J = 7.0
Hz, 3H), 1.40 (t, J = 7.5 Hz, 3H); LC-MS (ES!): 98.6%; m/z 462.3 (M + H );
(column: X
Select C-18, 50 x 3.0 mm, 3.5 [tm); RT 4.70 min; 5 mM NH40Ac: ACN; 0.8
mL/min).
Step 3: Synthesis of ethyl 34(2-bromo-6-chloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-
fluoro-1H-
indol-3-yl)thio)-2-fluorobenzoate (11):
[00337] To a stirred solution of compound 10 (200 mg, 0.43 mmol) in CC14 (10
mL) under inert
atmosphere was added NBS (178 mg, 0.99 mmol) at RT and stirred for 16 h. After
completion
of the reaction by TLC, the reaction mixture was diluted with water (10 mL)
and extracted with
CH2C12 (2 x 20 mL). The combined organic extracts were washed with brine (10
mL), dried
over Na2SO4, filtered and concentrated under reduced pressure to obtain the
crude. The crude
was purified (silica gel chromatography; 5-7% Et0Ac/Hexanes) to afford
compound 11 (180
mg, 77%) as an off-white solid. 111 NMR (500 MHz, CDC13): 6 7.70-7.67 (m, 1H),
7.65 (s,
2H), 7.30 (d, J = 8.0 Hz, 1H), 7.17 (dd, J = 8.5, 6.0 Hz, 1H), 7.00-6.98 (m,
2H), 4.40 (q, J = 7.5
Hz, 2H), 4.27 (q, J = 7.5 Hz, 2H), 1.58 (t, J = 7.5 Hz, 3H), 1.40 (t, J = 7.5
Hz, 3H); LC-MS
(ES!): 99.5%; m/z 542.4 (M++ 2); (column: X Select CSH C-18, 50 x 3.0 mm, 3.5
[tm); RT
4.80 min; 5 mM NH40Ac: ACN; 0.8 mL/min).
-77-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Step 4: Synthesis of ethyl 34(6-chloro-2-cyclopropy1-1-(1-ethy1-1H-pyrazol-4-
y1)-7-fluoro-
1H-indol-3-yl)thio)-2-fluorobenzoate (7):
[00338] A solution of compound 11(150 mg, 0.27 mmol) in toluene (10 mL) under
inert
atmosphere was purged with argon at RT for 10 min. To this, cyclopropylboronic
acid (48 mg,
0.55 mmol), tricyclohexyl phosphine (16 mg, 0.05 mmol), Pd(OAc)2 (6 mg, 0.02
mmol) and
potassium phosphate (202 mg, 0.01 mmol) were added at RT under argon. The
resultant solution
was purged again with argon at RT for 5 min. The reaction mixture was then
heated to reflux
temperature and stirred for 3 h. The reaction was monitored by TLC & LC-MS;
after completion
of the reaction, the reaction was cooled to RT, diluted with Et0Ac (20 mL) and
filtered. The
filtrate was washed with water (2 x 10 mL) and brine (10 mL), dried over
Na2SO4, filtered and
concentrated under reduced pressure to obtain the crude. This was purified
(silica gel
chromatography; 6% Et0Ac/Hexanes) to afford 7 as a pale yellow solid. 1H NMR
(400 MHz,
CDC13): 7.66-7.7.60 (m, 3H), 7.18 (d, J = 8.4 Hz, 1H), 7.08 (dd, J = 8.4, 6.5
Hz, 1H), 6.93 (t, J
= 8.4 Hz, 1H), 6.79-6.75 (m, 1H), 4.40 (q, J = 7.2 Hz, 2H), 4.26 (q, J = 7.6
Hz, 2H), 1.74-1.68
(m, 1H), 1.56 (t, J = 7.2 Hz, 3H), 1.41 (t, J = 7.6 Hz, 3H), 1.08-1.04 (m,
2H), 0.89-0.84 (m, 2H);
LC-MS (ES!): 92.9%; m/z 502.5 (M+); (column: X Select CSH C-18, 50 >< 3.0 mm,
3.5 um);
RT 4.85 min; 5 mM NH40Ac: ACN; 0.8 mL/min); HPLC: 93.1%; (column: Acquity BEH
C-18
(50 x 2.1 mm, 1.7 ); RT 3.44 min; ACN: 0.025% TFA (aq); 0.5 mL/min.
-78-
CA 02986759 2017-11-21
WO 2016/191427
PCT/US2016/033933
Example 2: Synthesis of 34(2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-y1)-
1H-indol-3-
yl)thio)-2-fluorobenzoic acid (Compound B)
401
Br 3
NN'-dimethyl HS F
5CO2Et
THF
CI NO2 CI 101 N ethylene diamine Cl N
K3PO4, Cul, toluene, F NCS,
CH2Cl2,
N-N
1 2 4 (
CO2Et CO2Et CO2H
S S S
io NCS, CH2Cl2 \ Cl UCH. H20 c,
CI N CI N CI
THF: Et0H: H20,
F F F
N-N
6 7 Compound B
CO2Na
S
40 Cl
Cl
F
N1-N
Compound B sodium salt
Step 1: Synthesis of 6-chloro-7-fluoro-1H-indole (2):
[00339] To a stirred solution of 1-chloro-2-fluoro-3-nitrobenzene 1 (10.0 g,
56.98 mmol) in THF
(100 mL) under inert atmosphere was added vinyl magnesium bromide (1M in THF
solution;
170 mL, 170.94 mmol) at RT, cooled to -40 C and stirred for 30 min. The
reaction was
monitored by TLC; after completion of the reaction, the reaction mixture was
quenched with
saturated NH4C1 solution (50 mL), extracted with Et0Ac (2 x 50 mL). The
combined organic
extracts were washed with NH4C1 solution (40 mL), dried over Na2SO4, filtered
and
concentrated under reduced pressure to obtain the crude. This was purified by
silica gel column
chromatography using 2% Et0Ac/ Hexanes to afford compound 2 (1.1 g, 11.4%) as
a brown oil.
1H NMR (500 MHz, CDC13): 6 8.36 (br s, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.25-
7.22 (m, 1H),
7.08-7.05 (m, 1H), 6.56-6.54 (m, 1H).
Step 2: Synthesis of 6-chloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-y1)-1H-indole
(3):
[00340] To a stirred solution of compound 2 (1.1 g, 6.48 mmol) in toluene (15
mL) under inert
atmosphere were added N,N'-dimethyl ethylene diamine (229 mg, 2.60 mmol),
potassium
-79-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
phosphate (3.44 g, 16.27 mmol), 4-bromo-1-propy1-1H-pyrazole 3 (Example 2,
Step 3; 121 g,
6.50 mmol), CuI (124 mg, 0.65 mmol) at RT, degassed under argon for 15 min;
heated to 140 C
and stirred for 20 h in sealed tube. The reaction was monitored by TLC; after
completion of the
reaction, the reaction mixture was diluted with Et0Ac (30 mL), filtered and
the filtrate was
concentrated under reduced pressure to obtain the crude. This was purified by
silica gel column
chromatography using 8-10% Et0Ac/ Hexanes to afford compound 4 (1.3 g, 72%) as
brown
liquid. 111 NMR (500 MHz, CDC13): 6 7.64 (s, 1H), 7.60 (s, 1H), 7.31 (d, J =
7.5 Hz, 1H), 7.12-
7.07 (m, 2H), 6.60 (s, 1H), 4.13 (t, J = 7.0 Hz, 2H), 1.99-1.91 (m, 2H), 0.97
(t, J = 8.0 Hz, 3H);
LC-MS (ES!): 93.5%; m/z 278.2 (M+ In; (column: X Select CSH C-18, 50 x 3.0 mm,
3.5
pm); RT 4.08 min; 5 mM NH40Ac: ACN; 0.8 mL/min).
Step 3: Synthesis of ethyl 34(6-chloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-y1)-
1H-indol-3-
yl)thio)-2-fluorobenzoate (6):
[00341] To a stirred solution of ethyl 2-fluoro-3-mercaptobenzoate (5; 108 mg,
0.54 mmol) in
CH2C12 (3 mL) under inert atmosphere was added NCS (72 mg, 0.54 mmol) at RT
and stirred
for 1 h. To this, compound 4 (150 mg, 0.54 mmol) was added and stirred for 16
h. The reaction
was monitored by TLC; after completion of the reaction, the reaction mixture
was diluted with
water (25 mL) and extracted with CH2C12 (2 x 25 mL). The combined organic
extracts were
washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under
reduced pressure
to obtain the crude. This was purified by silica gel column chromatography
using 10%
Et0Ac/Hexanes to afford compound 6 (130 mg, 50%) as an off-white solid. 111
NMR (500
MHz, CDC13): 67.69 (s, 1H), 7.67-7.64 (m, 2H), 7.44 (s, 1H), 7.29-7.27 (m,
1H), 7.17-7.14 (m,
1H), 7.01-6.94 (m, 2H), 4.40 (q, J = 7.5 Hz, 2H), 4.15 (t, J = 8.0 Hz, 2H),
1.98-1.94 (m, 2H),
1.40 (t, J = 7.5 Hz, 3H), 0.98 (t, J = 8.0 Hz, 3H); LC-MS (ES!): 97.6%; m/z
476.7 (M + H+);
(column: X Select CSH C-18, 50 x 3.0 mm, 3.5 m); RT 4.84 min; 5 mM NH40Ac:
ACN; 0.8
mL/min).
Step 4: Synthesis of ethyl 34(2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-
y1)-1H-indol-
3-yl)thio)-2-fluorobenzoate (7):
[00342] To a stirred solution of ethyl 346-chloro-7-fluoro-1-(1-propy1-1H-
pyrazol-4-y1)-1H-
indo1-3-yl)thio)-2-fluorobenzoate 6 (100 mg, 0.21 mmol) in CH2C12 (3 mL) was
added NCS
(33.7 mg, 0.25 mmol) at RT under inert atmosphere. After 8 h stirring,
additional NCS (33.7 mg,
0.25 mmol) was added at RT and stirred again for 24 h. The reaction was
monitored by TLC;
after completion of the reaction, the reaction mixture was diluted with water
(20 mL) and
extracted with CH2C12 (2 x 20 mL). The combined organic extracts were washed
with brine (15
mL), dried over Na2SO4, filtered and concentrated under reduced pressure to
obtain the crude.
This was purified by silica gel column chromatography using 9-11%
Et0Ac/Hexanes to afford
-80-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
compound 7 (50 mg, 47%) as an off-white solid. 114 NMR (400 MHz, CDC13): 6
7.71-7.67 (m,
1H), 7.66 (s, 1H), 7.64 (s, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.18 (dd, J = 8.4,
6.0 Hz, 1H), 7.04-6.97
(m, 2H), 4.40 (q, J = 7.2 Hz, 2H), 4.18 (t, J = 7.2 Hz, 2H), 2.04-1.93 (m,
2H), 1.40 (t, J = 7.2 Hz,
3H), 0.97 (t, J = 7.2 Hz, 3H); LC-MS (ES!): 98.8%; m/z 510.4 (M+ H+); (column:
X Select
CSH C-18, 50 x 3.0 mm, 3.5 m); RT 4.94 min; 5 mM NH40Ac: ACN; 0.8 mL/min).
Step 5: Synthesis of 34(2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-y1)-1H-
indol-3-
y1)thio)-2-fluorobenzoic acid (Compound B):
[00343] To a stirred solution of compound 7 (50 mg, 0.09 mmol) in THF:Et0H:H20
(3:1:1, 5
mL) under inert atmosphere was added Li0H.H20 (12.3 mg, 0.29 mmol) at RT and
stirred for 5
h. The reaction was monitored by TLC; after completion of the reaction, the
volatiles were
removed under reduced pressure. The residue was diluted with water (10 mL),
acidified with 1N
HC1 and extracted with CH2C12 (2 x 10 mL). The combined organic extracts were
washed with
brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced
pressure to obtain the
crude. This was triturated with n-pentane (2 x 5 mL) to afford the title
compound B (15 mg,
34%) as an off-white solid. 111 NMR (400 MHz, DMSO-d6): 6 13.24 (br s, 1H),
8.29 (s, 1H),
7.83 (s, 1H), 7.64-7.60 (m, 1H), 7.36-7.34 (m, 2H), 7.15-7.05 (m, 2H), 4.16
(t, J = 7.2 Hz, 2H),
1.89-1.80 (m, 2H), 0.85 (t, J = 7.2 Hz, 3H); MS (ER): 480.1 (M - H+); HPLC:
97.0%; (column:
Acquity BEH C-18 (50 x 2.1 mm, 1.7 ); RT 2.86 min; ACN: 0.025% TFA (aq); 0.5
mL/min.
Step 6: Synthesis of 3-((2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-y1)-1H-
indol-3-
y1)thio)-2-fluorobenzoic acid, sodium salt (Compound B sodium salt):
[00344] Ester 7 (27.6 g, 54.0 mmol) was dissolved in THF (400 mL) and Et0H
(100 mL).
NaOH (54 mL, 1.0 M aq.) was added and the mixture was heated for 1.5 hr at 65
C. An
additional 11 mL of NaOH was added and heated for 1.5 hr. The solvent was
removed and the
residue was dissolved in H20/Et0Ac. And acidified with saturated citric acid
to pH 3. The
mixture was extracted 2X with Et0Ac and washed with brine and dried over
sodium sulphate.
After concentrating the product precipitated out and the solids were filtered
and washed with
10% Et0Ac/Hx. Filtering and evaporation gave the title product Compound B
sodium salt as a
white powder (23.5 g) MS (ES!): 482.1 (M - El+).
[00345] Alternatively, Compound B (34.1 g, 71 mmol) was dissolved in THE (313
mL) and
cooled in an ice water bath. NaOH (62.6 mL, 1.0 M aq.) was added dropwise over
one hour. The
solvent was removed and the solid was dried under vacuum to give the title
compound as a
white solid (31.8 g). MS (ES!): 482.1 (M - H+)
-81-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 3: Synthesis of 4-(2-(6-(4-fluorobenzy1)-1,3-dioxo-5,6,11,11a-
tetrahydro-1H-
imidazo 11',5':1,61pyridol3,4-blindol-2(3H, 5H, 61/)-y1)ethyl)piperidin-1-ium
chloride
(Compound C)
COOH _Cri-jZok HCI
NH Hoi \ N410 4.0 M HCI in 40
N44
1,4-dioxane
CD!
1.1 DMF/THF
F 41111114-1. (Cl)
40 (C, HCI salt)
Step 1: Synthesis of (S)-2,3,4,9-tetrahydro-1H-pyridol3,4-blindole-3-
carboxylic acid:
[00346] Formaldehyde (37% aq. solution, 39.7 mL, 490 mmol) was added to a
stirred solution
of L-tryptophan (100.0 g, 490 mmol) in aqueous NaOH solution (19.6 gin 200 mL
of H20, 490
mmol) and stirred for 2 hr. The mixture was heated to reflux and stirred for
3.5 hr. The mixture
was cooled to 50 C and carefully acidified to pH 5-6 with 6.0 M HC1(aq)
solution. The mixture
was diluted with water (200 mL). The flask was removed from heat and cooled to
room
temperature. The precipitates filtered off and washed with water. The solids
were resuspended
in THF (800 mL), stirred at RT for 1 hr, and filtered to afford (S)-2,3,4,9-
tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylic acid (101.3 g, 95 %) as beige solid. 1H NMR
(300 MHz,
DMSO-d6): 6 10.93 (s, 1H), 8.88 (br s, 1H), 7.43 (d, 1H), 7.31 (d, 1H), 7.02
(t, 1H), 6.97 (t,
1H), 4.18 (q, 2H), 3.61-3.56 (m, 1H), 3.12 (dd, 1H), 2.83-2.75 (m, 1H); LC-MS
[M + H+ 217].
Step 2: Synthesis of (S)-2-(tert-butoxycarbony1)-2,3,4,9-tetrahydro-1H-pyrido
13,4-blindole-
3-carboxylic acid:
[00347] K2CO3 (129.5 g, 937 mmol) dissolved in water (470 mL) was poured into
a stirred
solution of (S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid
(101.3 g, 468
mmol) and di-tert-butyl dicarbonate (122.7 g, 562 mmol) in THF (470 mL) at 0
C. The
reaction was stirred at room temperature overnight. The next day the THF was
removed under
reduced pressure and the remaining residue was carefully acidified to pH 3-4
with saturated
citric acid solution. The precipitants filtered off and washed with water to
afford (S)-2-(tert-
butoxycarbony1)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid
(143.5 g, 97 %) as
a beige powder. 1H NMR (300 MHz, DMSO-d6): 6 12.75 (br s, 1H), 10.88 (s,
1/2H), 10.83 (s,
1/2H), 7.40 (d, 1H), 7.28-7.25 (m, 1H), 7.05 (t, 1H), 6.92 (t, 1H), 5.15-5.10
(m, 1H), 4.69 (t,
1H), 4.45-4.29 (m, 1H), 3.30-3.23 (m, 1H), 2.98-2.88 (m, 1H), 1.46 (s, 9 X
1/2H), 1.42 (s, 9 X
1/2H); LC-MS [M + H+ 317].
-82-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Step 3: Synthesis of (S)-2-(tert-butoxycarbony1)-9-(4-fluorobenzy1)-2,3,4,9-
tetrahydro-M-
pyrido[3,4-blindole-3-carboxylic acid:
[00348] (S)-2-(tert-butoxycarbony1)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-
3-carboxylic
acid (20.0 g, 63.2 mmol) in DMF (630 mL) was degassed and the flask was cooled
in ice water
bath. NaH (60% in mineral oil; 7.8 g, 196.0 mmol) was slowly added portionwise
over 45 min
at 0 C and stirred for 1 hr. 4-fluorobenzyl bromide (8.7 mL, 69.5 mmol) was
added dropwise
over 45 min at 0 C and stirred for 1.5 hr. The reaction quenched with water.
The mixture
diluted with water (1.8 L) and washed with Et0Ac (1 L). The aqueous layer was
acidified to pH
3-4 with solid citric acid. The mixture extracted with Et0Ac (3 x 300 mL). The
combined
organic extracts were washed with water (900 mL), brine (200 mL), dried over
Na2SO4, filtered,
and concentrated under reduced pressure. The crude was purified by silica gel
column
chromatography using 0-30 % Et0Ac/Hexane to give a solid. The solid was washed
with 10 %
CH2C12/hexane to afford (S)-2-(tert-butoxycarbony1)-9-(4-fluorobenzy1)-2,3,4,9-
tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylic acid (19.5 g, 72 %) as a white powder. 111
NMR (300 MHz,
DMSO-d6): 6 12.81 (br s, 1H), 7.48-7.42 (m, 2H), 7.13-6.97 (m, 6H), 5.41-5.28
(m, 2H), 5.14-
5.03 (m, 1H), 4.66-4.58 (m, 1H), 4.42-4.27 (m, 1H), 3.32-3.28 (m, 1H), 3.06-
2.96 (m, 1H), 1.40
(s, 9 X 1/2H), 1.39 (s, 9 X 1/2H); LC-MS [M + H+ 425].
Step 4: Synthesis of (S)-9-(4-fluorobenzy1)-2,3,4,9-tetrahydro-1n-pyrido 13,4-
b[indole-3-
carboxylic acid:
[00349] (S)-2-(tert-butoxycarbony1)-9-(4-fluorobenzy1)-2,3,4,9-tetrahydro-1H-
pyrido[3,4-
b]indole-3-carboxylic acid (18.9 g, 44.5 mmol), 4M HC1 in 1,4-dioxane solution
(56 mL, 222.7
mmol), and 1,4-dioxane (85 mL) stirred at RT overnight. The reaction diluted
with water (200
mL) and neutralized to pH 7 with Et3N. Water (400 mL) was added and the
mixture stirred for
30 min. The solid was collected by filtration and washed with water (300 mL)
to afford (S)-9-
(4-fluorobenzy1)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid
(13.0 g, 90 %) as
a pale yellow powder. 1H NMR (300 MHz, DMSO-d6): 6 8.95 (br s, 1H), 7.48 (d,
1H), 7.39 (d,
1H), 7.14-6.99 (m, 6H), 5.33 (s, 2H), 4.24 (d, 1H), 4.08 (d, 1H), 3.63-3.58
(m, 1H), 3.17-3.10
(m, 1H), 2.86-2.81 (m, 1H); LC-MS [M + H+ 325].
Step 5:
[00350] 1,1'-Carbonyl diimidazole (37 mg, 0.23 mmol) in DMF (0.5 mL) was added
dropwise to
a degassed solution of 4-(aminoethyl)-1-N-Boc-piperidine (53 mg, 0.23 mmol)
and THF (0.5
mL). The mixture stirred at RT overnight. (S)-9-(4-fluorobenzy1)-2,3,4,9-
tetrahydro-1H-
pyrido[3,4-b]indole-3-carboxylic acid (75 mg, 0.23 mmol) and DMF (1 mL) was
added and
heated at 95 C overnight. The reaction cooled to RT and diluted with water.
The mixture
extracted with Et0Ac (3 times). The combined organic extracts were washed with
brine, dried
-83-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
over Na2SO4, filtered, and concentrated under reduced pressure. The crude
material was
purified by silica gel column chromatography using 0-50 % Et0Ac/Hx to afford
(Cl) as a
yellow foam (61 mg, 47 %). LC-MS [M + Na 583].
Step 6:
[00351] (D1) (61 mg, 0.11 mmol) and 4MHC1 in 1,4-dioxane solution (1 mL)
stirred at RT for 1
hr. The reaction concentrated and then diluted with water (10 mL). It was
washed with Et0Ac
and basified with saturated NaHCO3(ao solution. The aqueous layer was
extracted with Et0Ac
(2 x 5 mL). The two organic extracts were combined, washed with brine, dried
over Na2SO4,
filtered, and concentrated under reduced pressure. The crude material was
purified by silica gel
column chromatography using 0-10 % Me0H/DCM with 2 % triethylamine to afford
an off
white solid. The solid was dissolved in THF (0.5 mL) and 2.0 M HC1 in diethyl
ether (0.05 mL)
was added. The solvent removed to afford (C, HC1 salt) as an off white solid
(31 mg, 57 %).
LC-MS [M + H+ 461].
Example 4: Synthesis of 4-(2-(6-(4-fluorobenzy1)-1,3-dioxo-5,6,11,11a-
tetrahydro-1H-
imidazo 11',5':1,6[pyrido[3,4-blindo1-2(3H, 5H, 6H)-yl)ethyl)piperazin-1-ium
chloride
(Compound D)
00H
("NH HCI
fla \ NH H,N C.3 t'ilj`ok Nqi j 0
co M HCI in
0 1,4-clioxane 0
COI N
40 DMF/THF 40 (1)1) (D HCI salt)
F
Step 1:
[00352] 1,1'-Carbonyl diimidazole (37 mg, 0.23 mmol) in DMF (0.5 mL) was added
dropwise to
a degassed solution of tert-Butyl 4-(2-aminoethyl) piperazine-1-carboxylate
(53 mg, 0.23 mmol)
and THF (0.5 mL). The mixture stirred at RT overnight. (S)-9-(4-fluorobenzy1)-
2,3,4,9-
tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (75 mg, 0.23 mmol) and
DIViF (1 mL) was
added and heated at 95 C overnight. The reaction cooled to RT and diluted
with water. The
mixture extracted with Et0Ac (3 times). The combined organic extracts were
washed with
brine, dried over Na2SO4, filtered, and concentrated under reduced pressure.
The crude material
was purified by silica gel column chromatography using 0-100 % Et0Ac/Hx to
afford (D1) as a
yellow solid (76 mg, 58 %). LC-MS [M + H+ 562].
Step 2:
[00353] (D1) (76 mg, 0.14 mmol) and 4MHC1 in 1,4-dioxane solution (1 mL)
stirred at RT for 1
hr. The reaction concentrated and then diluted with water (10 mL). It was
washed with Et0Ac
and basified with saturated NaHCO3(ao solution. The aqueous layer was
extracted with Et0Ac
-84-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
(2 x 5 mL). The two organic extracts were combined, washed with brine, dried
over Na2SO4,
filtered, and concentrated under reduced pressure. The crude material was
purified by silica gel
column chromatography using 0-10 % Me0H/DCM with 2 % Et3N to afford a pale
yellow solid.
The solid was dissolved in THE (0.5 mL) and 2.0 M HC1 in diethyl ether (0.05
mL) was added.
The solvent removed to afford (D, HC1, salt) as a pale yellow solid (37 mg, 55
%). LC-MS [M +
H+ 462].
Example 5: Synthesis of 34(2,6-dichloro-1-(1-ethy1-1H-pyrazol-4-y1)-7-fluoro-
1H-indol-3-
y1)thio)-2-fluorobenzoic acid sodium salt (Compound E)
F CO2Et F
CO,Et
40 \,..2.
341Nein ';ddiimametihriy, ci N\ HS--C) A
NCS, CH2C12;._ 40 \
Cl
H K3PO4, Cul, F ellCl
NCS, CH2Cl2, ClCI NI\ RT, 16 h Cl
N-N
F toluene, 140 C, 16 h 1 N-N N-N
2 RT, 17 h F F
3 4
F CO2Na
I.
- ci
Cl N
F
NI-N Compound E sodium salt
Step 1: Synthesis of ethyl 3-((6-chloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-fluoro-
1H-indol-3-
yl)thio)-2-fluorobenzoate (3):
[00354] Following the procedure of Example 2, Steps 2 and 3 using 4-bromo-1-
ethy1-1H-
pyrazole B (Example 4, Step 1) in place of 4-bromo-1-propy1-1H-pyrazole 3 in
Step 2, the title
compound 3 was obtained as a light brown solid. 1H NMR (500 MHz, CDC13): 6
7.69-7.64 (m,
3H), 7.44 (s, 1H), 7.27 (t, J= 8.0 Hz, 1H), 7.16 (dd, J= 8.5, 6.0 Hz, 1H),
7.01-6.94 (m, 2H),
4.40 (q, J = 7.5 Hz, 2H), 4.26 (q, J = 8.0 Hz, 2H), 1.57 (t, J= 8.0 Hz, 3H),
1.57 (t, J= 7.5 Hz,
3H); LC-MS (ES!): m/z 462.5 (M+ H+).
Step 2: Synthesis of ethyl 3-42,6-dichloro-1-(1-ethy1-1H-pyrazol-4-y1)-7-
fluoro-1H-indo1-3-
y1)thio)-2-fluorobenzoate (4):
[00355] To a solution of compound 3 (100 mg, 0.21 mmol) in CH2C12 (3 mL) under
inert
atmosphere was added NCS (58 mg, 0.43 mmol) at RT and stirred for 16 h. The
reaction
mixture was diluted with water (10 mL) and extracted with CH2C12 (2 x 15 mL).
The combined
organic extracts were dried over Na2SO4 and concentrated under reduced
pressure to obtain the
crude. The crude was purified (silica gel; 14-17% Et0Ac/Hexanes) to afford 4
(35 mg, 33%) as
-85-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
an off-white solid. 111 NMR (400 MHz, CDC13): 6 7.71-7.66 (m, 3H), 7.30 (d, J=
7.6 Hz, 1H),
7.19 (dd, J = 8.8, 6.4 Hz, 1H), 7.04-6.97 (m, 2H), 4.40 (q, J= 7.2 Hz, 2H),
4.27 (q, J= 7.6 Hz,
2H), 1.58 (t, J= 7.6 Hz, 3H), 1.49 (t, J= 7.2 Hz, 3H); LC-MS (ES!): m/z 496.7
(M+ H+).
Step 3: Synthesis of 3-42,6-dichloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-fluoro-1H-
indol-3-
yDthio)-2-fluorobenzoic acid (Compound E)
[00356] Following the procedure of Example 1, Step 9 but using Intermediate 4
in place of
Intermediate 7, the title Compound E sodium salt was obtained as an off-white
solid. LC-MS:
m/z 468 (M+1).
Example 6: Synthesis of methyl 6-mercaptopicolinate (Intermediate A)
sH
Me0 TFA
lEtr=Ncootme Xantphos, Pd2(dbe)3, PMBSNCOOMe Reflux, 16 h HSNCOOMe
DIPEA, 1, 4-dioxane,
1 Reflux, 1 h 2 A
Step!: Synthesis of methyl 6((4-methoxybenzyl) thio) picolinate (2):
[00357] To a stirred solution of methyl 6-bromopicolinate 1(8 g, 37.2 mmol) in
1, 4-dioxane
(110 mL) under inert atmosphere were added (4-methoxyphenyl) methanethiol (5.7
g, 37.0
mmol), xantphos (1.1 g, 1.9 mmol), diisopropyl ethyl amine (13.6 mL, 74.0
mmol), Pd2(dba)3
(847 mg, 0.9 mmol) at RT, degassed under argon for 15 min; heated to reflux
and stirred for 1 h.
After completion of the reaction (TLC), the reaction mixture was diluted with
water (500 mL)
and extracted with Et0Ac (3 x 500 mL). The combined organic extracts were
dried over
Na2SO4, filtered and concentrated under reduced pressure to obtain the crude.
The crude was
purified (silica gel; 10% Et0Ac/ hexanes) to afford compound 2 (8 g, 75%) as
yellow solid. 111
NMR (400 MHz, CDC13): 6 7.78 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H),
7.42-7.40 (m,
2H), 7.29-7.25 (m, 1H), 6.82 (d, J = 8.4 Hz, 2H), 4.44 (s, 2H), 4.00 (s, 3H),
3.77 (s, 3H); LC-
MS: 95.7%; 290.3 (M++1); (column: X Select C-18, 50x 3.0 mm, 3.5 p.m); RT 4.10
min. 5 mM
NH40Ac: ACN; 0.8 mL/min).
Step 2: Synthesis of methyl 6-mercantopicolinate (Intyermediate A):
[00358] A stirred solution of compound 2 (6 g, 20.7 mmol) in Trifluoro acetic
acid (50 mL)
under inert atmosphere was heated to reflux and stirred for 16 h. After
completion of the
reaction (TLC), the volatiles were removed under reduced pressure. The residue
was diluted
with Et0Ac (500 mL), washed with aqueous NaHCO3 solution (3 x 250 mL). The
organic
extract were dried over Na2SO4, filtered and concentrated under reduced
pressure to obtain the
compound 6 (3.5 g, crude) as pale brown solid. LC-MS: 61.1%; 170 (M++1);
(column: X Select
C-18, 50 x 3.0 mm, 3.5 p.m); RT 1.41 min. 5 mM NH40Ac: ACN; 0.8 mL/min).
-86-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 7: Synthesis of methyl 2-(2-fluoro-3-mercaptophenyl)acetate
(Intermediate B)
HS CO2me
[00359] Prepared according to the procedure described in W02012/024620,
Example 154, p
203.
Example 8: Synthesis of 64(2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-yl)-
1H-indol-3-
yl)thio)picolinic acid (Compound F)
0
S\/OH
\ CI
CI N
F
N-N
[00360] Using the procedure in Example 2 but substituting methyl 6-
mercaptopicolinate
(Intermediate A)for ethyl 2-fluoro-3-mercaptobenzoate in step 3 the title
compound was
prepared. LC-MS: 465.2(M++1).
Example 9: Synthesis of 64(2,6-dichloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-fluoro-
1H-indol-3-
y1)thio)picolinic acid (Compound G)
OH
= \
\ci
CI
F
N N
[00361] Using the procedure in Example 5 except substituting methyl 6-
mercaptopicolinate
(Intermediate A) for ethyl 2-fluoro-3-mercaptobenzoate in step 2 the title
compound was
prepared. LC-MS: 449.2(M++1).
-87-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 10: Synthesis of 2-(34(2,6-dichloro-7-fluoro-1-(1-propy1-1H-pyrazol-4-
y1)-1H-
indol-3-yl)thio)-2-fluorophenyl)acetic acid (Compound H)
0
OH
ci
S fit
110 \
CI N
F
N_N
[00362] Using the procedure in Example 2 except substituting methyl 2-(2-
fluoro-3-
mercaptophenyl)acetate (Intermediate B) for ethyl 2-fluoro-3-mercaptobenzoate
in step 3 the
title compound was prepared. LC-MS: 496.6(M++1).
Example 11: Synthesis of 2-(34(2,6-dichloro-1-(1-ethyl-1H-pyrazol-4-y1)-7-
fluoro-1H-
indol-3-yl)thio)-2-fluorophenynacetic acid (Compound I)
0
OH
S
I.
\CI
CI N
F
[00363] Using the procedure in Example 5 except substituting methyl 2-(2-
fluoro-3-
mercaptophenyl)acetate (Intermediate B) for ethyl 2-fluoro-3-mercaptobenzoate
in step 2 the
title compound was prepared. LC-MS: 482.3 (M++1).
Example 12: Parenteral Pharmaceutical Composition
[00364] To prepare a parenteral pharmaceutical composition suitable for
administration by
injection (subcutaneous, intravenous), 1-100 mg of a water-soluble salt of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt or solvate thereof, is dissolved in
sterile water and then
mixed with 10 mL of 0.9% sterile saline. A suitable buffer is optionally added
as well as
-88-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
optional acid or base to adjust the pH The mixture is incorporated into a
dosage unit form
suitable for administration by injection.
Example 13: Oral Solution
[00365] To prepare a pharmaceutical composition for oral delivery, a
sufficient amount of an
autotaxin inhibitor, or a pharmaceutically acceptable salt thereof, is added
to water (with
optional solubilizer(s),optional buffer(s) and taste masking excipients) to
provide a 20 mg/mL
solution.
Example 14: Oral Tablet
[00366] A tablet is prepared by mixing 20-50% by weight of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, 20-50% by weight of microcrystalline
cellulose, 1-10%
by weight of low-substituted hydroxypropyl cellulose, and 1-10% by weight of
magnesium
stearate or other appropriate excipients. Tablets are prepared by direct
compression. The total
weight of the compressed tablets is maintained at 100 -500 mg.
Example 15: Oral Capsule
[00367] To prepare a pharmaceutical composition for oral delivery, 10-500 mg
of an autotaxin
inhibitor, or a pharmaceutically acceptable salt thereof, is mixed with starch
or other suitable
powder blend. The mixture is incorporated into an oral dosage unit such as a
hard gelatin
capsule, which is suitable for oral administration.
[00368] In another pharmaceutical composition, 10-500 mg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, is placed into size 4 capsule, or
size 1 capsule
(hypromellose or hard gelatin) and the capsule is closed.
Example 16: Topical Gel Composition
[00369] To prepare a pharmaceutical topical gel composition, an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, is mixed with hydroxypropyl
cellulose, propylene
glycol, isopropyl myristate and purified alcohol USP. The resulting gel
mixture is then
incorporated into containers, such as tubes, which are suitable for topical
administration.
Example 17: Human Autotaxin Assay
[00370] ATX activity is assayed in concentrated conditioned media from Hep3B
human
hepatocellular carcinoma cells by measuring the amount of choline released
from the substrate,
lysophosphatidylcholine (LPC) as it is cleaved to LPA. Conditioned media is
collected from
confluent Hep3B cells and concentrated 10-20-fold using Centriprep-30 filter
devices
(Millipore). To assay for autotaxin inhibition, 10-20 iaL of the concentrated
conditioned media is
incubated with 2.51AL of a test compound in DMSO and 72.5-82.5 [EL lyso-PLD
buffer (100
mM Tris pH 9, 500 mM NaC1, 5 mM MgC12, 5 mM CaC12, 0.05% Triton X-100 in the
presence
or absence of 0.2% fatty-acid-free human serum albumin) for 15 min at 37 C.
After the 15 min
-89-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
incubation, 5 ul of 2 mM LPC (14:0; Avanti Polar Lipids Cat# 855575C) diluted
in lyso-PLD
buffer is added for a final concentration of 100 uM and the incubation
continued for 1.5-3 hours
at 37 C. 100 ul of a color mix containing 4.5 mM 4-aminoantipyrine, 2.7 mM N-
ethyl-N-(2-
hydroxy-3-sulfopropy1)-m-toluidine, 21 units/ml horseradish peroxidase and 3
units/m1 choline
oxidase in 50 mM Tris, pH 8, 4.5 mM MgC12 is added and the incubation
continued for 15
minutes at room temperature before reading the absorbance at 555 nm.
[00371] Illustrative biological activity of representative compounds in the
human autotaxin
assay described herein is presented in the following table:
Compound ICso (PM)
Compound A A
Compound B A
Compound C A
Compound D A
Compound E A
Compound F A
Compound G A
Compound H A
Compound I A
A is <0.5 uM; B is >0.5 uM but <1 uM; C >1 uM.
Example 18: Human Whole Blood Autotaxin Assay
[00372] Inhibition of ATX activity in human whole blood is assayed by
measuring the
concentration of 20:4 LPA in plasma after a prolonged incubation at 37 C.
Blood is drawn from
consenting human volunteers into heparin vacutainer tubes and 200 pl aliquots
are added to 2 ul
test compound in DMSO or DMSO alone. Several of the vehicle tubes are
centrifuged
immediately at 800 x g for 10 minutes at 4 C and the plasma removed for
processing to
determine the baseline concentration of 20:4 LPA. The remaining blood samples
containing
vehicle or test compound are incubated at 37 C for 4 hours before
centrifuging at 800 x g for 10
minutes at 4 C to obtain plasma. Plasma is processed for LCMS as follows: 40
ul plasma is
removed and 5 volumes of methanol containing 125 ng/ml 17:0 LPA as an internal
standard are
added and the mixture incubated at -20 C for 10 min before centrifuging at
4000 x g for 10
minutes at 4 C. 150 ul of the supernatant is transferred to a 96-well plate
and diluted with 100
ul of an organic solution (90:10:0.1 of water/acetonitrile/ammonium hydroxide)
for analysis of
20:4 LPA concentrations by LCMS. LPA 20:4 and the internal standard (LPA 17:0)
were
analyzed on a quadrupole mass spectrometer (ABI Sciex 4000QTrap) in the
negative ion mode
(ESI) by multiple reaction monitoring (MRM). The mobile phases contain 0.1%
ammonium
hydroxide in 90% water/10% acetonitrile (solvent A) and 0.1% ammonium
hydroxide in 90%
acetonitrile/10% water (solvent B). The flow rate was maintained at 0.8 mL/min
and the total
run time was 3 min. Analytes were separated using a linear gradient as
follows: 1) mobile phase
-90-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
was held for 0.5 min at 10% B; 2) B was increased from 10% to 90% over the
next 1 min; 3) B
was held constant for 0.5 min at 90%; and 4) B was returned to the initial
gradient conditions.
Example 19: Autotaxin-induced Itch Model
[00373] Mice are infected with adenovirus expressing autotaxin under control
of a CMV
(cytomegalovirus) or AFP (alpha-fetoprotein) promoter. Infected mice
experience an increased
scratch response after infection. After infection with the ATX expressing
adenovirus and
observation of increased scratch response, mice are treated with an autotaxin
inhibitor and
monitored for inhibition of itch.
[00374] An increased scratch response was seen in mice infected the CMV-ATX
adenovirus.
Example 20: Myelin Oligodendrocyte Glycoprotein (MOG)-induced Experimental
Autoimmune Encephalomyelitis (EAE) Model
[00375] EAE is induced in mice by immunization with MOG peptide (35-55) which
results in
progressive paralysis. Mice are treated with an autotaxin inhibitor at 60 mpk
BID either at the
time of immunization (prophylactic dosing) or after the first sign of symptoms
(therapeutic
dosing) and monitored for signs of paralysis.
Example 21: MDA-MB-435 Melanoma Cell Migration Assay
[00376] Cells from MDA-MB-435S human melanoma line are maintained in
subconfluent
culture in media containing FBS and penicillin/streptomycin. The day before
the assay, cells are
serum-starved overnight in media containing 0.1-0.2% fatty-acid-free BSA. On
the day of the
assay, the conditioned media is removed from the cells, centrifuged for
clarification and set
aside. The cells are then harvested by scraping, counted, and pelleted by
centrifugation. The
cells are resuspended at 1.05X the final desired density in the conditioned
media. The assays are
performed in duplicate using the Neuroprobe 96-well chemotaxis system with 8
[tm pore size
and fibronectin-coated filters. 152 !AL cells are added to 8 uL test autotaxin
inhibitor compound
and incubated for 15 min at 37 C. The lower chamber is loaded with 2-10 [LM
LPC and then 50
pL of the cell/test compound suspension is added to the top of each filter
well site. The filters
are incubated at 37 C for 1-24 hours and non-migrated cells removed from the
top of the filter
by rinsing with PBS and scraping. The filter is air dried then stained before
reading the
absorbance at 580 nm.
[00377] In this cell migration assay, compound A had an IC50 of 4 nM and
compound B had an
IC50 of 15 nM.
Example 22: Mouse Carbon Tetrachloride (CCl4)-induced Liver Fibrosis Model
[00378] Female or male balb/c mice receive CC14 (0.8-1.0 ml/kg body weight)
diluted in olive
oil via intraperitoneal injection twice a week for 6-8 weeks. (Higazi, A. A.
et al, Clin Exp
Immunol. 2008 Apr;152(1):163-73). Control mice receive an equivalent volume of
olive oil only.
-91-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Autotaxin inhibitor or vehicle is delivered orally daily starting at the time
of CC14 injection
(prophylactically) or starting at 1-3 weeks after the first CC14 injection
(therapeutically). At the
end of the study, mice are sacrificed using inhaled isoflurane and blood is
drawn via cardiac
puncture for subsequent analysis of ALT/AST levels. The liver is harvested and
frozen at -80 C
for the biochemical analysis of liver fibrosis or fixed in 10% neutral
buffered formalin for
histological assessment of liver fibrosis. For the biochemical assessment of
liver fibrosis, liver
tissue homogenates are analyzed for collagen concentration using a
hydroxyproline assay. For
the histological assessment of liver fibrosis, fixed liver tissue is stained
with Picrosirius red and
liver fibrosis is determined by quantitative, computer-assisted densitometry
using light
microscopy.
Example 23: Mouse Choline-deficient, L-amino acid-defined, High-fat Diet
(CDAA/HFD)
Model of Liver Fibrosis
[00379] Mice are fed a choline deficient diet supplemented with 0.1%
methionine and 60% kCal
fat (CDAA/HFD) for 12-14 weeks. Mice receive 1, 3, 10, or 30 mpk of autotaxin
inhibitor test
compound or vehicle starting at the beginning of week 6 after feeding
(therapeutically). The
following liver enzymes are measured weekly: aspartate transaminase, alkaline
phosphatase and
bilirubin. At the end of the study, mice are sacrificed and the liver
harvested and frozen at -80 C
for the biochemical analysis of liver fibrosis or fixed in neutral-buffered
formalin for
histological assessment of liver fibrosis. For the biochemical assessment of
liver fibrosis, liver
tissue homogenates are analyzed for collagen concentration using a
hydroxyproline assay. For
the histological assessment of liver fibrosis, fixed liver tissue is stained
with Picrosirius Red
(PSR) stain and severity of liver fibrosis scored using light microscopy.
After qualitative scoring
of liver fibrosis, quantitation of fibrosis was determined using whole slide
images captured at
20X magnification and calculating the percentage of the liver section that was
PSR-positive
using Indica Labs' Halo area quantification image analysis software.
[00380] In this liver fibrosis model, compound A significantly reduced liver
fibrosis when dosed
at 30 mpk and compound B significantly reduced liver fibrosis when dosed at 10
mpk.
Treatment with either compound A (30 mpk) or compound B (10 mpk) resulted in
an
approximately 35% decrease in % PSR positive area.
[00381] In this animal model, treatment of mice with 3mg/kg, 10mg/kg or
30mg/kg of
compound A resulted in about 72%, 76% and 90% inhibition of trough plasma
autotaxin
activity, respectively (as measured by choline production). Treatment of mice
with lmg/kg,
3mg/kg or 10mg/kg of compound B resulted in about 49%, 67%, and 75% inhibition
of trough
plasma autotaxin activity, respectively (as measured by choline production).
-92-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 24: Mouse Diet-induced NASH (Nonalcoholic Steatohepatitis) Liver
Fibrosis
Model
[00382] Mice are injected with a low dose of streptozotocin two days after
birth and then fed a
high-fat diet starting after 4 weeks of age until 12 weeks of age Mice are
treated with test
compound starting at 6 weeks of age. At the end of the study, mice are
sacrificed and blood
drawn for determination of non-fasting blood glucose and ALT/AST. The liver is
harvested,
weighed and frozen at -80 C for biochemical analysis of liver fibrosis and
liver triglycerides or
fixed in neutral-buffered formalin for histological assessment of liver
fibrosis, steatosis and
inflammation. For the biochemical assessment of liver fibrosis, liver tissue
homogenates are
analyzed for collagen concentration using a hydroxyproline assay and for liver
triglycerides
using the Triglyceride E-test kit (Wako, Japan). For the histological
assessment of inflammation
and steatosis, fixed liver tissue is stained with hematoxylin and eosin (H&E)
and severity of
inflammation and steatosis is scored using light microscopy. For the
histological assessment of
liver fibrosis, fixed liver tissue is stained with Picrosirius Red (PSR) stain
and severity of liver
fibrosis scored using light microscopy.
[00383] In this fibrosis model, compound A at 10 mg/kg showed a significant
reduction in liver
fibrosis and a significant reduction in NAFLD activity score (composite score
of inflammation,
steatosis and hepatocyte ballooning scores).
Example 25: Rat Diethvinitrosamine (DEN)-induced Liver Fibrosis and
Hepatocellular
Carcinoma
[00384] Male Wistar rats receive weekly intraperitoneal injections of 35-100
mg/kg
diethylnitrosamine (DEN) for 13-18 weeks in a total volume of 1.5 ml phosphate-
buffered saline
(PBS) to induce cirrhosis and hepatocellular carcinoma (HCC). Control rats
receive weekly
injections of an equivalent volume of PBS. An autotaxin inhibitor or vehicle
is delivered orally
daily starting 6-7 weeks after the initial DEN injection. At the end of the
study, rats are
sacrificed using inhaled isoflurane and blood is drawn via cardiac puncture
for subsequent
analysis of ALT/AST levels and drug concentrations. The liver is harvested and
frozen at -80 C
for biochemical analysis of fibrosis or fixed in 10% neutral buffered formalin
for histological
assessment of liver fibrosis. For biochemical assessment of fibrosis, liver
tissue homogenates are
analyzed for collagen concentration using a hydroxyproline assay. For
histological assessment
of liver fibrosis and HCC, fixed liver tissue is stained with Picrosirius
stain and H&E and liver
fibrosis and HCC is determined using light microscopy.
[00385] In this animal model, compound A had a positive effect on the
reduction of liver fibrosis
at 5 mpk.
-93-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 26: Mouse Model of Bleomycin-induced Skin Fibrosis
[00386] A mouse model of bleomycin-induced skin fibrosis was used to evaluate
the effect of
autotaxin inhibitors on skin fibrosis. Methods were adapted from (Yamamoto, T
et al. The
Journal of Investigative Dermatology, 112: 456-462, 1999). C57B1/6 mice were
anesthetized
with isoflurane and two areas shaved bilaterally on the lower dorsolateral
region. Bleomycin (10
- 50 g in 100 ill) prepared in sterile filtered PBS (or PBS control) was
administered
subcutaneously to each shaved region once daily for 5 to 7 days per week for a
total of 4 weeks
(28 days).
[00387] Compound A and Compound B were prepared in 0.5% methyl cellulose and
delivered
orally once daily from Day 1-28 (prophylactically) or from Day 7-28
(therapeutically).
[00388] On day 28 all animals were sacrificed. The dorsolateral skin removed,
trimmed of
adherent subcutaneous fat and a 6 mm biopsy punch was used to collect two skin
samples from
each subject. One sample was fixed in 10% neutral buffered formalin and
submitted for
histological analysis. The second sample was frozen at -80 C for further
processing of collagen
content using a hydroxyproline assay.
[00389] In this skin fibrosis model, compound A showed a significant reduction
in skin fibrosis
when dosed prophylactically or therapeutically.
[00390] Fig. 1 shows the average SEM hydroxproline content in a 6 mm skin
punch biopsy.
Compound A showed a significant reduction in skin hydroxyproline content when
dosed
prophylactically or therapeutically.
[00391] In this animal model, treatment of mice with 60mg/kg of compound A
resulted in an
approximately 95% inhibition of trough plasma autotaxin activity (as measured
by choline
production).
Example 27: Mouse Unilateral Ureteral Obstruction (UUO) Kidney Fibrosis Model
[00392] C57BL/6 mice mice undergo unilateral ureteral obstruction (UUO)
surgery or sham
surgery to the left kidney. Briefly, a longitudinal, upper left incision is
performed to expose the
left kidney. The renal artery is located and silk thread is passed between the
artery and the
ureter. The thread is looped around the ureter and knotted insuring full
ligation of ureter. The
kidney is returned to abdomen, the abdominal muscle is sutured and the skin is
stapled closed.
Test compound or vehicle is delivered orally once or twice daily either
prophylactically (starting
on Day 0) or therapeutically (starting on Day 3). All animals are sacrificed
using inhaled
isoflurane 10 days after UUO surgery. Following sacrifice, blood is drawn via
cardiac puncture
and both kidneys are harvested. Each kidney is either snap frozen at -80 C for
biochemical
analysis of fibrosis or fixed in 10% neutral buffered formalin for
histological assessment of
kidney fibrosis. Kidney tissue homogenates are analyzed for collagen content
using a
-94-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
hydroxyproline assay. Fixed kidney tissue is stained using hematoxylin and
eosin (H&E) and
Picrosirius red and kidney fibrosis is determined using light microscopy.
[00393] Fig. 2 shows the effect of prophylactic dosing (A) and therapeutic
dosing (B) of
compound A on hydroxyproline content in the non-ligated and ligated kidneys
after UUO.
[00394] Prophylactic or therapeutic dosing of compound A assay reduced
hydroxyproline
content in the ligated kidneys of mice by approximately 40%.
Example 28: Mouse Peritoneal Fibrosis Model
[00395] Peritoneal fibrosis is induced in mice by injection of 0.1%
chlorhexidine gluconate
(CG) dissolved in 15% ethanol/PBS into the peritoneal cavity every other day
for a period of 21
days An autotaxin inhibitor or vehicle is delivered orally once or twice daily
either
prophylactically (starting on the day of the initial CG injection) or
therapeutically (starting on
Day 7 after the initial CG injection). At the end of the study, mice are
sacrificed and peritoneal
tissue is excised. Peritoneal fibrosis is determined biochemically using a
hydroxyproline assay.
[00396] Fig. 3 shows the effect of compound A on hydroxyproline content in the
peritoneum of
mice at Day 21 after prophylactic dosing.
[00397] Compound A dosed at 60 mpk twice daily reduced hydroxyproline content
in the
peritoneum of mice by approximately 50%.
Example 29: Mouse Dextran Sodium Sulfate (DSS)-induced Chronic Colitis Model
[00398] Female C57BL/6 mice are subjected to 3 cycles of 2% DSS in drinking
water for 6
days, followed by drinking water without DSS for 15 days, for a total duration
of 64 days.
Autotaxin inhibitors are dosed at 30, 60 or 100 mpk PO once or twice daily
from Day 0 to 63.
For a positive control, Cyclosporin A (CsA) is dosed at 25 mpk on Days 1-7, 22-
28, and 43-49.
Mouse body weight, stool consistency, bleeding and overall Disease Activity
Index (DAI) is
recorded daily. After 64 days, mouse colons are removed and their length and
weights recorded.
Colonic sections are stained with hematoxylin and eosin stain (H&E stain) and
scored based on
inflammatory cell infiltration and tissue damage. Colonic sections are also
stained with
trichrome and scored for fibrosis.
[00399] In this colitis model, mice treated with compound A or compound B
showed a reduction
in colon weight/colon length/body weight ratio as compared to mice treated
with vehicle. For
example, the ratio of (colon weight/colon length/body weight)*100 in mice
induced with colitis
was at least about 20% lower in mice treated with compound A or compound B as
compared to
mice treated with vehicle. Mice treated with compound B showed a significant
increase in colon
length as compared to mice treated with vehicle. For example, the colon length
in mice treated
with compound B was at least about 30% longer than mice treated with vehicle.
-95-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
Example 30: Rat Dinitrobenzene sulfonic acid (DNBS)-induced Acute Colitis
Model
[00400] Male Wistar rats weighing 150-160 g are intracolonically administered
0.5 ml of 50
mg/ml DNBS in 30% ethanol on Day 1 or vehicle control. Autotaxin inhibitors
are dosed at 5
mpk in 0.5% MC once daily from Day 0 to Day 6. Sulfasalazine is dosed at 300
mpk in 0.5%
CMC-Na from Day 1 to Day 7. The rats are monitored for body weight and stool
consistency
daily. At study termination, colon length, colon weight, ulcer area and
Masson's trichrome
staining are assessed. In one DNB S-induced colitis model, compound A and
compound B had a
positive effect on colitis by reducing ulcer area.
[00401] In this acute colitis model, compound A and compound B had no
significant effect on
body weight loss or stool consistency. Compound A and compound B reduced ulcer
area and
colon weight similiar to sulfasalazine. For example, treatment with compound A
or compound B
resulted in a 30 to 60% reduction in ulcer area as compared to mice treated
with vehicle.
Example 31: Effects of autotaxin inhibitors on glucose tolerance in mice fed a
high fat diet.
[00402] C57B16/J male mice are fed a normal diet until 6-10 weeks of age. Mice
are then fed
either a normal diet (ND) or high-fat diet (HFD) (20% protein, 35%
carbohydrate, 45% fat;
Harlan Laboratories) for 8-10 weeks. For determination of blood glucose, mice
are administered
test compound orally in 0.5% methocel once or twice daily for several days
prior to the glucose
challenge. On the day of the glucose tolerance test (GTT) mice are fasted for
6-8 hours and a last
dose of test compound administered orally 1-3 hours before the intraperitoneal
(i.p.) injection of
lg/kg D-glucose (Sigma). Blood from the tail vein is sampled before the
glucose load (baseline
glucose) and every 15-30 min over the next 120 min after the glucose challenge
to monitor
blood glucose concentration. Blood glucose is quantified using a glucose meter
(Accu-Chek,
Roche Diagnostics or AlphaTRAK, Abbott Animal Health) and plotted vs. time.
Total blood
glucose area under the curve (AUC) after the i.p. glucose challenge is
calculated from the time
plot using GraphPad Prism6.
[00403] Administration of Compound B (15 mg/kg) twice daily for two days prior
to sampling
and once on the day of sampling decreased baseline glucose and total blood
glucose AUC.
[00404] Administration of Compound A (30 mg/kg) once daily for 5 days prior to
sampling
decreased baseline glucose.
Example 32: Mouse Air Pouch Assay
[00405] LPA and autotaxin activity are induced by carrageenan injection into a
mouse air pouch.
A mouse air pouch assay is utilized to determine pharmacodynamic activity of
autotaxin
inhibitors in reducing carrageenan-induced autotaxin activity and LPA
biosynthesis. An air
pouch is formed in mice by instilling 5 mL of 0.2 lam filtered air into the
subcutaneous space in
the scapular region on Day 1. On Day 3, 3 mL of air is instilled into the
pouch and on Day 6,
-96-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
another 3 ml air is instilled into the pouch. On Day 7, test compounds are
administered by oral
gavage. At the appropriate time (0-24 hr) after compound administration,
carrageenan dissolved
in sterile saline is injected into the air pouch. Two hours following
carrageenan challenge, mice
are sacrificed and blood obtained via cardiac puncture. A 0.5-1 mL bolus of
ice-cold phosphate
buffered saline solution is instilled into the air pouch and after 20 seconds
of gentle massaging,
the pouch is opened and the fluid removed. An aliquot of the air pouch fluid
is analyzed for LPA
concentrations by LC-MS as described in the Human Whole Blood Autotaxin Assay
(Example
10). A separate aliquot of the air pouch fluid is taken, centrifuged (800 x g,
10 min) and assayed
for ATX activity using a TOOS method or for drug concentrations by LCMS.
Plasma prepared
from blood is assayed for drug concentrations by LCMS.
Example 33: Spontaneous Metastasis Mouse Model
[00406] A syngeneic mouse model is used to test efficacy of compounds in
inhibiting tumor
metastases. 4T1 cells are in injected into the #7 mammary fat pad of female
Balb/c mice while
the mice are anesthetized. The primary tumors are measured by caliper twice
weekly until they
are resected under isofluorane anesthesia (between days 10-14). Test compound
is administered
orally daily at various times after the injection of the 4T1 cells. At 8-11
weeks after the 4T1
injection, lymph nodes, lungs, liver and any other organs suspected of
harboring metastases are
collected for histological analysis.
Example 34: Lung Metastases Model
[00407] An experimental lung metastasis model is used to test efficacy of
compounds in
reducing the number of metastases of injected B16-F 10 mouse melanoma cells to
the lung.
Briefly, female C57BL/6J mice, female (BALB/cByJ x C57BL/6J)Fi, mice
(CByB6Fi/J),
athymic nude female and male CByB6Fi/J mice (nu/nu), and control littermates
(nu/nu) are used
at ages 7-18 weeks, when they weighed between 18 and 28 g. A single-cell
suspension of
B16F10 cells, harvested in log phase (approx. 5-10 x 104 cells) in 0.2 mL of
Hanks balanced
salt solution are injected intravenously into the lateral tail vein of the
mice. Test compound or
vehicle is delivered daily. After 21 days, the mice are sacrificed, and the
lungs are removed.
Lungs are fixed in 10% buffered formalin overnight and weighed, and tumor
colonies at the
surface are scored with the aid of a dissecting microscope.
Example 35: Clinical Trial for Liver Fibrosis
[00408] A non-limiting example of a liver fibrosis clinical trial in humans is
described below.
[00409] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with liver fibrosis, collect information on any side effects the
compound may cause
-97-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
as single agent or in combination, and evaluate the pharmacokinetic properties
of the compound
as single agent or in combination.
[00410] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00411] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00412] Primary Outcome Measures: Liver enzymes (ALT, AST, ALP), liver biopsy
[00413] Secondary Outcome Measures: Pharmacodynamic markers may include:
Tissue PD
markers through mRNA expression, autotaxin, LOXL2, LOX, Other LOXL proteins,
aSMA,
Collagen 1A1, NF-KB1, Caspase 1, SMAD, and NOD; Serum and plasma PD markers
include:
AST-to-platelet ratio index (APRI), autotaxin activity, LOXL2, Osteopontin,
Hyaluronic Acid,
CXCL 9, 10 and 11, MMP1, MMP3, MMP9, TIMP1, CD4OL, TGF-131, ET-1, VEGF, GAL3,
IL-6 / IL-8 / TNFa / IFN7, a2-macroglobulin, Apolipoprotein Al, PINP, PILENP,
PVCP-1230,
PDGF; Assessing the effects of chronic dosing on liver structure and fibrotic
markers; incidence
of adverse events resulting from the administration of multiple doses of
compound.
[00414] Eligibility: Male and female subjects that are 18 to 60 years old.
[00415] Inclusion Criteria: Stage 1-3 fibrosis by Metavir score on a liver
biopsy; Body mass
index <36 kg/m2.
[00416] Exclusion Criteria: Any evidence of hepatic decompensation past or
present; subjects
currently abusing amphetamines, cocaine, opiates, or alcohol; clinically
significant cardiac
disease; history of cancer, other than non-melanomatous skin cancer, within 5
years prior to
screening; systemic fungal, bacterial, viral, or other infection that is not
controlled; use of
systemic immunosuppressants within 28 days of the Pre-treatment Phase; use of
approved
therapy for hepatitis C or hepatitis B virus within 28 days of the Pre-
treatment Phase; pregnant
or lactating; history of bleeding diathesis within the last 6 months of study
Day 1.
Example 36: Clinical Trial for Fatty Liver Disease /Steatosis (NAFLD, NASH)
[00417] A non-limiting example of a fatty liver disease/steatosis clinical
trial in humans is
described below.
[00418] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with hepatocellular carcinoma, collect information on any side
effects the compound
may cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
-98-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00419] Intervention: Patients are administered 0.1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00420] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00421] Eligibility: Male and female subjects that are 21 to 80 years old.
[00422] Inclusion Criteria: Patients with clinically confirmed diagnosis of
non-alcohol fatty liver
disease or non-alcohol steatohepatitis; histologic evidence of definite or
probable nonalcoholic
steatohepatitis (NASH) based upon a liver biopsy obtained no more than 90 days
prior to
randomization and a nonalcoholic fatty liver disease activity score (NAS) of 4
or greater.
[00423] Exclusion Criteria: Current or history of significant alcohol
consumption, use of drugs
historically associated with nonalcoholic fatty liver disease (NAFLD)
(amiodarone,
methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at
doses greater than
those used for hormone replacement, anabolic steroids, valproic acid, and
other known
hepatotoxins) for more than 2 weeks in the year prior to randomization, prior
or planned (during
the study period) bariatric surgery (e.g., gastroplasty, roux-en-Y gastric
bypass), uncontrolled
diabetes defined as Hemoglobin Al c 9.5% or higher within 60 days prior to
enrollment,
presence of cirrhosis on liver biopsy, platelet count below 100,000/mm3;
Clinical evidence of
hepatic decompensation as defined by the presence of any of the following
abnormalities: serum
albumin less than 3.2 grams/deciliter (g/dL), INR(international normalized
ratio) greater than
1.3, direct bilirubin greater than 1.3 milligrams per deciliter (mg/dL),
history of esophageal
varices, ascites or hepatic encephalopathy; Evidence of other forms of chronic
liver disease:
hepatitis B as defined by presence of hepatitis B surface antigen (HBsAg),
hepatitis C as defined
by presence of hepatitis C virus (HCV) ribonucleic acid (RNA) or positive
hepatitis C antibody
(anti-HCV), evidence of ongoing autoimmune liver disease as defined by
compatible liver
histology, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's
disease, Alpha-1-
antitrypsin(A1AT) deficiency, history of hemochromatosis or iron overload,
drug-induced liver
disease as defined on the basis of typical exposure and history, known bile
duct obstruction,
suspected or proven liver cancer, any other type of liver disease other than
nonalcoholic
steatohepatitis (NASH); serum alanine aminotransferase (ALT) greater than 300
units per liter
(U/L); serum creatinine of 2.0 mg/dL or greater; use of ursodeoxycholic acid
(Ursodiol, Urso)
within 90 days prior to enrollmentLinability to safely obtain a liver biopsy,
history of biliary
diversion, known positivity for Human Immunodeficiency Virus (HIV) infection;
pregnancy,
planned pregnancy, potential for pregnancy and unwillingness to use effective
birth control
-99-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
during the trial, breast feeding
[00424] Primary Outcome Measures: liver function tests, liver biopsy, NAS
score
[00425] Secondary Outcome Measures: fibrotic biomarkers, liver imaging
(ultrasound, MRI),
insulin resistance as measure by HOMA-1R, lipid panel.
Example 37: Clinical Trial for Ulcerative Colitis
[00426] A non-limiting example of an ulcerative colitis clinical trial in
humans is described
below.
[00427] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with ulcerative colitis, collect information on any side effects
the compound may
cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
[00428] Intervention: Patients are administered 0.1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00429] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00430] Primary Outcome Measures: Improvement in Mayo Score or other suitable
disease
activity index for colitis and/or 113D
[00431] Secondary Outcome Measures: Improvement in histological evaluation by
flexible
sigmoidoscopy and biopsy; bleeding score; quality of life instruments (113DQ,
SF36); assessing
the effects of chronic dosing on inflammation and fibrotic markers; overall
safety assessments
[00432] Eligibility: Male and female subjects that are 18 to 65 years old.
[00433] Inclusion Criteria: Confirmed diagnosis of colitis for at least 3
months.
[00434] Exclusion Criteria: Any evidence of hepatic decompensation past or
present; Crohn's
disease; patients hospitalized or exhibiting signs of toxicity; history or
colorectal cancer or
colorectal dysplasia; ALP, ALT, AST or bilirubin >1.5 x normal; pregnant or
lactating.
Example 38: Clinical Trial for Cholestatic Pruritus
[00435] A non-limiting example of a cholestatic pruritus clinical trial in
humans is described
below.
[00436] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof in the treatment of patients
with cholestatic
pruritus, collect information on any side effects the compound may cause and
evaluate the
pharmacokinetic properties of the compound as single agent or in combination.
-100-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00437] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day.
[00438] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day. Prior to
each dosing cycle, a
physical exam, blood work and assessment of any side effects will be
performed.
[00439] Eligibility: Male and female subjects that are 21 to 80 years old.
[00440] Inclusion Criteria: Patients with pruritus as a result of a
cholestatic disorder.
[00441] Exclusion Criteria: Use of cholestyramine; pregnancy; malignancy/life
expectancy <6
months.
[00442] Primary Outcome Measures: Normalization of liver enzymes (ALT, AST,
ALP),
Reduction of pruritus according to visual analogue scores.
[00443] Secondary Outcome Measures: Improvement in quality of life scores;
reduction in
pruritus score/scratch lesions.
Example 39: Clinical Trial for Pulmonary Fibrosis
[00444] A non-limiting example of a pulmonary fibrosis clinical trial in
humans is described
below.
[00445] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with pulmonary fibrosis, collect information on any side effects
the compound may
cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
[00446] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00447] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00448] Primary Outcome Measures: Progression-free survival, defined as free
of death or a
decrease from baseline in the FVC of at least 10%.
[00449] Secondary Outcome Measures: Number of Acute Exacerbations of IPF;
health related
quality of life; P02 at rest and at exercise from baseline; P(A-a)02 at rest
and at exercise from
baseline; Predicted FEV1 from baseline; forced expiratory volume in one second
(FEV1) to
FVC from baseline; plethysmographic lung volumes from baseline; diffusion
capacity for
carbon monoxide (DLco) from baseline; Six-Minute Walk test, from baseline:
resting and 6
minute Sp02, presence or absence of desaturation to 88% or lower at the end of
the six minute
-101-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
walk, walked distance; Pre and post modified Borg dyspnea scores; scoring of
extent of lung
fibrosis on HRCT, according to two independent chest radiologists, form
baseline; number and
severity of adverse effects.
[00450] Eligibility: Male and female subjects that are 40 years to 80 years.
[00451] Inclusion Criteria: Clinical symptoms of IPF for at least 3 months;
forced vital capacity
(FVC) between 50 to 90% of the predicted value; DLco at least 35% of the
predicted value;
Pa02 > 55 mm Hg while breathing ambient air at rest; High-resolution computed
tomography
(HRCT) showing definite or probable criteria of IPF.
[00452] Exclusion Criteria: Clinically significant exposure to known
fibrogenic agents (birds,
molds, asbestos, radiation and drugs known to cause pulmonary fibrosis
(amiodarone,
nitrofurantoin, bleomicin, etc)); history of neurofibromatosis, Hermansky-
Pudlak syndrome,
metabolic storage disorders, etc.; history of fever, weight loss, myalgias,
arthralgias, skin rash,
arthritis; active infection within one week before enrollment; alternative
cause of interstitial lung
disease; ratio of the forced expiratory volume in one second (VEF1) to FVC of
less than 0.6
after the use of a bronchodilator; residual volume more than 120% of the
predicted value (when
available); more than 20% of lymphocytes or eosinophils in bronchoalveolar
lavage (BAL)
(when available); granulomas, infection or malignancy in the transbronchial or
surgical biopsy
(when available); previous therapy with azathioprine, prednisolone (>0.5
mg/kg/day or more for
at least 3 months), cyclophosphamide or novel biotech drugs; unstable
cardiovascular or
neurologic disease; uncontrolled diabetes; pregnancy; lactation; likelihood of
death, as predicted
by the investigator, within the next year; white cell blood count < 4000/mm3;
platelet count <
100000/mm3; Hematocrit < 30% or > 59%; liver enzymes more than 3 times the
upper limit of
the normal range; creatinine level > 1.5 mg/dL; albumin level <3 g/dL; refusal
to sign informed
consent by patient or guardian.
Example 40: Clinical Trial for Pancreatic Cancer
[00453] A non-limiting example of a pancreatic cancer clinical trial in humans
is described
below.
[00454] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with pancreatic cancer, collect information on any side effects
the compound may
cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
[00455] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
-102-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00456] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00457] Eligibility: Male and female subjects that are 21 to 80 years old
with advanced
pancreatic cancer.
[00458] Inclusion Criteria: Radiographic or clinical evidence of measurable
advanced pancreatic
carcinoma (Stage II, II, IV),. Subjects must have measurable disease at least
2 cm in diameter.
ECOG performance status of 0 or 1
[00459] Exclusion Criteria: Prior history of malignancy (except basal cell or
squamous cell
carcinoma or carcinoma in situ of the breast) unless the subject has been free
of disease for > or
= to 1 year. Moderate or severe cardiac disease; Active infection; Not
pregnant or nursing;
Negative pregnancy test; Fertile patients must use effective contraception
during and for > 3
months after completion of study treatment; Able to swallow oral medication;
No other
malignancy within the past 5 years except for in situ cancers or basal cell or
squamous cell
carcinoma of the skin; No hypersensitivity or intolerance to statins; no other
non-malignant
systemic disease that would preclude rosuvastatin administration or prolonged
follow-up.
[00460] Primary Outcome Measures: Progression free survival, overall survival,
worsening of
pain, onset of pain
[00461] Secondary Outcome Measures: tumor size / response (RECIST)
Example 41: Clinical Trial for Hepatocellular Carcinoma (HCC)
[00462] A non-limiting example of a hepatocellular carcinoma clinical trial in
humans is
described below.
[00463] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with hepatocellular carcinoma, collect information on any side
effects the compound
may cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
[00464] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00465] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00466] Eligibility: Male and female subjects that are 21 to 80 years old.
-103-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00467] Inclusion Criteria: Patients with histopathologically or clinically
confirmed diagnosis of
hepatocellular carcinoma; unresponsive to standard therapy or for whom
standard therapy is
intolerable, or for whom there is no appropriate therapy; ECOG performance
status score of 0-2.
[00468] Exclusion Criteria: Patients with a primary malignant tumor; history
of liver transplant;
brain metastases; psychiatric disorder that might cause difficulty in
obtaining informed consent
or in conducting the trial; Not pregnant or nursing; Fertile patients must use
effective
contraception during and for? 3 months after completion of study treatment; No
other
malignancy within the past 5 years except for in situ cancers or basal cell or
squamous cell
carcinoma of the skin; No hypersensitivity or intolerance to statins; no other
non-malignant
systemic disease that would preclude rosuvastatin administration or prolonged
follow-up.
[00469] Primary Outcome Measures: time to progression, progression free
survival, overall
response (RECIST)
[00470] Secondary Outcome Measures: liver function tests, tumor biomarkers
Example 42: Clinical Trial for Multiple Sclerosis
[00471] A non-limiting example of a multiple sclerosis clinical trial in
humans is described
below.
[00472] Purpose: The purposes of this study are to assess the efficacy of an
autotaxin inhibitor,
or a pharmaceutically acceptable salt thereof, as single agent or in
combination, in the treatment
of patients with multiple sclerosis, collect information on any side effects
the compound may
cause as single agent or in combination, and evaluate the pharmacokinetic
properties of the
compound as single agent or in combination.
[00473] Intervention: Patients are administered 1-100 mg/kg of an autotaxin
inhibitor, or a
pharmaceutically acceptable salt thereof, per day as single agent or in
combination.
[00474] Detailed Description: Patients will be given an autotaxin inhibitor,
or a
pharmaceutically acceptable salt thereof, orally once or twice a day as single
agent or in
combination. Prior to each dosing cycle, a physical exam, blood work and
assessment of any
side effects will be performed.
[00475] Primary Outcome Measures: Multiple Sclerosis Functional Composite
(MSFC) score,
or other suitable for assessing response and relapse of symptoms in MS,
[00476] Secondary Outcome Measures: Total number of new GdE lesions, assessed
on brain
MRIs improvement in one or more signs or symptoms of multiple sclerosis as
measured
byFunctional Systems Scores (FSS) and Expanded Disability Status Scale (EDSS);
Multiple
Sclerosis Quality of Life 54 items (MSQOL-54); Timed 25-foot walk; Nine-hole
peg test
[00477] Eligibility: Male and female subjects that are 18 to 65 years old.
[00478] Inclusion Criteria: Confirmed diagnosis of multiple sclerosis.
-104-
CA 02986759 2017-11-21
WO 2016/191427 PCT/US2016/033933
[00479] Exclusion Criteria: Pregnant or lactating.
[00480] The examples and embodiments described herein are for illustrative
purposes only and
various modifications or changes suggested to persons skilled in the art are
to be included within
the spirit and purview of this application and scope of the appended claims.
-105-
